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ABSTRACT 
 Primary cancer treatment often includes a combination of surgery, 
chemotherapy, or radiation.  Chemotherapy and radiation have limited efficacy due to 
their negative side effects.  Recent research has moved towards the development of 
therapies that are designed to specifically target malignant cells only.  The majority of 
this work characterizes two novel enzyme prodrug therapies using fusion proteins 
containing annexin V to target only tumor vascular endothelial cells and cancer cells, 
reducing the burden of systemic toxicity in healthy tissue.  Methioninase enzyme will 
convert inert selenomethionine to toxic methylselenol and also deplete the cancer cells 
of methionine necessary for protein synthesis and continued growth.  Cytosine 
deaminase converts 5-fluorocytosine into the well-known cancer therapeutic 5–
fluorouracil.  Additionally, continued work using single-walled carbon nanotubes 
targeted to cancer cells by the F3 peptide was done.         
 Recombinant technology was used to express and purify methioninase-annexin 
V and cytosine deaminase-annexin V fusion proteins.  In vitro testing of binding and 
cytotoxicity were completed.  Studies of both fusion proteins binding to human 
endothelial cells and two breast cancer cell lines were done to obtain dissociation 
constants in the range of 0.6-6 nM, indicating relatively strong binding.  Cytotoxicity 
studies revealed that methioninase-annexin V with selenomethionine can kill those 
same cell lines in only 3 days; cytosine deaminase-annexin V accomplished the same 
goal in 9 days using 5-fluorocytosine.   
 The remaining enzyme prodrug work involved testing the methioninase-annexin 
V system in vivo.  Pharmacokinetic testing revealed complete clearance of 
xvii 
 
methioninase-annexin V from the bloodstream to occur within 8 hours following 
intraperitoneal injection.  Selenomethionine levels up to 12 mg/kg were shown to cause 
no apparent toxicity, while higher levels were lethal.  Tests were done with a maximum 
of 10 mg/kg.  The enzyme prodrug system demonstrated a significant slowing of tumor 
growth compared to untreated mice or mice treated only with the prodrug or fusion 
protein.  Using a fluorescent dye, it was shown that the blood flow through the treated 
tumor was significantly reduced.  The results obtained in vivo with this enzyme prodrug 
treatment are promising. 
 F3-targeted single-walled carbon nanotubes were tested for their ability to bind 
to and become internalized by endothelial cells and breast cancer cells.  Following 
incubation with SWNT-F3, cells were irradiated with a near-infrared laser 980 nm.  The 
irradiation increased the cell death as determined by a cell viability assay.  The 
photothermal therapy produced promising results in vitro, and tests with mice are 
recommended. 
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1.  INTRODUCTION 
 Nearly every person knows someone that has been affected by cancer at some 
point in their life.  Even though cancer death rates have been decreasing since ~1990, 
the Centers for Disease Control and Prevention statistics from 2009 indicate that nearly 
570,000 deaths per year were the result of cancer, second only to heart disease [1].  
According the American Cancer Society, males have a lifetime risk of 45% of acquiring 
some form of cancer and 23% risk of dying.  Risks for females are 38% and 20% 
respectively.  Prostate cancer for men is the highest risk of occurrence at 17% with one-
sixth of those dying due to the disease.  Breast cancer is the predominantly occurring 
disease for females with a 12% chance with one-quarter of those women dying [2].    
 The vast majority of cancer deaths are caused by metastatic lesions that occur as 
cancer progresses (Figure 1.1) [3].  There are several steps required for a primary tumor 
to become a malignant cancer.  Within the primary tumor, cells must lose cell-cell 
contacts and gain the ability to migrate.  Tumor cells must then breach the basement 
membrane using matrix proteases to enter blood or lymphatic vessels.  Specific cancers 
circulate in vessels to reach particular tissue types where they have to adhere to the 
vessel wall and extravasate into the native tissue.  For the metastatic legion to survive, 
the tumor cells must be able to recruit a blood and nutrient supply by forming new 
blood vessels in a process called angiogenesis.  The process of angiogenesis has been 
reviewed by Carmeliet and Jain [4].   
 Contrary to highly ordered healthy tissue containing mature blood vasculature 
[5], cancerous tissue exhibits structural abnormalities like irregular branching, vessel 
diameter, and increased vessel leakage [6].  Once cells become malignant, rapid          
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Figure 1.1.  Schematic of the complex metastatic process. Epithelial-
mesenchymal transition (EMT) alters the cell phenotype to allow intravasation 
into the systemic circulation. Mesenchymal-epithelial transition (MET) occurs at 
the site of distinct metastases (produced from Dotan et al.). 
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angiogenesis is essential to supply nutrients and oxygen for tumor growth and results in 
variable vessel structure with increased distance between tumor blood vessels, which 
leads to regions of hypoxia within the tumor [7, 8].  The limited diffusion of oxygen 
into these areas tends to inhibit cytotoxicity of chemotherapeutic agents because the 
cells are not rapidly dividing [9].  
Standard clinical treatments of cancer include a combination of surgery, 
chemotherapy, and radiation.  Systemically-administered chemotherapy drugs reach 
rapidly dividing tumor cells by the well-known enhanced permeability and retention 
effect [10].  Similarly, areas of rapidly dividing healthy cells such as cells of the bone 
marrow and intestinal epithelial cells are also affected, resulting in common severe side 
effects including hair loss, suppression of blood cell production, and inflammation of 
the intestines, among numerous other symptoms.  The lack of specific targeting results 
in little drug accumulation in the tumor tissue and can be one of the many causes of 
drug resistance in tumor cells [11], making the cancer cells even difficult to kill [12]. 
 The next sections will focus on directed prodrug therapies and how they are 
used to produce therapeutic drug levels without the inherent toxicity of typical 
chemotherapeutics.  Exposure of phosphatidylserine to the bloodstream will then be 
described as a way to target enzymes to specific cancer tissue.  The mechanisms 
employed by two specific enzyme prodrug systems, L-methioninase with 
selenomethionine and cytosine deaminase with 5-fluorocytosine, and how cell killing is 
expected to occur with each system will be discussed.  A discussion of a different 
approach to treating cancer, photothermal therapy using carbon nanotubes, is then 
given.  The following section introduces the F3 peptide used to target the carbon 
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nanotubes to the nucleolin receptor known to be expressed by proliferating tumor 
endothelial cells.  Finally, the experimental hypotheses to be tested are presented along 
with the experimental design for each section. 
Overview of Directed Prodrug Therapy 
Enzyme prodrug therapy for cancer was designed as a way to avoid the systemic 
toxicity of chemotherapy. A type of enzyme prodrug therapy known as antibody-
directed prodrug therapy (ADEPT) was first proposed in the 1980s as a means to 
confine the action of cytotoxic drugs to the tumor. In ADEPT, an antibody that binds to 
the tumors is linked to a drug-activating enzyme, and the resulting fusion protein is 
administered systemically and preferentially accumulates in the tumor [13] (see Figure 
1.2, reproduced from Tietze et al [14]).  A non-toxic prodrug is administered 
systemically and is converted in the tumor to a toxic drug by the enzyme. The enzyme 
should not have a human homolog to avoid prodrug activation in normal tissues. 
Gene-directed prodrug therapy (GDEPT) is a related therapy and uses a specific 
gene that codes for an enzyme of interest.  The gene, usually part of a vector, is 
administered to the patient by some means, and the gene is internalized in cancer cells 
and becomes part of the cell’s DNA, enabling the enzyme to be produced by the cell.  
With the enzyme expressed, the systemic administration of the prodrug is done as with 
ADEPT.    
A large amount of prodrug is able to be converted to the corresponding drug in 
the tumor tissue by every enzyme molecule bound or expressed by the cells.  Therefore, 
a high drug concentration can be achieved within the tumor environment, and tumor 
cells are able to be killed in an efficient manner. Due to the formation of these low  
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molecular weight drugs in the extracellular environment, neighboring tumor cells that 
may not express the desired antigen can be killed by drug diffusion.  This is known as a 
bystander effect and is a way to eliminate tumors cells that would not be susceptible to 
the treatment with traditional antibody–drug conjugates [15]. In order to have an 
effective therapy, a prodrug needs to maintain a low systemic toxicity and be soluble in 
aqueous solution.  To prevent prodrug conversion throughout the body, the enzyme 
being employed should either be expressed at very low levels or not at all in healthy 
tissue and come from an exogenous source.  The drug that results from the conversion 
of the prodrug should have low molecular weight, high cell uptake, and cytotoxicity. 
Furthermore, the enzyme complex needs to bind to only tumor-related cells and should 
have high enzymatic activity, should not be inactivated by the prodrug or the drug, and 
ideally should have low immunogenicity.  A potential problem with the use of non-
human enzymes in therapy is the possibility of an immune reaction.  A way to reduce a 
protein’s immunogenicity that has been well studied is the conjugation of polyethylene 
glycol (PEG) to the protein [16]. 
To accomplish the goal of developing a new cancer therapy that limits the 
inherit toxicity of standard chemotherapeutics, a specific target receptor and ligand must 
be identified.  Much research has looked at antibodies or other proteins that bind 
overexpressed proteins on the surface of cells within tumors.  However, the receptor is 
usually expressed in healthy tissue throughout the body as well.  Every cell within a 
given tumor does not express the same receptors, making it difficult to target malignant 
cells in a tumor.  For an enzyme prodrug system to be as effective as possible at 
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converting the prodrug to an active agent, the enzyme should be easily administered and 
accessible for rapid prodrug conversion.    
Annexin V Binds Exposed Phosphatidylserine (PS) in Tumor Vasculature 
  In healthy mammalian cells, most all anionic phospholipids, including PS, are 
known to reside exclusively on the internal leaflet of the plasma cell membrane with the 
outer leaflet containing primarily cationic phospholipids [17, 18].  The asymmetry of 
the phospholipids is controlled by aminophospholipid translocase, an ATP-dependent 
enzyme that internalizes PS back to the cytoplasmic leaflet, and scramblase, a calcium-
dependent transporter that flips PS to the external surface of the plasma membrane [19, 
20].  Upon exposure to certain external stimuli, the PS gets translocated to the outer 
leaflet of the lipid bilayer in vascular endothelial cells, making it accessible to the 
bloodstream.  Various conditions, both physiological and pathological--including 
platelet activation, cell aging, degranulation, apoptosis, necrosis, and malignancy--are 
responsible for the leaflet switching of the PS, which is controlled by two enzymes [21-
24].  In malignant tissue, PS externalization can occur without these stimuli [19, 20], 
and several carcinoma cell lines have been shown to expose up to seven times more PS 
than healthy cells.  Vascular endothelial cells are also known to expose PS which may 
be caused by acidity, hypoxia, inflammatory molecules, or oxygen species.  These 
conditions can be stressful to endothelial homeostasis and result in calcium uptake and 
subsequent aminophospholipid translocase inactivation or scramblase activation [25, 
26].   
 Work published in 2002 confirmed the translocation of anionic phospholipids 
including PS in mice bearing MDA-MB-231 tumors [25, 26].  A monoclonal antibody 
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that is reactive towards all anionic phospholipids was developed.  The antibody and 
protein annexin V were biotinylated and then injected intravenously to the mice.  Ex 
vivo staining proved that both proteins were bound to tumor vascular endothelial cells, 
tumor cells, and to necrotic regions of the tumor.  Staining done on healthy tissue 
revealed no antibody or annexin V binding, thus indicating anionic phospholipids, 
including PS, were not externalized.   
 Annexin is a family of proteins that bind anionic phospholipids and contain 70-
mer repeat sequences.  Annexin V (36 kDa, monomer) has four repeat domains and is 
known to specifically bind to PS in a calcium-dependent manner (Figure 1.3).  Each of 
the domains contains a calcium-binding site.  As mentioned above, biotinylated annexin 
V was shown to be bound to vascular endothelial cells within a breast cancer tumor and 
to the tumor cells.   
Mechanism of Cell Death via L-Methioninase and Selenomethionine 
For the enzyme component, L-methionine gamma-lyase (accession 
#AAB03240) that exists as a homotetramer, also known as L-methioninase, from 
Pseudomonas putida was chosen (Figure 1.4). This enzyme catalyzes the alpha, 
gamma-elimination of L-methionine and is not found in human tissue [27]. L-
methionine is converted to methanethiol, a-ketobutyrate, and ammonia.  Methionine is 
an essential amino acid and has been shown to be very important for the continued 
survival and proliferation of cancer cells.  Many tumor cell lines, such as those of brain, 
colon, kidney, lung and breast, have been shown to be methionine-dependent [28-30].  
All healthy cells are considered to be methionine-independent because of their ability to 
manufacture methionine from the precursor homocysteine [28, 31, 32].  Homocysteine  
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lacks the methyl group that is attached to sulfur on the side chain.  Below normal levels 
and activity of methionine synthase, one of the enzymes that methylates homocysteine 
to form methionine, have been shown for many methionine-dependent cancer cell lines 
[33, 34].   
The prodrug selenomethionine is also cleaved by alpha, gamma-elimination into 
toxic methylselenol, a-ketobutyrate, and ammonia [35]. Methylselenol has been shown 
to be approximately 200-fold more cytotoxic to various human cancer cells than the 
prodrug [36] and is known to induce apoptosis in cancer cells [37, 38].  Gene array data 
produced by Zeng et al. [39] indicated that cell cycle arrest and apoptosis were found to 
be most common effects observed following fibrosarcoma tumor cell incubation with 
methylselenol.  It is likely that cell cycle arrest and apoptosis play a key role in the 
inhibition of tumor cell invasion upon exposure to methylselenol.  Other reports 
indicate methylselenol blocks cell cycle progression, induces apoptosis, and regulates 
gene expression in prostate and mammary cancer cells [40, 41]. 
Several mechanisms of action of the methioninase-annexin V/selenomethionine 
system are envisioned.  The methylselenol generated at the surface of the endothelial 
cells in the tumor leads to destruction of these cells, which leads to clotting in the tumor 
vasculature and a cutoff of the supply of oxygen to the tumor.  Thus, the primary tumor 
and distant metastases can be treated simultaneously.  Methylselenol is also carried to 
the tumor cells by fluid permeating through the artery wall because of the pressure 
gradient across the artery wall.  The destruction of the endothelial cells will release 
tumor antigens directly in the bloodstream, which can cause the immune system to 
mount a systemic attack on any remaining tumor cells anywhere in the body; this 
12 
 
immune response can be boosted by the administration of immunoadjuvants [42].  
Finally, the L-methioninase will greatly reduce the supply of methionine in the tumor, 
which will weaken methionine-dependent cancer cells. 
Mechanism of Cell Death via Cytosine Deaminase and 5-Fluorocytosine 
The anti-metabolite 5-fluorouracil (5-FU) is widely used in the treatment of 
solid tumors, including those of the breast, gastrointestinal system, head and neck, and 
ovary [43].  It has been established that 5-FU is converted inside the cell to the active 
metabolites fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine 
triphosphate (FdUTP), and fluorouridine triphosphate (FUTP) [44].  These metabolites 
misincorporate into RNA and DNA and inhibit the nucleotide synthesis enzyme 
thymidylate synthase.  Unlike using a drug that rapidly disrupts the membrane, 5-FU 
requires DNA and RNA replication to induce toxicity.  Cytotoxicity to non-cancerous 
tissues limits the dosage and frequency of drug administration.  Common side effects of 
5-FU are bone marrow suppression leading to neutropenia and infections, and 
gastrointestinal toxicities such as stromatitis, nausea, vomiting, and diarrhea [45].   
To circumvent problems related to systemic administration, new delivery 
strategies have been studied to produce 5-FU at the site of the tumor using an inert 
prodrug.  As part of an enzyme prodrug system, 5-fluorocytosine (5-FC), a common 
antimicrobial compound known to exhibit high bioavailability [46], has been used in 
combination with cytosine deaminase (CD, Figure 1.5) to produce biologically relevant 
levels of 5-FU locally.  CD has been used in ADEPT by conjugating it to a single chain 
fragment variable (scFv) antibody [47, 48].  In ADEPT, however, the antibody-enzyme 
complex must diffuse across the vascular wall to reach the tumor cells.  In a study of the  
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local distribution of a monoclonal antibody injected i.v. in patients with malignant 
melanoma, the antibody was found to be heterogeneously distributed through the tumor, 
which was not primarily due to heterogeneity of antigen expression but could have been 
a result of differences in capillary wall permeability [49].  Other studies have used CD-
fusions for suicide GDEPT [50, 51] and viral-directed enzyme prodrug therapy 
(VDEPT) [52, 53].  Gene delivery is limited, however, by an inability to transfect large 
number of cells efficiently, while viral vectors have the potential of inducing severe 
immune responses and also suffer from a limited amount and size of plasmid DNA [54]. 
Hyperthermal Therapy using Single-Walled Carbon Nanotubes (SWNT) 
Many reports have proven that inducing prolonged hyperthermia is an approach 
that has been successful in vitro and in vivo for killing tumor cells.  The use of near-
infrared (NIR) lasers [55, 56], magnetic thermal ablation [57], and RF and microwave 
ablation [58-61] have been reported to heat tissue.  When occurring for a sufficient 
time, hyperthermia can cause severe tissue damage or complete necrosis.  Dissipation of 
heat in healthy cells is critical when experiencing periods of elevated temperature.  
Healthy cells and tissue are known to withstand hyperthermia better than malignant 
cells [62].  Vascular adaptation within healthy tissue causes blood vessels to dilate, 
increasing blood flow to dissipate the heat.  The lack of vasculature organization in 
tumors disrupts the adaption process and allows heat buildup inside the tumor [63].  An 
elevation in tumor cell temperature between 40-43oC for at least 5 minutes has been 
shown to induce protein coagulation, apoptosis, and necrosis [64].  However, 
temperatures reaching 54-60oC require less than 1 minute to induce apoptosis, necrosis, 
and lipid bilayer disruption [65].     
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 Photothermal therapy is one method to induce hyperthermia and has been used 
in a number of clinical settings including cancer.  In one type of photothermal therapy 
of cancer, nanoparticles are delivered to the tumor and then are heated by light at a 
specific wavelength, which causes heating of the tumor.  Work has been done using 
gold nanoshells [55], fullerenes [66], and carbon nanotubes [67-69]. 
 Carbon nanotubes have several intriguing properties that make them interesting 
candidates for biological research, including their electrical, optical, and thermal 
properties.   For this work, the property of interest is their strong near-infrared light 
absorbance from 700 to 1400 nm [70, 71].  Human tissue is known to be relatively 
transparent in this range of light and will allow the use of carbon nanotubes in 
combination with NIR to produce thermal cell injury.  Additionally, with their extreme 
length to diameter ratio, carbon nanotubes are able to transverse mammalian cell 
membranes with little effect on the cell [72].  Because of this, carbon nanotubes have 
been investigated as delivery vehicles for biological molecules.   
Several studies have used carbon nanotubes combined with NIR light as a way 
to treat cancer (see the review by Harrison et al. [73]).  To prepare carbon nanotubes for 
use as an injectable agent, usaully a surfactant must be employed with sonication to 
mechanically break up aggregates [74].  Being made from all carbon atoms, the surface 
of nanotubes is extremely hydrophobic which prohibits suspension in aqueous 
solutions.  To circumvent the problem, conjugation of water-soluble polyethylene 
glycol (PEG) to the nanotube surface [75] or use of heterobifunctional linkers have been 
used previously [76].  Single-walled and multi-walled carbon nanotubes (SWNTs and 
MWNTs, respectively) have been employed in several cancer studies.  A 2005 study 
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proved that HeLa cells cultured in vitro could be killed using a combination of folate-
targeted SWNTs and NIR light while cells receiving no SWNTs were unharmed [71].  
Studies targeting different moeities have also been done on neuroblastoma [77], prostate 
[78], and breast cancer cell lines [79].  
F3 Peptide Binds Nucleolin Receptor Expressed on Proliferating Cells 
It is known that vascular endothelial cells express specific molecules on their 
surface depending on where they are located within the body.  Extensive work has been 
done using phage display technology in order to map these vascular addresses and 
identify targets that are specific to healthy organs or tumor tissues.  Phage display 
techniques employ bacterial viruses, or phage, expressing short amino acid sequences 
on their surface protein coat [80], and have discovered numerous peptides that home to 
specific tissues, both healthy and malignant [81, 82].  Some of the peptides also act as 
cell-penetrating peptides as they become internalized by the cells that express their 
specific receptor [83].  One such sequence is the F3 peptide.   
The F3 peptide is a 31-amino-acid peptide fragment of the high mobility group 
protein 2 [84].  Upon binding to its cell surface receptor, F3 becomes internalized and 
homes towards the nucleus.  Tumor vascular endothelial cells and tumor cells have been 
used to demonstrate the F3 shuttling to the nucleus [84, 85].  The cell receptor that 
binds F3 is called nucleolin and is sequestered in the cytoplasm of healthy cells.  
Nucleolin is known to have the ability to catalyze its own degradation.  However, when 
a cell receives the signal to begin proliferation, this 105 kDa nucleolar phosphoprotein 
[86] gets transported to the cell surface of and is exposed to the extracellular 
environment [87, 88].  While undergoing proliferation, the ability of nucleolin to 
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degrade itself is thought to be inhibited.  A study done in 1991 proved that cells in the 
process of actively dividing have a majority of intact nucleolin versus stationary phase 
cells that contain higher amounts of fragmented nucleolin [89].  Additionally, the 
amount of nucleolin presented by proliferating cells is approximately 10 times that 
expressed by non-dividing cells [86].  To prove the shuttling of F3 to the nucleus, 
MDA-MB-435 human breast cancer cells were found to internalize fluorescently-
labeled F3 and translocate it to the cell nucleus in vitro and in mice [84].  This was 
confirmed by another group [90].  The expression of nucleolin on the cell surface of 
tumor vascular endothelial cells and tumor cells provide an excellent target for a new 
cancer therapy. 
Mechanism of Cell Death via Carbon Nanotube Heating 
 This therapeutic strategy reported here exploits the naturally occurring deficit of 
NIR-absorbing molecules in most tissue, permitting transmission of NIR light through 
tissue with little attenuation and minimal heating. Light within this spectral region has 
been shown to penetrate tissue at depths around 1 cm with no observable damage to the 
tissue [91].  The combination of SWNTs targeted to the tumor vasculature using the F3 
peptide, which binds to nucleolin, and NIR laser light presents a new therapy that 
allows for a targeted delivery of heat to tumor tissue.   
Overall Hypothesis and Experimental Plan 
 The hypotheses that are testes in this work are: 1) a cytosine deaminase-annexin 
V fusion protein can be expressed in E. coli and then purified, and this fusion protein 
will have cytosine deaminase enzymatic activity; 2) the L-methioninase-annexin V and 
cytosine deaminase-annexin V fusion proteins will bind to the surface of endothelial 
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cells (non-confluent) and breast cancer cells in vitro with good binding strength 
(dissociation constants under 10 nM); 3) L-methioninase-annexin V and cytosine 
deaminase-annexin V fusion proteins will convert nontoxic prodrugs to active drugs 
that will kill endothelial and breast cancer cells; 4) the L-methioninase-annexin 
V/selenomethionine enzyme prodrug system will kill or inhibit the growth of a human 
breast tumor in mice with the fusion protein and prodrug delivered by i.p. injection; 5) 
targeting single-walled carbon nanotubes to the surface of endothelial and breast cancer 
cells via the F3 peptide will cause internalization of the nanotubes; 6) application of a 
near-infrared laser in the presence of single-walled carbon nanotubes with F3 attached 
will cause thermal injury and death to cells grown in vitro. 
 The following experimental strategies were used to test the above hypotheses: 
1. Creation of a cytosine deaminase-annexin V fusion protein 
 Nucleotide primers will be designed and manufactured for use in the polymerase 
chain reaction.  A flexible triple repeat glycine-serine linker will be built in to fuse the 
cytosine deaminase gene (N-terminal) to the annexin V gene (C-terminal).  The linker 
will allow for the enzyme to remain active by preventing interference of the active site 
and maintain available binding residues of annexin V.   
 The fused gene will then be cloned into a bacterial expression vector for 
recombinant expression in E. coli.  The vector codes for a histidine tag at the N-
terminal, and a specific protease site will be added imediately prior to the fusion gene.  
The fusion protein is expected to be produced as a soluble protein with an active 
cytosine deaminase enzyme and functional annexin V.  The (His)6 tag will allow for use 
of a purification column containing nickel for immobilized metal affinity 
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chromatography, followed by cleavage of the (His)6 tag using a protease to yield a high 
purity fusion protein.  The Bradford protein assay and an enzymatic assay will be used 
to track the protein quantity and enzyme activity of the fusion throughout the 
purification process.  Denaturing sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) will be used to determine for during the various 
purification steps. 
Yeast CD was chosen since previous work has demonstrated a greater ability of 
yeast CD to convert 5-FC to 5-FU than bacterial CD [92].  Intravenous injection of this 
fusion protein will allow annexin V to bind rapidly to exposed PS on endothelial cells in 
the tumor vasculature, and the FP will also be transported from the bloodstream to 
tumor cells via the well-known enhanced permeability and retention (EPR) effect [10].  
Following clearance of unbound FP, 5-FC would be injected and converted to 5-FU 
within the tumor both at the surface of the tumor vasculature and at the surface of the 
cancer cells. 
2. Fusion proteins bind PS exposed on the surface of endothelial and cancer cells 
 To prove the methioninase-annexin V and cytosine deaminase-annexin V 
proteins can be used to effectively target cancer cells and remain bound to convert the 
prodrug to active drugs, binding tests will be done to determine specific binding 
dissociation constants for both fusion proteins on endothelial cells and MCF-7 and 
MDA-MB-231 breast cancer cells using the interaction of biotin and streptavidin tagged 
with an enzyme to developed a colorimetric substrate for quantification.  The duration 
of binding to these cells is also going to be tested using a modified binding test in 
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combination with a metabolic assay to produce binding data on a per-cell basis.  This 
will be  important to aid in designing sebsequent experiments. 
3. Fusion proteins convert specific prodrugs into active drugs that kill cancer cells 
 A metabolic activity assay will be used to determine cytotoxic effects of the 
fusion proteins, their prodrugs, and the combination of fusion proteins with their 
prodrugs.  Following binding of the fusion proteins to the surface of endothelial and 
cancer cells, the prodrug will be added and cell viability determined after a given period 
of time specific for each system.  Comparison of treated to untreated cells is expected to 
result in significant cell death of cells treated with the enzyme prodrug combinations 
with minimal effect of the prodrug alone.   
4. L-methioninase-annexin V with selenomethionine will reduce or inhibit MDA-
MB-231 tumor growth in immunodeficient mice 
 Using a mouse xenograft model, MDA-MB-231 breast cancer cells will be 
inoculated in the flank region of immunodeficient mice.  Once the tumors show signs of 
growth, three consecutive cycles of treatment with methioninase-annexin V and 
selenomethionine will begin with each cycle lasting 4 days.  The treatment is expected 
to produce toxic methylselenol that will rupture endothelial cells lining blood vessels 
within the tumor and cause clotting that will cut off the supply of oxygen and nutrients 
needed for continued tumor growth.  It is anticipated that the tumor will halt or even 
reduce the size of the tumor. 
5. Carbon nanotubes functionalized with the F3 peptide are internalized by 
endothelial and MCF-7 breast cancer cells 
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 The F3 peptide has been shown to be internalized in previous reports.  By 
attaching the peptide to the surface of single-walled carbon nanotubes, it is expected 
that the conjugate will be taken up by the cells following incubation with endothelial 
and cancer cells.  Fluorescence and confocal microscopy will be used for that 
determination. 
6. Application of near-infrared light will heat internalized carbon nanotubes to 
induce death in endothelial cells and 4T1 and MCF-7 breast cancer cells 
 The use of near-infrared light at specific wavelengths has been shown to 
produce heat when absorbed by carbon nanotubes.  Endothelial and the breat cancer 
cells will be incubated with the SWNT-F3 conjugate for varying times followed by NIR 
light to induce heating of the nanotubes.  The amount of toxicity will be determined by 
a metabolic activity assay and is expected to be increased when combining the SWNT-
F3 with NIR light. 
 
Note: Some of the information presented in the following sections has previously been 
published [56, 93, 94].    
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2.  MATERIALS 
Bacterial Plasmids, Strains, and Mutagenesis 
 L-methioninase-annexin V was previously constructed and cloned in this lab 
(reference Naveen’s thesis) using the linear pET-30 Ek/LIC vector from EMD 
Chemicals (Gibbstown, NJ).  Cytosine deaminase-annexin V also was cloned into the 
linear pET-30 Ek/LIC vector.  Figure 2.1 shows the layout of the vector and some of its 
general features and ligation independent cloning sequence.  NovaBlue Gigasingles 
were used for the amplification of the pET-30 Ek/LIC plasmid containing the two 
fusion genes (EMD Chemicals).  E. coli BL21(DE3) cells were used as the expression 
host of the fusion genes (EMD Chemicals).  Site-directed mutagenesis products used 
XL10-Gold Ultracompetent cells from Agilent Technologies (Santa Clara, CA). 
DNA Manipulation and Protein Purification 
 Oligonucleotide primers were synthesized by Integrated DNA Technologies 
(Coralville, IA) with standard desalting.  The polymerase chain reaction was done using 
the Expand High Fidelity PCR system (Boehringer Mannheim, Indianapolis, IN).  The 
DNA sequences encoding for the cytosine deaminase-annexin V gene were amplified 
from pQE30Xa/CD [95] (obtained from Dr. Maurizio Cianfriglia at the Superior Health 
Institute, Rome, Italy) and pET-22b(+)/STF-ANX (obtained from Dr. Stuart Lind at the 
University of Colorado).  T4 DNA polymerase and HRV 3C protease were obtained 
from EMD Chemicals.  BamHI restriction enzyme and T4 DNA ligase were purchased 
from New England Biolabs (Ipswich, MA).  The Qiaquick PCR purification kit, 
Qiaquick agarose gel purification kit, and Qiaquick plasmid purification kit were 
purchased from Qiagen (Vista, CA).  SeaKem® LE agarose was purchased from  
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Figure 2.1.  pET-30 Ek/LIC vector map. A general diagram of the features within 
the vector and the ligation independent cloning sequence (Novagen, 2012). 
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Cambrex Bio Science Rockland, Inc. (Rockland, ME).  LB medium contained yeast 
extract Hy-Yest® 412 and tryptone from Sigma Aldrich (St. Louis, MO).  IPTG, TPCK, 
PMSF, β-mercaptoethanol, pyridoxal phosphate, MBTH, acrylamide, and Triton X-114 
were all from Sigma Aldrich.  HisTrap HP columns containing nickel sepharose were 
purchased from GE Healthcare Biosciences (Piscataway, NJ).  Imidazole, BCA protein 
assay kit, and cellulose acetate filters were from Thermo Fisher Scientific (Waltham, 
MA).  The Bradford protein reagent was from Bio-Rad (Hercules, CA).   
Mammalian Cell Lines and Culture Media 
 HAAE-1 endothelial cells were from Coriell Cell Repositories (Camden, NJ).  
MCF-7, MDA-MB-231, and 4T1 cells were obtained from the American Type Culture 
Collection (Manassas, VA).  F-12K (Kaighn's modification of Ham's F-12 medium), 
Eagle's minimum essential medium (EMEM), Leibovitz's L-15 medium, and RPMI-
1640 medium were also purchased from American Type Culture Collection.  Premium 
heat inactivated fetal bovine serum and trypsin were from Atlanta Biologicals 
(Lawrenceville, GA).  Heparin sodium salt was from Polysciences.com (Warrington, 
PA).  Endothelial cell growth supplement, bovine insulin, and matrigel were purchased 
through Fisher Scientific.  Penicillin/streptomycin was from Life Technologies 
(Carlsbad, CA).  MDA-MB-231 cells expressing GFP were from Cell Biolabs (San 
Diego, CA).   
In Vitro Binding, Binding Duration, and Cytotoxicity Assays 
 SureLINK chromophoric biotin and streptavidin-HRP was purchased from KPL 
(Gaithersburg, MD).  Bovine serum albumin, EDTA, O-phenylenediamine, phosphate 
citrate buffer, fluorescein isothiocyanate (FITC), 5-fluorocytosine, and 5-fluorouracil 
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were obtained from Sigma Aldrich.  Alamar Blue solution was obtained from 
BioSource (Camarillo, CA).  Selenomethionine and Fluoro-gel were from Fisher 
Scientific.  Chambered microscope slides, streptavidin coated 96-well plates, dialysis 
tubing, and dialysis cassettes were from Thermo Fisher Scientific.   
In Vivo Pharmaokinetics, Enzyme Prodrug, Phosphatidylserine Detection, 
Biodistribution and Tumor Blood Flow Assays in Mice 
 Inbred NU/J and outbred SCID mice were purchased from Jackson Labs (Bar 
Harbor, ME), and outbred athymic nu/nu mice were from Charles River (Wilmington, 
MA).  Mice were maintained on a 5053 lab rodent diet 20 from Lab Supply 
(labsupplytx.com, Fort Worth, TX).  Modified L-amino acid defined Lombardi choline 
and methionine deficient diet with 1.7 g/kg DL-homocysteine added (pelleted 
#518787GI) was purchased from Dyets, Inc (Bethlehem, PA).  Anti-human annexin V 
antibody produced in rabbit was purchased from Abcam (Cambridge, MA).  Tween 20 
and anti-rabbit IgG (whole molecule)–horseradish peroxidase secondary antibody 
produced in goat were from Sigma Aldrich.  The DAB reagent kit was bought from 
KPL and hematoxylin was from Fisher Scientific.  DyLight 680 fluorescent dye was 
from Thermo Fisher Scientific.   
In vitro Assays for Single-Walled Carbon Nanotubes with F3 Peptide 
 CoMoCAT® Single-walled (SG 6,5) carbon nanotubes were provided courtesy 
of Dr. Daniel Resasco and SouthWest NanoTechnologies (Norman, OK).  DSPE-PEG-
maleimide (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol-
maleimide) linker was obtained from Creative PEGworks (Winston Salem, NC).  The 
F3 peptide (KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC) with FITC added to 
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the N-terminus was synthesized by Biomatik, Inc (Wilmington, DE).  CellMask™ deep 
red plasma membrane stain was bought from Life Technologies.  Fluoro-gel was from 
Fisher Scientific.   
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3.  METHODS 
Primer Design for PCR 
         Primers for the construction of the cytosine deaminase-annexin V fusion gene 
were designed to contain the reverse complement of a region of template DNA. In order 
to insert the fusion gene into the pET-30 Ek/LIC linear vector, ligation independent 
cloning (LIC) sites needed to be incorporated at the N- and C- terminals of the gene.  
The cytosine deaminase gene was positioned at the N-terminal, so its forward primer 
contained the ligation independent cloning sequence and also the HRV 3C protease site 
sequence to allow for removal of the histidine tag during the purification process.  The 
reverse primer for the cytosine deaminase gene and the forward primer for the annexin 
V gene contained BamHI restriction enzyme sites to fuse the genes together.  The 
forward primer for annexin V followed the BamHI site with a sequence encoding a 6-
amino acid flexible linker before the start of annexin V.  Its reverse primer added the C-
terminal ligation independent cloning.  The following are the complete primer 
sequences.    
 Sequence of the primers for amplifying the cytosine deaminase gene: 
Forward primer:   
5’-gAC/ gAC /gAC/ AAg/ ATg/ CTT/ gAA/ gTC/ CTC/ TTT/ CAg/ ggA/ CCC/ 
gTg/ ACA/ ggg/ ggA/ ATg/ gCA/ AgC -3’ 
Reverse primer:   
5’- gC/ CgC/ ATT/ ggA/ TCC/ AgA/ ACC/ gTC/ gCC/ CTC/ ACC/ AAT/ ATC/ 
TTC/ AAA/ CC -3’ 
 Sequence of the primers for amplifying the annexin V gene: 
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Forward primer:   
5’- Cg/ ATT/ CgC/ ggA/ TCC/ gCA/ CAg/ gTT/ CTC/ AgA/ ggC -3’ 
Reverse primer:   
5’-gA/ ggA/ gAA/ gCC/ Cgg/ TTA/ gTC/ ATC/ TTC/ TCC/ ACA/ gAg/ C -3’ 
Notes:      Underlined = Ligation independent cloning sites 
                BOLD = HRV 3C protease site 
                Italics = BamHI sites 
             
The melting temperature (Tm) of primers and the dimer formation with itself were 
calculated by using a program provided by the website http://www.basic. 
northwestern.edu/ biotools/ oligocalc.html.  All primers were designed with these 
criteria: 1) length of primers were ≥ 17 bases, 2) G + C composition was at least 50%, 
3) 3’ end of primer was G or C, or CG or GC, 4) Tm of primers was between 55-80oC, 
and 5) ability of primer to form secondary structure was minimized.  Integrated DNA 
Technologies synthesized all the primers with standard desalting in aqueous solution.   
Construction of Cytosine Deaminase-Annexin V Fusion Gene 
 The polymerase chain reaction was used to amplify the cytosine deaminase gene 
from the pQE30Xa/CD plasmid obtained from the Cianfriglia lab in Italy using the 
above-mentioned primers.  The annexin V gene was amplified from the pET-
22b(+)/STF-ANX plasmid previously obtained.  The Expand High Fidelity PCR system 
was used for all reactions.  Table 3.1 contains the composition of the PCR reactions for 
cytosine deaminase and annexin V.  The difference in the size of the specific primers 
caused the amount of each primer to vary.  Table 3.2 gives the PCR cycling parameters 
that were used.  Following the PCR reactions, the Qiaquick PCR purification kit was 
used to remove reaction components to retain pure DNA (Appendix B has the complete  
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protocol).  [96] To verify the PCR amplification was successful, agarose gel 
electrophoresis was performed (see Appendix B).  Both correctly-sized genes were 
digested separately with the BamHI restriction enzyme for 1 hr at 37oC to make them 
compatible.  The Qiaquick PCR purification kit was used again to retain only digested 
genes.  T4 DNA ligase was used to fuse the digested cytosine deaminase and annexin V 
genes together for 10 min at room temperature.  Another agarose gel was run to confirm 
the ligation work.  From the gel, the band of the appropriate size was cut out, and the 
DNA was purified using the Qiaquick gel extraction kit (see Appendix B).  Sticky ends 
were created on the LIC portions of the fusion gene by treatment with T4 DNA 
polymerase at room temperature for 30 min followed by inactivating the polymerase by 
incubation at 75oC for 20 min.  Table 3.3 gives the reaction composition to create the 
sticky ends.  The sticky ends were used to anneal the fusion gene to the pET-30 Ek/LIC 
vector.  Table 3.4 shows the annealing reaction.  An agarose gel was run to confirm the 
successful annealing to the linear vector, which will close the vector into a circular 
plasmid.  The pET-30 Ek/LIC/CD-Anx plasmid was transformed into NovaBlue 
GigaSingles for amplification.  Following an overnight liquid culture in LB media 
containing 30 mg/L kanamycin, the cells were harvested by centrifugation, and the 
plasmid was extracted using the QIAprep spin mini-prep kit (see Appendix B).  The 
plasmid was sent for gene sequencing using the T7 promoter and T7 terminator primers 
at Oklahoma Medical Research Foundation (Oklahoma City, OK).  With confirmation 
of the correct fusion gene sequence, the plasmid was transformed into E. coli 
BL21(DE3) cells that are used as the expression host.     
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Site-Directed Mutagenesis of L-Methioninase-Annexin V Fusion Gene 
 It was determined that the methioninase-annexin V fusion gene constructed 
previously in this laboratory contained two separate point mutations.  Methioninase 
arginine 326 (CGC) needed to be corrected to glycine 326 (GGC), and annexin V 
phenylalanine 11 (TGC) needed to be corrected to cysteine 11 (TTC).  Primers were 
designed as follows with the correct sequence: 
Forward primer for methioninase 326 mutation: 
5’- gAg/gCC/ggg/Cgg/ggC/TTC/ATg/AAT/gC -3’    Tm = 69.6 oC 
Reverse primer for methioninase 326 mutation: 
5’- gCA/TTC/ATg/AAg/CCC/CgC/CCg/gCC/TC -3’   Tm = 69.6 oC 
Forward primer for annexin V 11 mutation: 
5’- ggC/ACT/gTg/ACT/gAC/TTC/CTT/ggA/TTT/gAT/gAg -3’  Tm = 63.1 oC 
Reverse primer for annexin V 11 mutation: 
5’- CTC/ATC/AAA/TCC/Agg/gAA/gTC/AgT/CAC/AgT/gCC -3’  Tm = 64.3 oC 
 The Quikchange II XL site-directed mutagenesis kit was used to make the 
corrections. Tables 3.5 and 3.6 contain the composition of the mutagenesis PCR 
reactions and thermocycling conditions, respectively (see Appendix B for complete 
protocol).  Following thermocycling, the Dpn I enzyme (10 U) provided was used to 
digest the parental plasmid for 1 hr at 37oC.  E. coli XL10-Gold ultracompetent cells 
were transformed with the mutated plasmid and plated on agar with IPTG and X-gal.  
The plates were allowed to incubate for at least 16 hr at 37oC.  Several colonies that 
appeared blue in color were selected, and an overnight liquid culture of each was done  
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to amplify the plasmid for extraction using the mini-prep protocol.  The plasmid was 
sent for sequencing. 
 The length of the methioninase-annexin V fusion gene (2268 bases) requires an 
additional set of primers to sequence the middle section of the gene.  Primers can 
identify approximately 600 bases from each end with accuracy.  These sequencing 
primers were used to detect the middle of the gene: 
Forward sequencing primer 1: 
5’- ggC/TTg/CCg/TCg/TTT/gCC/CAg/TAC/g -3’  Tm = 66.2 oC 
Forward sequencing primer 2: 
5’- g/TTT/gAT/ggC/TCT/CAg/TTC/TTC/Agg -3’  Tm = 57.7 oC 
Sequencing of Fusion Proteins 
 All DNA samples requiring sequencing were sent to Oklahoma Medical 
Research Foundation (OMRF) DNA sequencing core facility.  An ABI 3730 capillary 
sequencer analyzed all samples.  The T7 promoter and T7 terminator primers were 
provided by OMRF.  Primers were made to overlap by 30-60 bases to ensure quality 
sequencing.   
Fusion Protein Expression, Purification, Analysis, and Storage   
The E. coli BL21(DE3) expression host was transformed with the pET-30 
Ek/LIC plasmid containing methioninase-annexin V or cytosine deaminase-annexin V 
and kanamycin resistance.  Luria Bertani (LB) medium containing yeast extract (5 g/L), 
tryptone (10 g/L), NaCl (10 g/L), and kanamycin (35 mg/L) was used to grow the 
bacteria.  A 10 ml pre-culture was done for ~10 h at 37oC and shaking at 200 rpm 
35 
 
before being added to the remaining 990 ml of LB medium.  The 1 L culture was split 
into four 1-L Erlenmeyer flasks and grown for ~4 h to achieve mid-log phase growth 
(optical density in the range of 0.6-0.8).  Fusion protein production was induced using 
isopropyl β-D-thiogalactopyranoside (IPTG) at a total concentration of 0.4 mM with the 
temperature lowered to 30oC and shaking at 180 rpm for 5 h.  Cells were harvested by 
centrifugation at 1,000 x g for 10 minutes and resuspended in sonication buffer 
containing 0.05 mM N-p-tosyl-L-phenylalanine chloromethyl ketone (TPCK), 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 1% HPLC grade ethanol, 0.01% β-
mercaptoethanol, and 20 mM sodium phosphate dibasic and adjusted to pH 7.4.  The 
methioninase-annexin V fusion requires 0.02 mM pyridoxal 5’-phosphate as a cofactor 
throughout to maintain enzymatic activity but is not included for cytosine deaminase-
annexin V purification.  Sonication of the suspension was done to lyse the cells in an ice 
bath at 4.5 W for 30 s followed by 30 s of rest and repeated four times.  Centrifugation 
of the entire suspension at 12,000 x g for 30 min separated the soluble proteins from the 
cell debris. 
All the following purification steps were performed at 4oC.  Samples were taken 
during each step to track the protein concentration and enzyme activity.  An absorbance 
detector at 280 nm and fraction collector assisted throughout the chromatography.  
Imidazole (40 mM) and NaCl (500 mM) were used to reduce non-specific binding when 
the soluble protein lysate was fed into the 5 ml HisTrap HP chromatography column 
with immobilized Ni2+.  Wash buffer #1 containing 20 mM sodium phosphate, 40 mM 
imidazole, 500 mM NaCl, and 0.02 mM pyridoxal phosphate at pH 7.4 was used to 
equilibrate the column prior to applying the lysate.  With the fusion protein secured to 
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the column by the (His)6-tag, 70 column volumes of wash buffer #2 (wash buffer #1 
plus 0.1% Triton X-114) removed endotoxin bound to the protein.  The column was 
washed with 20 column volumes of wash buffer #1 to remove residual Triton X-114 
detergent.  By applying elution buffer (20 mM sodium phosphate, 500 mM imidazole, 
500 mM NaCl, and 0.02 mM pyridoxal phosphate at pH 7), the fusion protein was 
removed from the column.  Eluted fractions were pooled and dialyzed for 3 h against 20 
mM sodium phosphate and 0.02 mM pyridoxal phosphate at pH 7.4 to remove NaCl 
and ready the protein for cleavage using the HRV 3C protease.  The protease was used 
at 10 U/mg of fusion protein with the addition of 10X cleavage buffer provided with the 
protease for 16 h at 4oC with gentle agitation.  Again, imidazole (40 mM) and NaCl 
(500 mM) were added to the cleaved protein to reduce non-specific binding and applied 
to same HisTrap HP column that was regenerated.  Lacking the (His)6-tag, the cleaved 
fusion protein flows through the column.  Any uncleaved fusion protein and the HRV 
3C protease remained in the column because both have the (His)6-tag.  The cleaved 
protein collected from the column was dialyzed against 20 mM sodium phosphate, 100 
mM NaCl, and 0.02 mM pyridoxal phosphate at pH 7.4 for 3 hr at 4oC.  The protein 
solution was sterilized by passing the protein solution through a 0.2 µm cellulose 
acetate filter.  The final purified protein was put into 1-ml aliquots in cryovials and flash 
frozen in liquid nitrogen.  The HisTrap HP columns can be used many times if the 
regeneration is done after each use and then stored in 1 M HPLC grade ethanol to 
prevent the nickel sepharose resin from drying out.  Regeneration of the column is done 
using 25 ml of 1 M KCl, 1 M NaOH, DI water, and then 1 M HPLC grade ethanol.  
 Samples were taken at each step to track the purification.  The protein 
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concentration of each sample was determined using either the Bradford protein assay or 
the BCA protein assay.  Bovine serum albumin was used as the standard for both 
protein assays.  Methioninase activity was determined by converting methionine to α-
ketobutyrate and developing it with colorimetric substrate 3-methyl-2-benzo-
thiazolinone hydrazone hydrochloride hydrate (MBTH).  Cytosine deaminase activity is 
measured by the change in absorbance as 5-FC is deaminated to 5-FU.  Samples were 
analyzed for size and purity by denaturing gel electrophoresis using the SDS-PAGE 
method with Coomassie blue staining method [97].  The Limulus Amebocyte Lysate 
(LAL) QCL-1000 testing kit was used to determine the amount of endotoxin remaining 
in the fusion protein samples at the conclusion of the purification.  Briefly, the 
endotoxin converts a proenzyme to an enzyme, which then converts a substrate into a 
peptide and p-nitroaniline that is measured.  Appendix B has the complete protocols for 
methods of analysis.   
 Flash frozen proteins underwent lyophilization to convert the liquid solution into 
a dried powder.  Holes were punched in caps of cryovials to allow the moisture to be 
vacuumed out.  Protein samples were freeze-dried overnight, recapped to have no holes, 
and stored at -80oC.    
Binding of Fusion Proteins to Exposed Phosphatidylserine on Endothelial and Cancer 
Cells 
 Human HAAE-1 aortic endothelial cells were grown in F-12K medium with 2 
mM L-glutamine and 1.5 g/L sodium bicarbonate and supplemented with 10% fetal 
bovine serum (FBS), 0.03 mg/ml endothelial cell growth supplement, and 0.1 mg/ml 
heparin.  MCF-7 human breast cancer cells were maintained as monolayer cultures in 
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Eagle’s minimum essential medium containing Earle’s balanced salt solution, non-
essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, 1.5 g/L sodium 
bicarbonate, and supplemented with 10% FBS and 0.01 mg/ml bovine insulin.  MDA-
MB-231 human breast cancer cells were grown in Leibovitz’s L-15 medium 
supplemented with 10% FBS and 2 mM L-glutamine.  Penicillin (100 U/ml) and 
streptomycin (100 µg/ml) were also added to each medium.  HAAE-1 and MCF-7 cells 
were grown at 37oC in a 5% CO2 atmosphere, while MDA-MB-231 cells were grown 
without additional CO2 at 37oC, as recommended by the American Type Culture 
Collection.  Each cell line was grown to 70–80% confluence in T-75 flasks.  Cells were 
transferred to 24-well culture plates (5x104 cells/well) and grown to 80–85% 
confluence.  Cells were fixed to the plate using 0.25% glutaraldehyde in binding buffer 
(phosphate buffer saline, or PBS, with 2 mM Ca2+).  Excess aldehyde groups were 
quenched using 50 mM NH4Cl in binding buffer. Varying concentrations of biotinylated 
fusion proteins, using SureLINK Chromophoric Biotin in a 60 molar excess during 
biotinylation (see Appendix B), were diluted in binding buffer containing 0.5% BSA 
and incubated at 37oC for 2 h.  After washing with binding buffer with 0.5% BSA, 
streptavidin-HRP was added at 2 µg/ml and incubated at room temperature for 1 h. 
Following washing with binding buffer, HRP was measured by adding the chromogenic 
substrate O-phenylenediamine (0.4 mg/ml) and hydrogen peroxide (0.012 vol.%) in 
0.05 mM phosphate-citrate buffer (pH 5.0).  After 30 min at room temperature in the 
dark, the solution was transferred to a transparent 96-well plate, and the absorbance was 
read at 450 nm on a BioTek Synergy HT microtiter plate reader (Winooski, VT).  All 
experiments had a blank that was subjected to the same procedure but with no fusion 
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protein added.  To determine non-specific binding, the same procedure was performed 
with no Ca2+ and 5 mM EDTA in the binding buffer, with the addition of a 1 h BSA 
(0.5%) pretreatment for the cancer cells prior to adding the fusion protein.  The 
complete protocol for measuring fusion protein binding is given in Appendix B. 
 To assess how long the fusion proteins remain bound to the surface of the 
endothelial and cancer cells, a modified binding assay was used.  Cells on 24-well 
plates were first incubated for 2 hr at 37oC in a saturating concentration of biotinylated 
fusion protein (100 nM) in complete growth medium with 2 mM Ca2+.  The Alamar 
Blue assay was done on separate sets of cells at days 0–3 to determine viability, 
followed by fixing with 0.25% glutaraldehyde in binding buffer. Excess aldehyde 
groups were quenched by incubation in a 50 mM NH4Cl in binding buffer.  The binding 
of fusion protein was then quantified using streptavidin-HRP and OPD as above.  The 
complete protocol for quantifying the stability of fusion protein binding is given in 
Appendix B. 
 To prove the fusion proteins bind to the surface of the cells and not to the 24-
well plate surface, a visualization procedure was used.  Cells were plated into 
chambered slides at 80–85% confluence.  Fusion proteins tagged with FITC (see 
Appendix B), were diluted to 100 nM in binding buffer and incubated with the cells for 
2 h at 37oC.  Cells were washed with binding buffer to remove unbound protein.  The 
chamber was removed from the slide, a drop of fluoro-gel in TES buffer was placed 
over the cells, and a coverslip was applied.  Alternatively, 35 mm petri dishes could be 
used with 22 mm square coverglasses with the cells seeded on top.  The coverglass 
would be removed from the petri dish after the protein binding, fluoro-gel applied, and 
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then flipped over onto a microscope slide.  A Nikon Eclipse E800 fluorescence 
microscope with a Nikon DXM1200F digital camera was used to document FITC 
fluorescence on the cells.  The complete protocol for visualizing fusion protein binding 
is found in Appendix B. 
Cytotoxicity of the Enzyme Prodrug Systems to Endothelial and Cancer Cells 
 The experiment was carried out over 3 days for methioninase-annexin V, using 
the same cells for each of the days. Cells were grown and plated in 24-well plates with 
respective growth media using the same procedure as for the binding assay (see above).  
Each medium was supplemented with 2 mM Ca2+ and 0.02 mM pyridoxal phosphate 
and the level of L-methionine was adjusted to 1000 µM.  On day 0, the cells were 
incubated in medium containing 100 nM methioninase-annexin V for 2 h at 37oC. The 
plates were washed, and medium containing selenomethionine varying from 0 to 1000 
µM was added. The Alamar Blue assay was performed on all wells on day 1. The 
Alamar Blue assay was performed by adding Alamar Blue solution to each well to give 
10% Alamar Blue and then incubated for 4 h at 37 oC. The solution (250 µl) was 
transferred to an opaque 96-well plate, and the fluorescence was read at 590 nm using 
excitation at 530 nm. The blank consisted of wells containing only medium and Alamar 
Blue solution. After the fluorescence reading, the plates were washed, replaced with 
fresh medium containing appropriate levels of selenomethionine, and placed in the 
incubator. The readings were taken every 24 h for the duration of the experiment.  The 
complete protocol is given in Appendix B. 
 The experiment with cytosine deaminase-annexin V was carried out over 9 days 
using the same set of cells.  Cells were grown and plated out in 24-well plates with 
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respective growth media using the same procedure as for the binding assay above.  Each 
medium was supplemented with 2 mM Ca2+.  On day 0, the cells were incubated in 
medium containing 100 nM cytosine deaminase-annexin V for 2 hr at 37oC.  The plates 
were washed and medium containing 5-FC or 5-FU varying from 0 to 2000 µM was 
added.  Cells receiving 5-FU did not receive cytosine deaminase-annexin V.  Each day 
throughout the experiment, the medium was replaced with fresh medium containing 5-
FC or 5-FU.  The Alamar Blue assay was performed on all wells on days 3, 6, and 9 (as 
above).  After the fluorescence readings on days 3 and 6, the plates were washed, and 
the cells were incubated with new cytosine deaminase-annexin V using the same 
procedures as before.  The cells were washed again, and fresh medium containing 
appropriate levels of 5-FC or 5-FU was added before further incubation.   
ELISA for L-Methioninase-Annexin V Detection in Mouse Serum 
 All work involving the use of mice was done in accordance with the Institutional 
Animal Care and Use Committee at the University of Oklahoma Health Sciences 
Center.  The complete ELISA protocol is presented in Appendix B.  NU/J mice were 
injected i.p. with 1 and 10 mg/kg of biotinylated methioninase-annexin V.  At 1, 4, 8, 
and 24 h post injection, four mice for each dosage level were sacrificed following a 
cardiac blood draw.  As a blank sample, four mice did not receive any injection.  The 
blood was centrifuged, serum was collected, and flash frozen.  Using a streptavidin-
coated 96-well plate, serum samples were added and allowed to incubate for 1 h at 37oC 
to allow the biotinylated methioninase-annexin V to bind to the streptavidin.  Wells 
were washed with wash buffer containing 0.05% Tween 20 in PBS.  Polyclonal anti-
annexin V antibody was diluted in diluting buffer (0.005% Tween 20 and 0.25% BSA 
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in PBS) and added to each well.  Plates were incubated for 1 h at 37oC and washed as 
above.  Anti-rabbit IgG-HRP conjugate was diluted in diluting buffer and added to the 
wells and incubated for 1 h at 37oC and washed.  O-phenylenediamine was added, 
incubated for 30 min at room temperature in the dark, and the absorbance was read at 
450 nm.   
 The strain of mice used was changed to SCID mice.  To prove that 
methioninase-annexin V was cleared from the bloodstream in a similar time as in NU/J 
mice, the above procedure was done using three mice that were sacrificed 14 hr post-
injection.  Serum samples were compared to mice that did not receive methioninase-
annexin V.  The complete protocol for the ELISA is given in Appendix B.   
Dose Safety Injections of Selenomethionine 
 Selenomethionine is known to have a toxic limit, so the appropriate level must 
be determined.  Thirty total NU/J mice were injected with selenomethionine at varying 
dosages to determine the level of prodrug that could be tolerated by the mice.  Dosages 
of 0, 6, 12, 24, and 60 mg/kg were administered via i.p. injection every 24 h for three 
consecutive days to simulate the anticipated enzyme prodrug treatment schedule.  Mice 
were monitored for three days after the injections to determine an acceptable 
selenomethionine level.   
Development of Tumor Xenografts in Mice 
 MDA-MB-231 breast cancer cells expressing GFP were grown at 37oC.  For 
each mouse to be injected, two 150-mm petri dishes containing cells were grow to give 
~7-8x106 cells.  The day prior to the cell injections, the medium was changed to contain 
no penicillin/streptomycin.  Cells were lifted using typical cell culture procedures and 
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resuspended so each mouse will receive 100 µl of cell suspension.  Matrigel basement 
membrane matrix was thawed overnight in a water bath at 4oC.  Cell suspension was 
mixed with matrigel at a 1:1 ratio and immediately injected into the flank of mice under 
anesthesia using a 25G needle.  The needle was left in the flank for ~1-2 min to allow 
for the matrigel to solidify.  Tumor volumes, in cubic millimeters using V = (width)2 x 
length/2, were measured every 3-4 days thereafter using digital calipers.  The detailed 
protocol for the injection of cancer cells into mice is given in Appendix B.   
Detection of Externally Positioned Phosphatidylserine in MDA-MB-231 Tumor 
Vasculature 
 This enzyme prodrug therapy is based on binding of the methioninase-annexin 
V fusion protein to phosphatidylserine exposed on the surface of endothelial cells that 
line the blood vessels within a tumor.  SCID mice were injected MDA-MB-231/GFP 
cancer cells as above, and the tumors were allowed to develop.  Biotinylated 
methioninase-annexin V was injected i.p. at 10 mg/kg.  One h after injection, the mice 
placed under anesthesia, and the chest cavity was opened to expose the heart.  A 27G 
butterfly needle was inserted into the left ventricle, and the ascending vena cava was 
cut.  Heparinized saline with 2 mM Ca2+ was used to perfuse the circulation, followed 
by fixation with 0.25% glutaraldehyde in saline with calcium.  The tumor was 
immediately resected and soaked in 20% sucrose and calcium overnight at 4oC.  Tumor 
samples were sent to the imaging core facility at OMRF for cryoembedding and 
cryosectioning.  A slide stained with hematoxylin and eosin (H&E) and slides unstained 
were obtained.  Slides were incubated with streptavidin-HRP to bind biotinylated 
methioninase-annexin V, washed, and developed with 3,3'-diaminobenzidine (DAB).  
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Counterstaining was done with hematoxylin to visualize cell nuclei and slides were 
preserved with ImmuniHistoMount (Santa Cruz Biotechnology, Santa Cruz, CA).  The 
fluorescence microscope above was used for brightfield detection and documentation.  
Appendix B has the complete protocol.     
 Biodistribution of Methioninase-Annexin V in SCID Mice 
 The conversion of selenomethionine prodrug into toxic methylselenol is 
expected to occur only within the local tumor environment to prevent systemic drug 
toxicity.  To evaluate the location of methioninase-annexin V binding, SCID mice (n = 
3) with developed MDA-MB-231/GFP tumors were injected i.p. with methioninase-
annexin V tagged with DyLight 680 fluorescent dye.  At 1, 12, and 24 h post-injection, 
whole-body images of the mice were taken with the IVIS Spectrum small animal 
imaging system located in the Rodent Barrier Facility (OU HSC).  After the last images, 
the tumor, kidneys, lungs, heart, stomach, and spleen were removed and imaged ex vivo.  
The complete protocol is given in Appendix B.   
Treatment of MDA-MB-231 Breast Tumors in Mice with Methioninase-Annexin V 
 Methioninase-annexin V in combination with selenomethionine produced 
significant endothelial and cancer cell death in vitro.  To determine the efficacy of this 
enzyme prodrug system in a living system, mice bearing MDA-MB-231/GFP breast 
xenografts were treated with three cycles of methioninase-annexin V and 
selenomethionine.  Each cycle consisted of a methioninase-annexin V injection at 10 
mg/kg, followed by three consecutive days of selenomethionine (10 mg/kg).  The 
experiment included four groups (n = 7 mice/group):  1) untreated control, 2) 
methioninase-annexin V only, 3) selenomethionine only, and 4) methioninase-annexin 
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V with selenomethionine.  Mice were maintained on a normal mouse chow diet.  Tumor 
volumes and mouse weight were measured two or three times per week to track the 
effect of the treatment.  Post-treatment observation was done until the tumor volumes 
required the mice to be sacrificed at which time the lungs, liver, and tumor were 
removed and soaked in formaldehyde.  Samples were delivered to Dr. Stanley Kosanke 
(OU HSC Pathology) for paraffin embedding.  Precision Histology Lab, Inc (Oklahoma 
City, OK) sectioned and stained the slides with H&E.  Dr. Kosanke performed 
histological analysis for all mice samples.     
 Knowing methionine is an essential amino acid required for the continued 
growth of cancer cells and that methioninase enzyme catalyzes the conversion of 
methionine to byproducts, an experiment was done to see the effect of the 
methioninase-annexin V with selenomethionine treatment of MDA-MB-231/GFP breast 
tumors with mice on a methionine-deficient diet. The same treatment schedule of three 
cycles was used as above, with the selenomethionine dosage lowered to 5 mg/kg.  
Experiment groups of 1) untreated control, 2) methioninase-annexin V only, and 3) 
methioninase-annexin V were done with n = 7 mice/group.  One the day before the 
treatment began, the mice were changed from the normal diet to the methionine-
deficient diet.  Histological analysis at the end of the experiment was done as above.  
The complete protocol for the treatment of tumors in mice is given in Appendix B.      
Determination of Blood Flow Through MDA-MB-231/GFP Tumors 
 The main effect of the methioninase-annexin V with selenomethionine treatment 
is expected to be the generation of toxic methylselenol at the surface of the endothelial 
cells lining the tumor vasculature ultimately resulting in clot formation and blood flow 
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interruption.  SCID mice (n = 3 for treated and control groups) bearing MDA-MB-
231/GFP tumors were subjected to the above treatment (10 mg/kg of methioninase-
annexin V + 10 mg/kg of selenomethionine for three cycles).  The day after the 
conclusion of the treatment, all six mice were injected with DyLight 680 fluorescent 
dye at 1 mg/kg.  The IVIS imaging system was used to document the amount of dye 
flowing through the control and treated tumors.  Then, the circulation of the mice was 
perfused with heparinized saline with 2 mM Ca2+.  The same procedure used for 
detection of PS was used for fixation, resection of the tumor, and preparation for H&E 
staining was done prior to delivering to Dr. Kosanke.  The complete protocol for the 
experiments to determine blood flow through the tumors is given in Appendix B.  
Conjugation of F3 Peptide to Single-Walled Carbon Nanotubes with a Phospholipid 
Linker 
 Functionalizing the carbon nanotubes allows them to be targeted to specific 
cells.  To get the single-walled carbon nanotubes (6 mg) into aqueous solution, 1% 
sodium dodecyl sulfate (SDS, 5 ml) was used with sonication.  For producing long 
nanotubes, samples underwent two rounds of sonication at 7 W for 30 min and a 30 min 
centrifugation at 15,680 x g in a microcentrifuge.  Short and very short nanotubes were 
produced using two rounds of 3 and 6 hr of sonication, respectively.   
 The F3 peptide was manufactured by Biomatik, Inc with a lysine residue at the 
N-terminal for attachment of FITC and an additional cysteine residue at the C-terminal.  
The initial reaction was a 15 h overnight incubation of 1 mg of F3 (0.33 mg/ml) diluted 
in phosphate-buffered saline with 2 mg of DSPE-PEG-maleimide linker (2 mg/ml) in 
deionized water at room temperature with gentle shaking.  Unreacted maleimide groups 
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were blocked with the addition of a 4-molar excess of L-cysteine to linker.  The 
nanotube suspension was combined with the F3-linker and mixed for 30 min at room 
temperature followed by an 8 h dialysis against deionized water using a 50k MWCO 
cellulose acetate membrane water to remove SDS.  The SWNT-F3 conjugate was 
centrifuged at 15,680 x g for 1 h to remove any aggregates [98] and stored at 4oC.  The 
complete protocol for the conjugation of F3 to the nanotubes is given in Appendix B.  
 Analysis of the F3 content in the SWNT-F3 conjugate was done using a 
Bradford protein microassay (see Appendix B).  Nanotube concentration was 
determined by measuring the absorbance at 800 nm using a BioTek Synergy HT 
microtiter plate reader and comparing the results to a standard curve developed by 
sonicating a nanotube suspension for 1 h and making dilutions without centrifuging.  It 
was assumed that 100% of the nanotubes were in suspension.   
SWNT-F3 Cell Binding Using Fluorescence and Confocal Microscopy 
 The SWNT-F3 conjugate is expected to bind to the nucleolin receptor on the 
surface of dividing endothelial cells and cancer cells and become internalized.  Cells 
were plated into chambered slides at 80–85% confluence.  During conjugation 
procedure, all steps were done wrapped in foil to protect the FITC attached to the F3 
peptide from exposure to light.  The SWNT-F3 conjugate was diluted to 60 mg/L 
(nanotube concentration) in cold cell medium and incubated with the cells for varying 
times at 37oC.  Cells were washed, the chamber was removed, a drop of Fluoro-gel was 
placed on the cells, and a coverslip was applied.  Alternatively, 35 mm petri dishes have 
been used with 22 mm square coverglasses with the cells seeded on top.  The coverglass 
would be removed from the petri dish after the protein binding, Fluoro-gel applied, and 
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then flipped over onto a microscope slide.  A Nikon Eclipse E800 fluorescence 
microscope with a Nikon DXM1200F digital camera was used to document FITC 
fluorescence on the cells.  To prove the SWNT-F3 conjugate was internalized, cells 
were stained with 7.5 µg/ml CellMask deep red plasma membrane stain for 30 min at 
37oC, washed, and fixed with formalin.  Fluoro-gel was used to preserve the 
fluorescence signal for viewing under an Olympus Fluoview laser scanning microscope.   
Cytotoxicity of Varying Length SWNT-F3 Conjugates with NIR Laser 
 Endothelial and MCF-7 cells were grown and plated at ~80% confluence in 24-
well plates (see Appendix B for the layout of plates) in a manner that prevents the use 
of adjacent wells.  Cells were incubated for 24 h at 37oC to allow firm attachment to the 
plates.  The varying length SWNT-F3 conjugates was diluted to 60 mg/L in cold cell 
medium, added to the wells, and incubated for 2, 8, 16, and 24 h at 37oC.  Cells were 
washed with medium and irradiated with a Diodevet-50 Laser (B&W TEK, Inc., 
Newark, DE).  Previous work in the lab determined that MCF-7 cells can be irradiated 
at 350 J/cm2.  All cell plates were incubated at 37oC for 1 h following the laser before 
measurement of cell viability using the Alamar Blue assay (as above).  Fresh medium 
was replaced in the wells and the cells were incubated for another 13 h, at which time 
another Alamar blue assay was done.  The complete protocol for the treatment with the 
laser is given in Appendix B.   
Data Analysis 
 Dissociation constant determination was done using GraphPad software 
(GraphPad, La Jolla, CA).  In vitro cytotoxicity and in vivo tumor volumes were 
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compared using a one-way ANOVA employing a Tukey-Kramer multiple comparisons 
test was performed using GraphPad InStat software.     
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4.  RESULTS AND DISCUSSION 
Construction of Cytosine Deaminase-Annexin V Fusion Gene 
 The cytosine deaminase-annexin V fusion gene was successfully produced using 
PCR.  The template pQE30Xa/CD was used to clone the cytosine deaminase gene, 
while annexin V was from pET-22b(+)/STF-ANX.  Primers were synthesized to add 
useful features to assist in the cloning, ligation, and annealing process.  The 
amplification of cytosine deaminase added an N-terminal ligation independent cloning 
site (LIC) and an engineered protease site, while a BamHI restriction enzyme site was 
added to the C-terminal.  Annexin V had a BamHI site added to its N-terminal and a 
LIC site to the C-terminal. Figure 4.1A shows an agarose gel following the PCR 
amplification of cytosine deaminase and annexin V genes with the additions mentioned 
above.  The sizes of the annexin V and cytosine deaminase genes (988 and 524 base 
pairs, respectively) are consistent with the sizes of the PCR fragments shown in Figure 
4.1A.  Both genes were digested with the BamHI restriction enzyme for 1 at 37oC to 
create compatible ends, which were fused together for 10 min at room temperature 
using T4 DNA ligase.  Figure 4.1B presents the results of the ligation reaction.  The 
genes for cytosine deaminase-annexin V (1449 base pairs), cytosine deaminase-cytosine 
deaminase (~1040 base pairs), and annexin V-annexin V (~1980 base pairs) were 
observed following the ligation.  The cytosine deaminase-annexin V gene was extracted 
from the gel and purified using the Qiaquick agarose gel purification kit (see Appendix 
B).  Purified product was treated with T4 DNA polymerase to create sticky ends and 
annealed to the linear pET-30 Ek/LIC vector.  E. coli NovaBlue GigaSingles were 
transformed with the plasmid for amplification.  An overnight culture was done, and the 
plasmid was extracted using the QIAprep spin mini-prep protocol (see Appendix B).  
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Plasmid samples were sent for sequencing, and results for the cytosine deaminase-
annexin V sequence are presented in Appendix A.  No mutations were found in the 
sequence. 
 For the correct protein to be produced by the plasmid, the proper DNA reading 
frame must be maintained following the insertion of the fusion gene into the vector.  
The pET cloning system makes this easy since both LIC sites have distinctive 
complementary overhangs following treatment with the T4 DNA polymerase, which 
results in only one direction of gene insertion.  The polymerase uses its 3’ -> 5’ 
endonuclease activity to remove bases on each side of double-stranded DNA until it 
reaches a dATP base (the kit provided contains dATP bases for use in creating sticky 
ends).  The polymerase activity then adds the dATP base to leave an overhang of single-
stranded DNA.  Insertion of the cytosine deaminase-annexin V fusion gene into the 
vector was efficient and required only one attempt. 
Site-Directed Mutagenesis of L-Methioninase-Annexin V  
 It was determined that the methioninase-annexin V gene that was constructed 
previously in the lab [99] contained point mutations within the sequence, with one 
mutation in methioninase (arginine 326) and the other in annexin V (phenylalanine 11).  
Before continuing in vitro experimentation, site-directed mutagenesis was performed 
using the Quikchange II XL site-directed mutagenesis kit, which employs PCR with 
new primers designed to incorporate the correct base.  Parental pET-30 
Ek/LIC/METHANX was digested using 10 U of Dpn I enzyme for 1 h.  The remaining 
plasmid in solution was used to transform E. coli XL10-Gold ultracompetent cells.  
Blue colonies were observed on the agar plates containing IPTG and X-gal after at least 
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16 h at 37oC.  Several colonies were chosen for sequence analysis following a mini-prep 
plasmid preparation.  The sequence was found to be correct after the site-directed 
mutagenesis (see Appendix A).   
 The Dpn I enzyme is able to recognize the parental plasmid in the PCR 
mutagenesis reaction because the plasmid has been methylated during replication in E. 
coli [100].  PCR does not have the ability to methylate plasmids, so the Dpn I will leave 
the mutated plasmid unharmed.  Methylation of E. coli has been discussed previously 
[101].   
Fusion Protein Expression, Purification, Analysis, and Storage 
 E. coli BL21(DE3) cells were transformed with the pET-30 Ek/LIC/CD-Anx or 
pET-30 Ek/LIC/METHANX plasmids to serve as the bacterial host for fusion protein 
expression.  Cells were grown at 37oC in either 250 ml or 4 L flasks using 1 L of LB 
culture medium containing yeast extract, salt, and tryptone.  The temperature was 
lowered to 30oC and IPTG (0.4 mM final concentration) was added to induce the 
expression of cytosine deaminase-annexin V or methioninase-annexin V for 5 h.  Cells 
were harvested, lysed by sonication, and the soluble proteins were collected in the 
supernatant after centrifugation.     
 IPTG binds to the repressor in the lac operon, which inactivates it and allows 
gene expression to proceed.  Induction at 37oC resulted in the majority of fusion protein 
expression to be contained in inclusion bodies.  However, when the temperature was 
lowered to 30oC, both cytosine deaminase-annexin V and methioninase-annexin V were 
expressed in soluble form.    
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 The (His)6 tag added to the N-terminal of both fusion proteins enabled 
immobilized metal affinity chromatography (IMAC) to be used to purify the fusion 
proteins with a nickel HisTrap HP column.  Applying the soluble protein fraction to the 
column allowed the fusion protein to bind to the column and unwanted proteins were 
washed out.  A wash of the column with a buffer containing Triton X-114 was 
performed to remove endotoxin associated with the fusion protein.  The application of a 
high concentration of imidazole eluted the fusion proteins by displacing the (His)6 tag 
bound to the nickel column.  Following dialysis to remove NaCl and imidazole, the 
(His)6 tag was cleaved off using 10 U/mg of HRV 3C protease for 16 h at 4oC.  The 
cleaved protein solution was applied to the regenerated column where only uncleaved 
protein and protease bound.  The flow-through was collected, dialyzed, and sterile-
filtered.  Aliquots were flash frozen in liquid nitrogen in preparation for freeze-drying. 
 Table 4.1 shows a summary of a typical purification from a 1 L culture.  Each 
peak was pooled together, and samples were taken after each step throughout the 
purification process for analysis of protein and enzymatic activity.  A typical 
chromatograph of the chromatography portion of the purification is given in Appendix 
A is given in Appendix A.  Figure 4.2 is an SDS-PAGE gel image with Coomassie blue 
staining showing the purification of the methioninase-annexin V fusion protein at 
different stages.  Lane 1 represents the total soluble protein lysate.  Lanes 2 and 3 are 
the unwanted protein flow-through and the eluted methioninase-annexin V, 
respectively.  Lane 4 corresponds to methioninase-annexin V that has been cleaved with 
the HRV 3C protease.  Figure 4.3 is an SDS-PAGE gel for cytosine deaminase-annexin 
V purification with the same samples as methioninase-annexin V.   
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Figure 4.2.  SDS-PAGE of methioninase-annexin V. Coomassie blue 
was used to stain the gel. Lane 1, total soluble cell lysate; lane 2, 
unwanted flow-through; lane 3, eluted methioninase-annexin V; lane 
4, methioninase-annexin V with the (His)6 tag removed. 
Figure 4.3.  SDS-PAGE of cytosine deaminase-annexin V. Coomassie 
blue was used to stain the gel. Lane 1, total soluble cell lysate; lane 2, 
unwanted flow-through; lane 3, eluted cytosine deaminase-annexin V; 
lane 4, cytosine deaminase-annexin V with the (His)6 tag removed. 
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 Previous work regarding freezing and storing of proteins was done by Naveen 
Palwai [99] in the laboratory.  The buffer used most often throughout the purification is 
20 mM sodium phosphate, and a different fusion protein containing methioninase, ATF-
methioninase, was shown to retain 69% of its activity following flash freezing in that 
buffer.  It was hypothesized that small ice crystals were formed during flash freezing, 
which came into contact with the protein to cause denaturation.  The addition of 100 
mM NaCl resulted in a loss of only 6% when flash frozen and an additional 7% after 
freeze-drying.  This is believed to be caused by a reduction of ice crystal interaction 
with the protein [102].  Because of this, both methioninase-annexin V and cytosine 
deaminase-annexin V proteins were stored in 20 mM sodium phosphate and 100 mM 
NaCl.  Both enzymes retained nearly all activity for at least 3 months when stored in a 
freezer at -80oC as lyophilized powder. 
Specific Fusion Protein Binding to Endothelial and Cancer Cells In Vitro 
 The ability of the fusion proteins to bind to endothelial cells and breast cancer 
cells with PS exposed on the cell surface was evaluated by equilibrium binding 
experiments in which increasing concentrations of biotinylated fusion protein were 
used. In initial experiments with endothelial cells, hydrogen peroxide was used at a low 
concentration (1 mM) to induce exposure of PS.  In later experiments, the H2O2 was 
omitted with little change in the results; therefore, the data reported here is with no 
H2O2 added.  No H2O2 was added in the experiments with the breast cancer lines, since 
it has been reported that cancer cells express PS in vitro [103, 104].  A typical 
equilibrium binding result is shown in Figure 4.4 for the binding of methioninase-
annexin V to endothelial cells.  The non-specific binding, obtained in the absence of  
58 
 
 
 
 
 
 
 
 
 
 
 
59 
 
Ca2+, was subtracted from the total binding to obtain the specific binding. The 
dissociation constant (Kd) for each cell line tested was obtained from the specific 
binding data using GraphPad Prism 5 software to give the following results for 
methioninase-annexin V: 0.5 ± 0.2 nM for endothelial cells (with saturation A450 nm = 
1.3), 6.2 ± 1.6 nM for MCF-7 breast cancer cells (with saturation A450 nm = 0.9), and 4.9 
± 0.9 nM (with saturation A450 nm = 1.8) for MDA-MB-231 breast cancer cells.  
Similarly, cytosine deaminase-annexin V binding results were the following: 1.5 ± 0.2 
nM for the endothelial cells (with saturation A450nm = 0.6), 0.6 ± 0.4 nM for MCF-7 
cells (with saturation A450nm = 0.5), and 4.2 ± 1.8 nM (with saturation A450nm = 1.2) for 
MDA-MB-231 cells.  An equilibrium binding result for the binding of cytosine 
deaminase-annexin V to endothelial cells is shown in Appendix A.  These results 
indicate that the binding of the fusion proteins to these cells is relatively strong. In a 
control test, the specific binding assay was performed on endothelial cells that were 
100% confluent. The result was that the total and non-specific data were essentially 
identical, indicating no specific binding.  The binding of annexin V to endothelial cells 
was determined using the same procedures.  The Kd for the specific binding data was 
found using GraphPad Prism 5 software to be 0.9 ± 0.2 nM (with saturation A450 nm = 
1.2), which is similar to the Kd determined for the binding of the fusion proteins to 
endothelial cells. Literature values of annexin V binding alone to endothelial cells have 
been reported from 2.7–15.5 nM [105, 106]. 
 The low Kd values for the endothelial cells is favorable for these enzyme 
prodrug systems because they are primarily directed to the tumor vasculature.  The fact 
that the fusion proteins exhibit the same degree of binding to endothelial cells with or 
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without hydrogen peroxide leads us to believe that endothelial cells grown in vitro by 
our techniques expose PS on their surface. It has been shown previously in tumor-
bearing mice that PS is exposed on the external surface of vascular endothelial cells in 
tumor blood vessels but not on endothelial cells outside of the tumor; this was 
demonstrated using biotinylated annexin V [25, 26].  When endothelial cells were 
grown to confluence, no specific binding was observed, meaning there was a lack of PS 
expression on the cell surface.  Normal vasculature does not express PS, as proven by 
the lack of biotinylated annexin V binding to endothelial cells in healthy tissue [25, 26].  
The strength and specificity of binding of annexin V not part of a fusion protein to 
endothelial cells is very similar to that of the fusion proteins using the same procedures; 
therefore, there is no reason to believe that the fusion proteins will bind with any 
different strength or specificity in vivo compared to annexin V.   
 As further evidence of the fusion proteins binding to exposed PS on the surface 
of cells, MDA-MB-231 cells were incubated with FITC-labeled methioninase-annexin 
V or cytosine deaminase-annexin V.  Figure 4.5 shows a light microscopy image (left) 
of MDA-MB-231 cells and a fluorescence microscopy image (right) of cytosine 
deaminase-annexin V bound to the cell surface.  As hypothesized, the fusion protein 
remains on the cell surface after binding to exposed PS on the surface.  Similar 
experiments with endothelial cells showed fluorescence only at the cell surface when 
they were 70-80% confluent, but no fluorescence was observed when endothelial cells 
were 100% confluent.  This indicates binding of the fusion proteins and thus no 
expression of PS on the surface of the cells.   
 The stability of both fusion proteins binding to the cell surface was determined  
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and used to design cytotoxicity experiments.  Fusion protein bound per cell was studied 
over 3 days for the three cell lines by measuring the absorbance at 450 nm, determined 
by the binding assay, and dividing by the fluorescence at 590 nm, determined by the 
Alamar Blue assay.  Figure 4.6 indicates that binding methioninase-annexin V declined 
over 3 days for all three cell lines, with the MDA-MB-231 cancer cells showing the 
most rapid decline; however, the fusion protein was still present at day 3 for all three 
cell lines.  Similar results were obtained for the cytosine deaminase-annexin V fusion 
protein (see Appendix A).  Cell viability, as measured by the Alamar Blue assay, was 
found to be linearly proportional to the number of cells. 
Cytotoxicity of Methioninase-Annexin V + Selenomethionine In Vitro 
 The ability of the enzyme prodrug system to eliminate human endothelial cells 
and breast cancer cells was evaluated using a saturating concentration (100 nM) of 
methioninase-annexin V, followed by concentrations of selenomethionine ranging from 
0 to 1000 µM (Figures 4.7, 4.8, 4.9).  The methionine concentration in the medium was 
set at a level (1000 µM) that would not lead to a significant decrease in cell viability 
because of methionine depletion with methioninase-annexin V present.  Each of the cell 
lines metabolized the Alamar Blue reagent to produce a fluorescence that was measured 
to quantify total cell viability.  The fluorescence data from the Alamar Blue assay was 
expressed as a percentage of the fluorescence for the cells with no methioninase-
annexin V and 0 µM selenomethionine (control).  Cells that were treated with different 
selenomethionine concentrations but no methioninase-annexin V were compared to the 
control on the same day, whereas cells that had methioninase-annexin V were compared  
to cells with the same selenomethionine concentration but no methioninase-annexin V 
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on the same day.   
 The cytotoxicity results for the endothelial cells are shown in Figure 4.7.  
Treatment with methioninase-annexin V gave significant cell killing for 500 and 1000 
µM selenomethionine on days 1–3 (p < 0.001).  With no methioninase-annexin V 
present, significant cell cytotoxicity was not observed at the levels of selenomethionine 
tested.   
 Cytotoxicity results for the two breast cancer cell lines are shown in Figure 4.8 
and 4.9.  For MCF-7 cells with FP present, there was significant killing at days 2 and 3 
with 50–1000 µM SeMet (Figure 4.8, p < 0.001).  Cell killing without FP present was 
not significant on day 3 until the SeMet concentration reached 1000 µM.  MDA-MB-
231 cells showed a greater sensitivity to the SeMet than MCF-7 and endothelial cells 
(Figure 4.9); significant cell cytotoxicity was observed with the FP present on days 1–3 
with 10–1000 µM SeMet (p < 0.001).  Even without the addition of the SeMet, binding 
of the FP alone produced significant cell killing.  With no FP present, cell killing did 
not occur until the SeMet level was 1000 µM and was relatively small and not 
statistically significant (p < 0.001). 
 In an attempt to remove what was thought to be methionine depletion-related 
cell death with methioninase-annexin V and 0 µM selenomethionine, an experiment was 
done adding up to 20,000 µM methionine for MDA-MB-231 cells.  A steady decline in 
cell viability was observed as the level of methionine increased for the 2 days of the 
experiment after the addition of the extra methionine (Figure 4.10).  Methionine 
toxicity is believed to be contributing to the cell death, but has not been confirmed.  
 The effectiveness of the enzyme in the methioninase-annexin V during the test  
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period is reinforced by the cytotoxicity data for the endothelial cells and breast cancer 
cell lines (Figures 4.7, 4.8, and 4.9) for the selenomethionine concentrations at which 
there was a statistically significant decline in cell viability compared to the same 
selenomethionine concentrations with no methioninase-annexin V present on the same 
day (indicated by a *); for this data there was in almost every case a decline in cell 
viability from days 1 to 2 and from days 2 to 3.  The medium for the cells was changed 
at days 1 and 2, meaning the enzyme would have to produce additional methylselenol 
for more cells to be killed; if additional methylselenol were not produced, then no 
methylselenol would be present (since the medium was changed), and additional cell 
killing would likely not occur.   
 In the enzyme prodrug test of cytotoxicity for the endothelial cells, which are the 
primary target in the tumor for this enzyme prodrug therapy, the cytotoxic effect was 
evident after only one day of treatment at 500 µM selenomethionine. At either 500 µM 
or 1000 µM selenomethionine, there was no effect on endothelial cell viability with no 
methioninase-annexin V present; this indicates that endothelial cells in the normal 
vasculature, which will not bind to the methioninase-annexin V (since PS is not 
externalized), will not be affected by these concentrations of selenomethionine.  At 
selenomethionine concentrations well below 500 µM, however, the cancer cells will be 
killed by toxic methylselenol being carried across the artery wall by fluid permeation; 
the effect of methylselenol on normal cells outside of the tumor is expected to be 
minimal or none because it will be greatly diluted by the bloodstream before it reaches 
the normal cells.  MDA-MB-231 breast cancer cells were found to be the more sensitive 
to the enzyme prodrug treatment than MCF-7 breast cancer cells, even producing killing 
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when the methioninase-annexin V was bound but no selenomethionine prodrug was 
added.   
 We have not found evidence that the sensitivity of the three cell lines to the 
enzyme prodrug treatment is dependent on the degree of exposure of PS on the cell 
surface.  The saturation A450 values measured in the methioninase-annexin V binding 
assay, which are a measure of the amount of methioninase-annexin V bound to PS, do 
not correlate with the sensitivity to the enzyme prodrug treatment indicated.  Therefore, 
other cell properties besides the degree of PS exposure are contributing to the sensitivity 
to the effect of methylselenol. 
Cytotoxicity of Cytosine Deaminase-Annexin V + 5-Fluorocytosine In Vitro 
 Cell viability was determined on days 3, 6, and 9 to demonstrate the cytotoxic 
effects of 5-FC, with or without cytosine deaminase, against human endothelial cells 
and breast cancer cells (Figures 4.11, 4.12, and 4.13).  In addition, treatment with 
commercially available 5-fluorouracil was performed.  The viability data is presented as 
the percentage of fluorescence produced relative to control samples (no cytosine 
deaminase-annexin V and 0 µM 5-fluorocytosine). All of the experimental groups were 
compared to the control for that day (no cytosine deaminase-annexin V and the same 5-
fluorocytosine or 5-fluorouracil concentration).  For all three cell lines, no significant 
cell death was found with 5-fluorocytosine present and cytosine deaminase-annexin V 
absent, or with 5-fluorocytosine absent but cytosine deaminase-annexin V present.   
 For the endothelial cells (Figure 4.11), there was negligible cell killing in the 
first 3 days of the experiments; however, significant killing (p < 0.001) was observed on  
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day 9 for cells with cytosine deaminase-annexin V plus 5-fluorocytosine and on days 6 
and 9 for cells with 5-fluorouracil.  Killing was observed to be dose-dependent.   
 The breast cancer cell lines exhibited similar patterns of cell death.  Both MCF-7 
(Figure 4.12) and MDA-MB-231 (Figure 4.13) cells receiving the cytosine deaminase-
annexin V plus 5-fluorocytosine showed significant cell killing that was dose-
dependent, compared to the control group, on days 3, 6, and 9 (p < 0.001).  By day 9, 
treatment with the cytosine deaminase-annexin V plus 5-fluorocytosine resulted in less 
than 10% viability at 500 µM 5-fluorocytosine for MCF-7 cells and at 1000 µM 5-
fluorocytosine for MDA-MB-231 cells.  As for the endothelial cells, the combination of 
5-fluorocytosine and the cytosine deaminase-annexin V gave less cytotoxicity than with 
5-fluorouracil directly at the same 5-fluorocytosine concentration and incubation time. 
 Comparison between the efficacy of the enzyme prodrug treatment and 5-
fluorouracil at the same concentration as 5-fluorocytosine resulted in higher toxicity 
with 5-fluorouracil alone (Figures 4.11, 4.12, 4.13).  This finding is consistent with 
other reports comparing drug and prodrug toxicity [92, 107].    
Pharmacokinetics of Methioninase-Annexin V in Mice 
 The relatively small size of the methioninase-annexin V fusion protein (~316 
kDa) allows for rapid diffusion into the bloodstream following i.p. injection.  A 
pharmacokinetics test was done by injecting NU/J mice (n = 4/dosage/time point) with 
1 and 10 mg/kg of biotinylated methioninase-annexin V.  After 1, 4, 8, and 24 h post-
injection, a blood sample was extracted from each mouse by cardiac draw.  Mice that 
did not receive methioninase-annexin V were used as the control.  The serum was 
collected and flash frozen for analysis after all samples were taken.   
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 An ELISA was used to determine the time required for clearance from the 
bloodstream.  Serum samples were incubated for 1 h at 37oC in streptavidin-coated 
plates.  A rabbit polyclonal antibody against annexin V was added to bind 
methioninase-annexin V and incubated for 1 h at 37oC.  The amount of fusion protein 
binding was then determined by adding an anti-rabbit IgG secondary antibody 
conjugated to horseradish peroxidase (1 h at 37oC) and developing with the 
chromogenic substrate OPD (Figure 4.14).  Both 1 and 10 mg/kg doses were detected 
in the bloodstream after 1 h of circulation, with the concentrations falling to near 
undetectable levels at 4 h and complete clearance by 8 h.  The results of this experiment 
were used to design the experimental design of treating mice with MDA-MB-231 breast 
tumors using methioninase-annexin V and selenomethionine. 
Selenomethionine Toxicity in Mice 
 Methylselenol is known to be 200 times more toxic to various cancer cells than 
selenomethionine [36].  To determine a selenomethionine dosage level that can be used 
for the treatment of MDA-MB-231 breast tumors, NU/J mice (n = 6/dosage level) were 
injected i.p. with selenomethionine ranging up to 60 mg/kg every 24 h for three 
consecutive days.  After only one dose, all mice receiving 60 mg/kg were found dead, 
indicating severe toxicity.  At 24 mg/kg, only one mouse survived the injections but 
appeared sick, had noticeable behavioral changes, and lost significant weight.  
However, all mice receiving either 6 or 12 mg/kg selenomethionine survived a week of 
post-injection observation and did not show any signs of changed behavior or 
movement, with only minimal weight-loss that was recovered after the injections ended.   
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Detection of Exposed Phosphatidylserine in Tumor Vasculature in Mice 
 Annexin V is known to bind to exposed PS on the surface of endothelial cells 
and cancer cells.  This was demonstrated by Ran et al. [25] in mice bearing MDA-MB-
231 xenografts using biotinylated annexin V.  Similarly, SCID mice bearing MDA-MB-
231 tumors were injected i.p. with 10 mg/kg of biotinylated methioninase-annexin V.  
At 1 h post-injection, their circulation was perfused with heparinized saline with 
calcium and by glutaraldehyde.  Tumors were removed and stored in sucrose in 
preparation for cryosectioning at OMRF.  Streptavidin-HRP was used to bind to any 
biotinylated methioninase-annexin V, and bound streptavidin-HRP was developed with 
DAB substrate to produce a dark brown image.  Figure 4.15 shows a stained section of 
the MDA-MB-231 tumor.  The presence of activated DAB is shown on the perimeter of 
a blood vessel within the tumor tissue.  This experiment was done to demonstrate 
annexin V has retained its ability to bind to PS in vivo as part of a fusion protein and 
allows the presentation of methioninase at the blood vessel surface.  This allows for the 
rapid conversion of selenomethionine upon intravenous administration into toxic 
methylselenol.  The methylselenol will act on the endothelial cells and also penetrate 
into the tumor parenchyma via permeation and diffusion.   
Biodistribution of Methioninase-Annexin V in Mice 
 Methioninase-annexin V is expected to bind to PS that is exposed by tumor 
vascular endothelial cells and tumor cells.  To detect the location of methioninase-
annexin V after i.p. injection, three mice with MDA-MB-231 tumors were injected with 
the fusion protein labeled with DyLight 680 red fluorescent dye.  After 1, 12, and 24 h 
post-injection, the mice were imaged using the IVIS Spectrum small animal imaging  
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system looking for the GFP signal from the tumor cells and the red signal from 
methioninase-annexin V.  After the final images were acquired, the tumor, heart, lungs, 
liver, kidneys, and spleen were removed and imaged ex vivo to detect the DyLight 680 
signal.   
 Figure 4.16 shows the three mice at 1 h (A), 12 h (B), and 24 h (C) post-
injection.  In Figure 4.16A, it appears that the fusion protein has not diffused away 
from the site of injection in one mouse, but the other mice show a systemic signal 
indicating the methioninase-annexin V made it into the bloodstream.  Figure 4.16B 
shows one mouse has a very weak signal signifying near complete clearance of the 
fusion protein, while the others show a vibrant red signal near the tumor region, near the 
bladder, and in the tail.  At 24 h, all mice once again have a bright signal near the tumor 
region and a signal near the bladder (Figure 4.16C).  The red signal coming from above 
the tumor appeared to represent the spleen, however, after resection of the organs, no 
DyLight 680 signal was observed from any of the tissues collected.  It is possible that 
the injected protein contained free DyLight 680 even though an extensive dialysis was 
done with two buffer changes following protein labeling.  The GFP signal was easily 
detectable ex vivo and only coming from the tumor sample.   
MDA-MB-231 Breast Tumor Treatment with Methioninase-Annexin V Plus 
Selenomethionine in Mice 
 NU/J mice were initially used to test the efficacy of the methioninase-annexin V 
enzyme prodrug system.  Tumor formation of MDA-MB-231 cells expressing GFP 
appeared to be normal, indicating treatment needed to begin.  The experimental 
treatment design consisted of three cycles, with each cycle beginning with an injection  
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of methioninase-annexin V (10 mg/kg), followed by a 2-week observation period.  
Based on the pharmacokinetics data, a minimum of 8 h was allowed for unbound 
methioninase-annexin V clearance, followed by three consecutive injections of 
selenomethionine (10 mg/kg) every 24 h.  Figure 4.17 shows the results of the 
treatment and observation of period of the NU/J mice.  Noticeably, the tumors in the 
treatment group steadily declined in volume; however, the tumors in the control groups 
only maintained similar sizes but did not grow, except for tumors in the 
selenomethionine group that grew after 67 days post-inoculation.  Two mice in the 
selenomethionine group and one in the treatment group died during the treatment 
period.  For each methioninase-annexin V and selenomethionine injection, each group 
was weighed.  The average group weight was used to determine the injection dose for 
those mice, presumably the reason for the dead mice, since some of the mice actually 
received more than 10 mg/kg selenomethionine.  The stagnant growth of the tumors was 
hypothesized to be because the cells inoculated had been passaged too long and had lost 
their tumorigenicity.  New MDA- MB-231 cells expressing GFP were purchased to 
repeat the study.  The new cells produced inconsistent formation in the NU/J mice as 
only 4 of 26 mice developed stable tumors.  It is unclear why the tumors were not 
forming as expected. 
 Before more treatment experiments were done, it was necessary to find a mouse 
model that would allow for consistent, repeatable MDA-MB-231 tumor development.  
In addition to NU/J, SCID and athymic nude (NU/NU) mice were tested (n = 3).  As 
shown in Figure 4.18A, NU/J and athymic nude mice did not form stable tumors; 
however, all three SCID mice developed large tumors in 25 days.  IVIS Spectrum  
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images taken of the SCID mice showed the presence of GFP signal, confirming the 
MDA-MB-231 cells were alive and growing at day 25 (Figure 4.18B), while NU/J and  
NU/NU mice showed no GFP.  Based on this result, SCID mice were used for the 
remaining tests in vivo.   
  Pharmacokinetics and selenomethionine dosage experiments were initially done 
using NU/J mice and needed to be confirmed in SCID mice.  The experimental design 
calls for the injection of methioninase-annexin V in the afternoon and selenomethionine 
the following mornings, an average of 14 h later.  The ELISA assay was repeated using 
SCID mouse blood samples (n = 3) taken 14 h after the injection of biotinylated 
methioninase-annexin V.  No difference in signal was observed for the 14 h sample 
compared to a blank sample.  The prodrug toxicity study was done with three SCID 
receiving 10 mg/kg of selenomethionine for three consecutive days, 24 h apart.  The 
mice tolerated the selenomethionine with no behavioral changes. 
 For the enzyme prodrug study using SCID mice (n = 7 per group), the MDA-
MB-231 cells were injected, and all tumors developed as expected.  When the tumors 
began to increase in size, the IVIS imaging system was used, and the GFP signal was 
documented for all mice, indicating living MDA-MB-231 cells.  The treatment was 
done as described above with mice on a normal chow diet, and the results are presented 
in Figure 4.19.  The tumors in mice receiving methioninase-annexin V and 
selenomethionine reduced in size throughout the treatment period, while mice receiving 
no treatment, methioninase-annexin V, or selenomethionine only steadily increased.  
One mouse in the selenomethionine group died during the treatment period.  All mice in 
the treatment group tolerated the selenomethionine, presumably because the  
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selenomethionine was converted to methylselenol and did not build up in tissue.  During 
the 2-week observation period, mice in the treatment group showed tumor regrowth, 
indicating that all the cancer cells were not killed.  Still, tumors in the treated group 
were only a third of the size of the control groups.  Histological analysis of three mice 
per control group and all seven treated mice revealed there were no metastatic legions 
found in lungs or liver of any of the mice (see Appendix A for the complete pathology 
report).       
 From the data in Figure 4.19, it is apparent that the enzyme prodrug treatment 
did not kill all of the tumor cells.  This could have occurred because the period of 
hypoxia was not long enough or because the duration of exposure to the methylselenol 
generated was not long enough.  Also, some tumor cells still alive at the end of the 3-
day selenomethionine treatment could have regrown during the day of treatment with 
the fusion protein, when no methylselenol is being produced.   
 Methionine dependence in cancer cells has been well-documented [32, 108].  
The methioninase enzyme has the ability to convert selenomethionine; additionally, 
methionine required for protein production and sustained cancer cell proliferation is 
cleaved.  While healthy cells are able to produce methionine for protein synthesis from 
its precursor homocysteine, cancer cells typically express below normal levels of the 
enzyme methionine synthase that is responsible for making methionine from 
homocysteine [33, 34].  To determine the therapeutic potential of the enzyme prodrug 
therapy with reduced methionine available, a diet containing no methionine replaced the 
normal mouse chow was used.  The experimental design was similar to that above, with 
methioninase-annexin V fusion protein administered at 10 mg/kg, but the 
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selenomethionine dosage was cut in half (5 mg/kg).  The mice were placed on a 
methionine-deficient diet supplemented with D,L-homocysteine 24 h prior to the start of 
treatment.  The selenomethionine dosage was reduced for two reasons: 1) to prevent 
unwanted selenomethionine-related toxicity, and 2) the methionine-deficient diet had 
previously been shown to cause reversible weight loss in mice [109], as has the 
selenomethionine in control mice (data not shown).   
 Figure 4.20 shows the tumor volume curves obtained throughout the treatment 
and observation period.  As expected, the methioninase-annexin V plus 
selenomethionine treatment resulted in a significant reduction in tumor growth 
compared to the untreated control.  During the treatment period, the size of the tumors 
in the group of mice receiving the enzyme prodrug treatment increased slightly, and 
there was regrowth of the tumors after the end of the treatment.  When the tumor 
volumes of the control group required the mice to be sacrificed (tumor weight was 
~10% of body weight), the average size of the tumors in the group treated with 
methioninase-annexin V and selenomethionine was 42% of that in the control group, 
which is similar to what was found in the study with mice on a normal diet.  In addition, 
although not significant, methioninase-annexin V only showed an effect during the 
treatment period, but its efficacy did not last after the conclusion of the therapy. 
 Significant attention has been given to enzyme prodrug systems as potential 
therapeutic strategies for cancer.  As shown in Figures 4.19 and 4.20, the combination 
of methioninase-annexin V and selenomethionine leads to a significant inhibition of 
tumor growth compared to those untreated.  These findings are consistent with other 
enzyme prodrug systems, which inhibit tumor growth during treatment, but fail to kill  
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all malignant cells, which results in tumor regrowth.  Vrudhula et al. [110] used a 
monoclonal antibody to target β-lactamase in a lung adenocarcinoma model.  A 
cephalosporin prodrug was used to generate toxic cephalosporin mustard, which was 
shown to inhibit lung tumor growth by roughly 60%.  A different type of mustard drug 
developed by carboxypeptidase G2 was compared to treatment with 5-fluorouracil and 
showed complete tumor regression in a colorectal model, but tumor regrowth was 
eventually observed [111].  Other groups have shown different enzyme prodrug 
combinations can cause prolonged tumor growth inhibition [112, 113], including a 
therapy targeting cytosine deaminase to colon cancer with 5-fluorocytosine prodrug 
[114].   
Tumor Blood Flow Interrupted After Methioninase-Annexin V + Selenomethionine 
Treatment 
 The methylselenol generated by the conversion of selenomethionine by L-
methioninase at the surface of the endothelial cells in the tumor vasculature will cause 
destruction of these cells, which leads to clotting in the tumor vasculature and a cutoff 
of the supply of oxygen to the tumor.  To test this hypothesis, SCID mice with MDA-
MB-231 tumor xenografts underwent the standard three-cycle treatment of 
methioninase-annexin V (10 mg/kg) and selenomethionine (10 mg/kg).  The day after 
treatment concluded, untreated and treated mice (n = 3) were injected i.p. with DyLight 
680 fluorescent dye at 1 mg/kg.  The dye was allowed to circulate for 1 h followed by 
imaging with the IVIS Spectrum system.  Figure 4.21 contains images from untreated 
(4.21A) and treated (4.21B) mice, in which the DyLight 680 signal was spectrally 
unmixed using the IVIS Spectrum’s Living Image software.  The outline of the GFP  
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Figure 4.21.  Interruption of blood flow through tumor vasculature. 
Female SCID mice were injected with DyLight 680 red fluorescent 
dye the day after the completion of the three-cycle enzyme prodrug 
treatment with methioninase-annexin V and selenomethionine. The 
outline of the GFP signal showing the living tumor cell perimeter is in 
green. Mice were either untreated (A) or treated with methioninase-
annexin V (B) to compromise tumor vasculature.   
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signal showing the living tumor cell perimeter is in green on both figures.  Untreated 
mice showed significant red fluorescence in the tumor area, indicating blood flow 
through the tumor vasculature, while treated mice showed much less red fluorescence, 
indicating a lack of blood in the tumor region.  This suggests that treated mice had 
compromised tumor vasculature resulting from the production of methylselenol from 
selenomethionine.  The black hole on the left side of the mice in Figure 4.21B is the 
tumor void of blood flow.  The area of the untreated tumor was 100% red fluorescence, 
while that in the treated tumor was 66% fluorescent.  Thus, the percentage of the treated 
tumor tissue receiving blood flow was approximately 66% based on the pictures 
showing red fluorescence.  This result provides significant support of the hypothesis 
that methioninase-annexin V and selenomethionine are able to selectively destroy tumor 
vasculature.     
SWNT-F3 Internalization Confirmed by Fluorescence and Confocal Microscopy 
 F3 peptide was commercially synthesized to contain an N-terminal FITC 
attached to a lysine residue and an extra cysteine residue at the C-terminus.  The 
cysteine was used to react with a maleimide group of a heterobifunctional polyethylene 
glycol linker to create a stable disulfide bond.  The other end of the linker contained a 
DSPE phospholipid that is used to for attachment to SWNTs suspended in 1% sodium 
dodecyl sulfate through hydrophobic interaction.  Appendix A contains a table with 
results of numerous SWNT-F3 conjugate preparations.  SWNT concentrations 
approaching 300 mg/L were observed after the conjugation to F3, giving a final yield of 
nearly 25% of the SWNTs put into the initial suspension.  The absorbance spectra of 
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stable SWNT-F3 conjugate has been described previously in the laboratory [56, 115]. 
Optimizing the conjugation parameters still needs to be done.   
 The F3 peptide is known to be a cell-penetrating peptide that binds to surface 
nucleolin, becomes internalized, and homes to the nuclei of tumor endothelial cells and 
tumor cells.  Following the attachment of F3 to SWNTs, it is believed that the F3 
homing activity will be retained.  Human endothelial cells, used to confirm the 
internalization ability, were seed onto chambered microscope slides, allowed to adhere 
for 24 h, and incubated with SWNT-F3 conjugate for 12 h at 37oC.  The cells were 
washed, stained with CellMask deep red plasma membrane stain, and fixed to the slides 
with formalin.  Fluorescence from FITC and CellMask were verified to be present using 
a Nikon Eclipse E800 fluorescence microscope.  To prove the SWNT-F3 conjugate was 
internalized, the same slides were visualized using an Olympus Fluoview laser scanning 
microscope.  Figure 4.22 shows the fluorescent signals obtained from a scan at the 
center of the cell layer.  Each cell in the image emitted a green signal indicating 
presence of the F3 peptide.  Previous work in the laboratory proved that SWNTs were 
also present inside the cells with a Raman spectra [56, 115].   
Cell Death Induced by SWNT-F3 Incubation and Near-Infrared Light 
 Dividing MCF-7 and 4T1 cancer cells were grown in 24-well plates and 
incubated with 60 mg/L of SWNT-F3 conjugate containing different length nanotubes 
for varying time up to 24 h.  The cells were washed and subjected to photothermal 
treatment using a Diodevet-50 980 nm laser.  Previously, MCF-7 cells were shown to 
handle an energy density of 350 J/cm2 [56, 115], so that energy density was used for the 
tests.  Cell viability results for the test with MCF-7 cells were determined using the  
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Alamar Blue assay on the same cells at 1 h (Figure 4.23) and 18 h (Figure 4.24) after 
the laser irradiation.  Figure 4.23 shows SWNT-F3 conjugates with long nanotubes 
(graph A) showed significant killing with and without the laser at 16 and 24 h of 
incubation, while experiments with short (graph B) and very short (graph C) nanotubes 
showed minimal cell death.  Figure 4.24 shows reduced viability for cells receiving the 
SWNT-F3 conjugate at all nanotube lengths with laser irradiation.  Long nanotubes 
with the laser completely killed the cells, while short and very short nanotubes produced  
~80% cell death.  Mouse mammary tumor cells were found to be much more sensitive 
to the laser irradiation only, significantly reducing the cell viability of cells not treated 
with SWNT-F3.  The data are shown in Appendix A, with short and very short 
nanotubes represented as graphs A and B, respectively.  The uptake of SWNTs by the 
cells is thought to cause cell lysis and could explain the reason for death of cells that 
receive only the SWNT-F3 conjugate.   
 The actual lengths of the long, short, and very short nanotubes have yet to be 
determined, but it was the difficulty of injecting a single-walled carbon nanotube-
annexin V conjugate into the tail vein of mice for a different project that led to 
experimenting with shorter nanotubes.  As can be seen from data obtained by colleague 
Luis Neves (see Appendix A), the absorption peak steadily declines the longer the 
carbon nanotubes are sonicated during preparation of the suspension for the 
conjugation.  The decline in the absorption peak as sonication time increases is likely 
due to the walls of the nanotubes being damaged as a result of collisions.   
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5.  CONCLUSIONS AND FUTURE DIRECTIONS 
 The main objective of this work was to investigate the effectiveness of novel 
cancer therapeutics on two different classes.  First, two enzyme prodrug systems 
(methioninase-annexin V with selenomethionine and cytosine deaminase-annexin V 
with 5-fluorocytosine) were examined for their ability to selectively target 
phosphatidylserine exposed on the surface of endothelial cells and two breast cancer 
cell lines and then induce cell death by the conversion of a specific nontoxic prodrug to 
an active anti-cancer metabolite.  Both systems were tested in vitro followed by in vivo 
testing of methioninase-annexin V with selenomethionine in immunodeficient mice.  
Second, a project using single-walled carbon nanotubes targeted to tumor endothelial 
cells and tumor cells in combination with near-infrared light as a photothermal therapy 
was continued with the ultimate goal of performing in vivo testing. 
 The main conclusions of this research are the following: 
1. Both the methioninase-annexin V and cytosine deaminase-annexin V fusion 
proteins could be produced with a high yield in E. coli and purified to greater than 96% 
purity.   
2. Binding of both fusion proteins to exposed PS on cells was relatively strong, 
giving dissociation constant values in the low nanomolar range. 
3.  A high degree of killing of human endothelial and breast cancer cells was 
achieved by both enzyme prodrug systems in vitro.  Cell killing in the methioninase-
annexin V/selenomethionine system was much faster (by about three times) than in the 
cytosine deaminase/5-fluorocytosine system.  This is probably because the 
methylselenol produced from selenomethionine acts directly to kill cells, while the 5-
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fluorouracil produced from 5-fluorocytosine kills cells by incorporation into DNA and 
RNA and by inhibition of thymidylate synthetase and therefore requires more time. 
4. Tests of the methioninase-annexin V/selenomethionine system in SCID mice 
showed that MDA-MB-231 breast tumor growth could be arrested or greatly slowed but 
tumor growth resumed after the end of the 11 day treatment period.   
5. The two novel fusion proteins were designed to bind to the tumor vasculature, 
where a prodrug could be converted to a drug to attack the tumor vasculature and the 
tumor.  Two experiments validated this hypothesis.  When biotin-labeled methioninase-
annexin V was injected into mice, binding in the tumor was observed on stained tissue 
slides only at the blood vessel surface.  In another experiment in mice with MDA-MB-
231 tumors that had been subjected to treatment with methioninase-annexin 
V/selenomethionine, a red fluorescent dye was injected.  Using an animal imaging 
system, dye was seen throughout the untreated tumor, but substantially less dye was 
observed in the treated tumor.  This confirms a substantial cutoff of blood flowing 
through the treated tumor and means that a substantial degree of hypoxia has been 
created in the treated tumor.   
6. The SWNT-F3 conjugate was shown to be internalized in endothelial cells by 
confocal laser scanning microscopy.  Laser treatment at 980 nm was shown to be 
significantly more effective in killing cells in vitro that previously been incubated with 
the conjugate, compared to cells that had only been incubated with the conjugate.  An 
important finding in these tests is that more than 1 h is needed for the cell killing 
process to take place after the laser treatment. 
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 Future experiments that could be done to increase the efficacy of this enzyme 
prodrug therapy system include:     
1. Increasing the methioninase-annexin V dose beyond 10 mg/kg.  It is unknown if 
the 10 mg/kg dose of methioninase-annexin V saturates all the PS molecules exposed 
by tumor endothelial cells, so increasing the concentration could provide extra 
methioninase enzyme to convert more selenomethionine into toxic methylselenol.  
2. Extending the number of treatment cycles.  Because the enzyme prodrug system 
has been well tolerated, adding more treatment cycles could provide more killing and 
the potential for eradicating the tumor with minimal side effects.  More than an 11-day 
period of hypoxia may be required to completely kill the tumor.   
3. Modifying the dosing schedule.  Because the fusion protein completely clears 
bloodstream in 8 h (see Figure 4.14), the dosing schedule could be modified to inject 
the fusion protein and the prodrug on the same day, 8 h apart.  This would increase the 
amounts of both the fusion protein and the prodrug compared to the treatment schedule 
that was used in this study.    
4. PEGylating the fusion protein so experiments could be performed in immune 
competent mice.  Testing of this enzyme prodrug system in immune competent mice 
would determine if tumor antigen release directly into the bloodstream would create an 
immune response that would increase the efficacy of the system in eradicating the 
primary tumor and distant metastases.  An immunostimulant could also be administered 
simultaneously to boost the immune response.  One possible immunostimulant is 
cyclophosphamide, which has been shown using low doses in combination with 
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photothermal therapy to greatly increase the cure rate in mice with implanted tumors 
[116]. 
5. Combining this enzyme prodrug therapy with treatment with docetaxel to 
increase the exposure of PS in the tumor vasculature and thus increase the effectiveness 
of the treatment.  Docetaxel has been found to about double the percentage of tumor 
vessels in mice that expose anionic phospholipids, while not leading to any exposure of 
these phospholipids in the vasculature of any of the normal organs [117].  
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APPENDIX A 
Cytosine Deaminase–Annexin V Fusion Gene Sequence 
Note: The flexible (Gly-Ser)3 linker attaching cytosine deaminase to annexin V is 
underlined. 
gtgacagggggaatggcaagcaagtgggatcagaaaggcatggacattgcctatgaagag 
 V  T  G  G  M  A  S  K  W  D  Q  K  G  M  D  I  A  Y  E  E  
gccgcactgggctacaaagaaggcggtgtgccgattggcggttgtctgatcaataacaaa 
 A  A  L  G  Y  K  E  G  G  V  P  I  G  G  C  L  I  N  N  K  
gacggctccgtgctgggccgtgggcacaacatgcgcttccagaaaggcagcgccaccctg 
 D  G  S  V  L  G  R  G  H  N  M  R  F  Q  K  G  S  A  T  L  
cacggcgaaatctccaccctggaaaactgcgggcgtctcgagggcaaagtgtacaaagat 
 H  G  E  I  S  T  L  E  N  C  G  R  L  E  G  K  V  Y  K  D  
accaccctgtatacgaccctgagcccgtgcgacatgtgtacgggcgccatcatcatgtac 
 T  T  L  Y  T  T  L  S  P  C  D  M  C  T  G  A  I  I  M  Y  
ggcattccacgctgcgtggtcggcgaaaacgtgaatttcaaatccaagggcgagaaatac 
 G  I  P  R  C  V  V  G  E  N  V  N  F  K  S  K  G  E  K  Y  
ctgcagacccgcggccacgaagtggtcgtggtggacgatgaacgctgcaaaaagatcatg 
 L  Q  T  R  G  H  E  V  V  V  V  D  D  E  R  C  K  K  I  M  
aaacagttcatcgatgagcgtccacaggattggtttgaagatattggtgagggctccggt 
 K  Q  F  I  D  E  R  P  Q  D  W  F  E  D  I  G  E  G  S  G  
tctggatccgcacaggttctcagaggcactgtgactgacttccctggatttgatgagcgg 
 S  G  S  A  Q  V  L  R  G  T  V  T  D  F  P  G  F  D  E  R  
gctgatgcagaaactcttcggaaggctatgaaaggcttgggcacagatgaggagagcatc 
 A  D  A  E  T  L  R  K  A  M  K  G  L  G  T  D  E  E  S  I  
ctgactctgttgacatcccgaagtaatgctcagcgccaggaaatctctgcagcttttaag 
 L  T  L  L  T  S  R  S  N  A  Q  R  Q  E  I  S  A  A  F  K   
actctgtttggcagggatcttctggatgacctgaaatcagaactaactggaaaatttgaa 
 T  L  F  G  R  D  L  L  D  D  L  K  S  E  L  T  G  K  F  E   
aaattaattgtggctctgatgaaaccctctcggctttatgatgcttatgaactgaaacat 
 K  L  I  V  A  L  M  K  P  S  R  L  Y  D  A  Y  E  L  K  H   
gccttgaagggagctggaacaaatgaaaaagtactgacagaaattattgcttcaaggaca 
 A  L  K  G  A  G  T  N  E  K  V  L  T  E  I  I  A  S  R  T   
cctgaagaactgagagccatcaaacaagtttatgaagaagaatatggctcaagcctggaa 
 P  E  E  L  R  A  I  K  Q  V  Y  E  E  E  Y  G  S  S  L  E   
gatgacgtggtgggggacacttcagggtactaccagcggatgttggtggttctccttcag 
 D  D  V  V  G  D  T  S  G  Y  Y  Q  R  M  L  V  V  L  L  Q   
gctaacagagaccctgatgctggaatcgatgaagctcaagttgaacaagatgctcaggct 
 A  N  R  D  P  D  A  G  I  D  E  A  Q  V  E  Q  D  A  Q  A   
ttatttcaggctggagaacttaaatgggggacagatgaagaaaagtttatcaccatcttt 
 L  F  Q  A  G  E  L  K  W  G  T  D  E  E  K  F  I  T  I  F   
ggaacacgaagtgtgtctcatttgagaaaggtgtttgacaagtacatgactatatcagga 
 G  T  R  S  V  S  H  L  R  K  V  F  D  K  Y  M  T  I  S  G   
tttcaaattgaggaaaccattgaccgcgagacttctggcaatttagagcaactactcctt 
 F  Q  I  E  E  T  I  D  R  E  T  S  G  N  L  E  Q  L  L  L   
gctgttgtgaaatctattcgaagtatacctgcctaccttgcagagaccctctattatgct 
 A  V  V  K  S  I  R  S  I  P  A  Y  L  A  E  T  L  Y  Y  A   
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atgaagggagctgggacagatgatcataccctcatcagagtcatggtttccaggagtgag 
 M  K  G  A  G  T  D  D  H  T  L  I  R  V  M  V  S  R  S  E   
attgatctgtttaacatcaggaaggagtttaggaagaattttgccacctctctttattcc 
 I  D  L  F  N  I  R  K  E  F  R  K  N  F  A  T  S  L  Y  S   
atgattaagggagatacatctggggactataagaaagctcttctgctgctctgtggagaa 
 M  I  K  G  D  T  S  G  D  Y  K  K  A  L  L  L  L  C  G  E   
gatgactaa 
   D     D     - 
 
DNA Sequence: 
gtgacagggggaatggcaagcaagtgggatcagaaaggcatggacattgcctatgaagag
gccgcactgggctacaaagaaggcggtgtgccgattggcggttgtctgatcaataacaaa
gacggctccgtgctgggccgtgggcacaacatgcgcttccagaaaggcagcgccaccctg
cacggcgaaatctccaccctggaaaactgcgggcgtctcgagggcaaagtgtacaaagat
accaccctgtatacgaccctgagcccgtgcgacatgtgtacgggcgccatcatcatgtac
ggcattccacgctgcgtggtcggcgaaaacgtgaatttcaaatccaagggcgagaaatac
ctgcagacccgcggccacgaagtggtcgtggtggacgatgaacgctgcaaaaagatcatg
aaacagttcatcgatgagcgtccacaggattggtttgaagatattggtgagggctccggt
tctggatccgcacaggttctcagaggcactgtgactgacttccctggatttgatgagcgg
gctgatgcagaaactcttcggaaggctatgaaaggcttgggcacagatgaggagagcatc
ctgactctgttgacatcccgaagtaatgctcagcgccaggaaatctctgcagcttttaag
actctgtttggcagggatcttctggatgacctgaaatcagaactaactggaaaatttgaa
aaattaattgtggctctgatgaaaccctctcggctttatgatgcttatgaactgaaacat
gccttgaagggagctggaacaaatgaaaaagtactgacagaaattattgcttcaaggaca
cctgaagaactgagagccatcaaacaagtttatgaagaagaatatggctcaagcctggaa
gatgacgtggtgggggacacttcagggtactaccagcggatgttggtggttctccttcag
gctaacagagaccctgatgctggaatcgatgaagctcaagttgaacaagatgctcaggct
ttatttcaggctggagaacttaaatgggggacagatgaagaaaagtttatcaccatcttt
ggaacacgaagtgtgtctcatttgagaaaggtgtttgacaagtacatgactatatcagga
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tttcaaattgaggaaaccattgaccgcgagacttctggcaatttagagcaactactcctt
gctgttgtgaaatctattcgaagtatacctgcctaccttgcagagaccctctattatgct
atgaagggagctgggacagatgatcataccctcatcagagtcatggtttccaggagtgag
attgatctgtttaacatcaggaaggagtttaggaagaattttgccacctctctttattcc
atgattaagggagatacatctggggactataagaaagctcttctgctgctctgtggagaa
gatgactaa 
Amino Acid Sequence: 
V T G G M A S K W D Q K G M D I A Y E E A A L G Y K E G G V 
P I G G C L I N N K D G S V L G R G H N M R F Q K G S A T L 
H G E I S T L E N C G R L E G K V Y K D T T L Y T T L S P C 
D M C T G A I I M Y G I P R C V V G E N V N F K S K G E K Y 
L Q T R G H E V V V V D D E R C K K I M K Q F I D E R P Q D 
W F E D I G E G S G S G S A Q V L R G T V T D F P G F D E R 
A D A E T L R K A M K G L G T D E E S I L T L L T S R S N A 
Q R Q E I S A A F K T L F G R D L L D D L K S E L T G K F E 
K L I V A L M K P S R L Y D A Y E L K H A L K G A G T N E K 
V L T E I I A S R T P E E L R A I K Q V Y E E E Y G S S L E 
D D V V G D T S G Y Y Q R M L V V L L Q A N R D P D A G I D 
E A Q V E Q D A Q A L F Q A G E L K W G T D E E K F I T I F 
G T R S V S H L R K V F D K Y M T I S G F Q I E E T I D R E 
T S G N L E Q L L L A V V K S I R S I P A Y L A E T L Y Y 
A M K G A G T D D H T L I R V M V S R S E I D L F N I R K E 
F R K N F A T S L Y S M I K G D T S G D Y K K A L L L L C G 
E D D Stop 
 
112 
 
Methioninase-Annexin V Sequence Following Site-Directed Mutagenesis 
ggaccccgcgactcccataacaacaccggtttttccacacgggccattcaccacggctacgacccg 
 G  P  R  D  S  H  N  N  T  G  F  S  T  R  A  I  H  H  G  Y  D  P  
ctttcccacggtggtgccttggtgccaccggtgtaccagaccgcgacctatgccttcccg 
 L  S  H  G  G  A  L  V  P  P  V  Y  Q  T  A  T  Y  A  F  P  
actgtcgaatacggcgctgcgtgcttcgccggggaggaggcggggcacttctacagccgc 
 T  V  E  Y  G  A  A  C  F  A  G  E  E  A  G  H  F  Y  S  R  
atctccaaccccaccctggccttgctcgagcaacgcatggcctcgttggagggtggtgag 
 I  S  N  P  T  L  A  L  L  E  Q  R  M  A  S  L  E  G  G  E  
gcgggattggcgctggcgtcggggatgggagccattacttcgaccctctggaccctgctg 
 A  G  L  A  L  A  S  G  M  G  A  I  T  S  T  L  W  T  L  L  
cggcctggtgatgagctgatcgtggggcgcaccttgtatggctgcacctttgcgttcctg 
 R  P  G  D  E  L  I  V  G  R  T  L  Y  G  C  T  F  A  F  L  
caccatggcattggcgagttcggggtcaagatccaccatgtcgaccttaacgatgccaag 
 H  H  G  I  G  E  F  G  V  K  I  H  H  V  D  L  N  D  A  K  
gccctgaaagcggcgatcaacagcaaaacgcggatgatctacttcgaaacaccggccaac 
 A  L  K  A  A  I  N  S  K  T  R  M  I  Y  F  E  T  P  A  N  
cccaacatgcaactggtggatatagcggcggtcgtcgaggcagtgcgggggagtgatgtg 
 P  N  M  Q  L  V  D  I  A  A  V  V  E  A  V  R  G  S  D  V  
cttgtggtggtcgacaacacctactgcacgccctacctgcagcggccactggaactgggg 
 L  V  V  V  D  N  T  Y  C  T  P  Y  L  Q  R  P  L  E  L  G  
gcagacctggtggtgcattcggcgaccaagtacctcagtggccatggcgacatcactgcg 
 A  D  L  V  V  H  S  A  T  K  Y  L  S  G  H  G  D  I  T  A  
ggcctggtggtggggcgcaaggctttggtcgaccgcattcggctggaagggctgaaagac 
 G  L  V  V  G  R  K  A  L  V  D  R  I  R  L  E  G  L  K  D      
atgaccggggcagccttgtcaccgcatgacgctgcgttgttgatgcgcggcatcaagacc 
 M  T  G  A  A  L  S  P  H  D  A  A  L  L  M  R  G  I  K  T   
ctggcgctgcgcatggaccggcattgcgccaacgccctggaggtcgcgcagttcctggcc 
 L  A  L  R  M  D  R  H  C  A  N  A  L  E  V  A  Q  F  L  A   
gggcagccccaggtggagctgatccactacccgggcttgccgtcgtttgcccagtacgaa 
 G  Q  P  Q  V  E  L  I  H  Y  P  G  L  P  S  F  A  Q  Y  E   
ctggcacagcggcagatgcgtttgccgggcgggatgattgcctttgagctcaagggcggt 
 L  A  Q  R  Q  M  R  L  P  G  G  M  I  A  F  E  L  K  G  G   
atcgaggccgggcggggcttcatgaatgccctgcagctttttgcccgtgcggtgagcctg 
 I  E  A  G  R  G  F  M  N  A  L  Q  L  F  A  R  A  V  S  L   
ggggatgccgagtcgctggcacagcacccggcgagcatgacgcactccagttacacgcca 
 G  D  A  E  S  L  A  Q  H  P  A  S  M  T  H  S  S  Y  T  P   
caagagcgggcgcatcacgggatatcagaggggctggtgaggttgtcagtggggctggag 
 Q  E  R  A  H  H  G  I  S  E  G  L  V  R  L  S  V  G  L  E   
gatgtggaggacctgctggcagatatcgagttggcattggaggcgtgtgcaggcagcggt 
 D  V  E  D  L  L  A  D  I  E  L  A  L  E  A  C  A  G  S  G   
tctggatccgcacaggttctcagaggcactgtgactgacttccctggatttgatgagcgg 
 S  G  S  A  Q  V  L  R  G  T  V  T  D  C  P  G  F  D  E  R   
gctgatgcagaaactcttcggaaggctatgaaaggcttgggcacagatgaggagagcatc 
 A  D  A  E  T  L  R  K  A  M  K  G  L  G  T  D  E  E  S  I   
ctgactctgttgacatcccgaagtaatgctcagcgccaggaaatctctgcagcttttaag 
 L  T  L  L  T  S  R  S  N  A  Q  R  Q  E  I  S  A  A  F  K   
actctgtttggcagggatcttctggatgacctgaaatcagaactaactggaaaatttgaa 
 T  L  F  G  R  D  L  L  D  D  L  K  S  E  L  T  G  K  F  E   
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aaattaattgtggctctgatgaaaccctctcggctttatgatgcttatgaactgaaacat 
 K  L  I  V  A  L  M  K  P  S  R  L  Y  D  A  Y  E  L  K  H   
gccttgaagggagctggaacaaatgaaaaagtactgacagaaattattgcttcaaggaca 
 A  L  K  G  A  G  T  N  E  K  V  L  T  E  I  I  A  S  R  T   
cctgaagaactgagagccatcaaacaagtttatgaagaagaatatggctcaagcctggaa 
 P  E  E  L  R  A  I  K  Q  V  Y  E  E  E  Y  G  S  S  L  E   
gatgacgtggtgggggacacttcagggtactaccagcggatgttggtggttctccttcag 
 D  D  V  V  G  D  T  S  G  Y  Y  Q  R  M  L  V  V  L  L  Q   
gctaacagagaccctgatgctggaatcgatgaagctcaagttgaacaagatgctcaggct 
 A  N  R  D  P  D  A  G  I  D  E  A  Q  V  E  Q  D  A  Q  A   
ttatttcaggctggagaacttaaatgggggacagatgaagaaaagtttatcaccatcttt 
 L  F  Q  A  G  E  L  K  W  G  T  D  E  E  K  F  I  T  I  F   
ggaacacgaagtgtgtctcatttgagaaaggtgtttgacaagtacatgactatatcagga 
 G  T  R  S  V  S  H  L  R  K  V  F  D  K  Y  M  T  I  S  G   
tttcaaattgaggaaaccattgaccgcgagacttctggcaatttagagcaactactcctt 
 F  Q  I  E  E  T  I  D  R  E  T  S  G  N  L  E  Q  L  L  L   
gctgttgtgaaatctattcgaagtatacctgcctaccttgcagagaccctctattatgct 
 A  V  V  K  S  I  R  S  I  P  A  Y  L  A  E  T  L  Y  Y  A   
atgaagggagctgggacagatgatcataccctcatcagagtcatggtttccaggagtgag 
 M  K  G  A  G  T  D  D  H  T  L  I  R  V  M  V  S  R  S  E   
attgatctgtttaacatcaggaaggagtttaggaagaattttgccacctctctttattcc 
 I  D  L  F  N  I  R  K  E  F  R  K  N  F  A  T  S  L  Y  S   
atgattaagggagatacatctggggactataagaaagctcttctgctgctctgtggagaa 
 M  I  K  G  D  T  S  G  D  Y  K  K  A  L  L  L  L  C  G  E   
gatgactaa 
 D  D  -   
The regions underlined are the corrected mutations (methioninase 326 and 
annexin V 11), the sequences in italics are where the forward and reverse 
mutation sequencing primers aligned, and the bold region is the flexible linker.   
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BCA Protein Assay Standard Curve 
 
 
 
 
Bradford Protein Assay Standard Curve 
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Bradford Protein Microassay Standard Curve 
 
 
L-Methioninase Enzymatic Activity Assay Standard Curve 
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Chromatograph from  the Purification of Methioninase-Annexin V 
 
 
Dissociation Constant for Methioninase-Annexin V Binding to Endothelial Cells 
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Binding Stability of Cytosine Deaminase-Annexin V 
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Pathology Report of Treated MDA-MB-231 Breast Tumors in SCID Mice 
 Mice from each group were sent for analysis.  Animals 234, 235, and 251 were 
untreated (saline only); animals 236, 240, and 241 received methioninase-annexin V; 
animals 244, 245, and 294 received selenomethionine; and animals 247, 250, 252, 932, 
966, 973, and 988 received methioninase-annexin V and selenomethionine.   
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Single-Walled Carbon Nanotube Standard Curve 
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Conjugation History of F3 Peptide to Carbon Nanotubes 
SWNT Suspension History   SWNT-F3 Conjugation History 
 
Date 
Initial 
SWNT 
(mg) 
SDS 
(%) 
Theoretical 
[SWNT] 
(mg/L) 
[SWNT] 
(mg/L)  
SWNT 
Recovery 
(%) 
 
Date 
F3 
(mg) 
Final 
[F3] 
(mg/L) 
Final 
[SWNT] 
(mg/L)  
SWNT 
Recovery 
(%) 
5.18.11 3 1 600 - - 
 
5.18.11 1 74.2 89.5 - 
5.25.11 3 1 600 496.2 82.7 
 
5.25.11 1 - 121.9 24.6 
5.25.11 3 1 600 348.1 58.0 
 
5.25.11 1 - 110.9 31.9 
6.5.11 3 1 600 413.6 68.9 
 
6.4.11 1 103.2 68.3 16.5 
6.5.11 3 1 600 309.5 51.6 
 
6.4.11 1 138.5 60.1 19.4 
6.6.11 3 1 600 403.4 67.2 
 
6.6.11 1 - 145.4 36.0 
6.6.11 6 1 1200 771.5 64.3 
 
6.6.11 1 232.6 262.6 34.0 
6.7.11 3 1 600 418.3 69.7 
 
6.7.11 1 - 117.0 28.0 
6.9.11 6 1 1200 627.2 52.3 
 
6.8.11 1 - 283.0 45.1 
6.20.11 6 1 1200 686.22 57.2 
 
6.20.11 1 0 153.16 22.3 
6.20.11 6 1 1200 663.98 55.3 
 
6.20.11 1 34.4 206.22 31.1 
6.28.11 6 1 1200 633.98 52.8 
 
6.29.11 1 194.62 230.31 36.3 
7.6.11 6 1 1200 683.57 57.0 
 
7.6.11 1 229.93 209.69 30.7 
7.12.11 6 1 1200 766.02 63.8 
 
7.11.11 1 266.14 247.86 32.4 
7.18.11 6 1 1200 602.76 50.2 
 
7.18.11 1 266.14 198.27 32.9 
7.28.11 6 1 1200 858.57 71.5 
 
7.27.11 1 294.2 282.14 32.9 
9.1.11 6 1 1200 674.59 56.2 
 
9.15.11 1 348.51 233.16 34.6 
1.13.12 6 1 1200 846.17 70.5 
 
1.16.12 1 343.98 309.18 36.5 
1.29.12 6 1 1200 849.74 70.8 
 
1.29.12 1 378.38 311.22 36.6 
1.29.12 6 1 1200 626.79 52.2 
 
1.29.12 1 435.41 201.02 32.1 
2.16.12 6 1 1200 778.83 64.9 
 
2.19.12 1 671.68 236.12 30.3 
2.16.12 6 1 1200 780.36 65.0 
 
2.19.12 1 407.35 313.27 40.1 
2.16.12 6 1 1200 805.36 67.1 
 
2.19.12 1 532.27 341.02 42.3 
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Cytotoxicity of SWNT-F3 with NIR Laser to 4T1 Mammary Tumor Cells 
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Single-Walled Carbon Nanotube Absorption Spectra 
  
 
 
 
Figure A.10.  Carbon nanotube absorption spectra after 1 h, 6 h, 12 h, 
and 24 h of sonication in 1% sodium dodecyl sulfate. The spectra for 
a sample of 6 h nanotubes with annexin V attached is shown in light 
blue. (A) Range: 360 – 1350 nm. (B) Range: 900 – 1100 nm. 
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APPENDIX B 
Construction of Cytosine Deaminase – Annexin V Fusion Gene 
1. Design primers for manufacturing by Integrated DNA Technologies (Coralville, 
IA). 
a. CD  primers:  5’ LIC, HRV 3C Protease site;  3’ BamHI site  
 
i. Sense primer:  5’-gAC/ gAC/ gAC/ AAg/ ATg/ CTT/ gAA/ gTC/ CTC/ 
TTT/ CAg/ ggA/ CCC/ gTg/ ACA/ ggg/ ggA/ ATg/ gCA/ AgC -3’ 
 
ii. Antisense primer:  5’- gC/ CgC/ ATT/ ggA/ TCC/ AgA/ ACC/ gTC/ gCC/ 
CTC/ ACC/ AAT/ ATC/ TTC/ AAA/ CC -3’ 
 
b. Annexin V primers:  5’ BamHI site;  3’ LIC 
i. Sense primer:  5’- Cg/ ATT/ CgC/ ggA/ TCC/ gCA/ CAg/ gTT/ CTC/ AgA/ 
ggC -3’ 
 
ii. Antisense primer:  5’-gA/ ggA/ gAA/ gCC/ Cgg/ TTA/ gTC/ ATC/ TTC/ 
TCC/ ACA/ gAg/ C -3’ 
  
2. Amplify yCD and annexin V genes using PCR (Expand High Fidelity PCR 
system purchased from Roche Applied Sciences; Madison, WI). 
 
Step # of Cycles Temperature Time 
Initial Denaturation 1 94 oC 2 min 
Amplification 31 
        - Denaturation 94 oC 15 sec 
        - Annealing (CD) 55 oC 30 sec 
(Annexin V) 55 oC 30 sec 
        - Elongation 72 oC 90 sec 
Final Elongation 1 72 oC 7 min 
Cooling 1 4 oC ∞ 
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PCR Reaction Mixtures for Yeast Cytosine Deaminase                 
(pQE30Xa + CD – 7/2009) 
Mix 1 
Volume 
(µl) Mix 2 
Volume 
(µl) 
PCR nucleotide 
mix 1 Enzyme mix 0.75 
Sense primer 1.1 
10X Buffer, w/ 
MgCl2 5 
Antisense primer 1.4 ddH2O, Sterile 19.25 
Template DNA 1 
PCR grade water 20.5 
TOTAL 25 25 
PCR Reaction Mixtures for Annexin V           
(pET 22b + STF-annexin -03/15/2006) 
Mix 1 
Volume 
(µl) Mix 2 
Volume 
(µl) 
PCR nucleotide 
mix 1 Enzyme mix 0.75 
Sense primer 1.2 
10X Buffer, w/ 
MgCl2 5 
Antisense primer 1.2 ddH2O, Sterile 19.25 
Template DNA 2.5 
PCR grade water 19.1 
TOTAL 25 25 
 
3. Purify PCR products using Qiaquick PCR purification kit protocol. 
• To analyze purified DNA on a gel, add 1 volume of Loading Dye to 5 
volumes of DNA.  (Mix 1 µl loading dye with 5 µl DNA).  Pipet up & 
down to mix before loading gel. 
• After the PCR products were purified, an agarose gel was run to check if 
the PCR worked. NO BANDS WERE DETECTED.  After consulting 
Dr. Harrison, we decided the amount of primers added was insufficient, 
the annealing temperatures for both genes should be changed to 55oC, 
and the number of cycles during amplification should be 31.  Steps 2 and 
3 were repeated using 1 µl more than the value given in the above table.  
Below is a picture of the agarose gel obtained after the second PCR run.  
4 µl of PCR product was mixed with 1 µl of loading buffer provided in 
the QIAquick PCR purification kit.  4 µl of 500 bp DNA ladder was also 
mixed with 1 µl of loading buffer to easily determine the amount of 
DNA present in the PCR reactions. 
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4. Digest CD and annexin V genes with BamHI restriction enzyme (separately) 
purchased from New England BioLabs (Beverly, MA). 
• One unit of enzyme will digest 1 µg of DNA in 1 hour @ 37 oC (in a 
total reaction volume of 50 µl). 
• Allow digestion to occur for 1 hour @ 37 oC using 20 U from a stock of 
20,000 U/ml. 
• From the stock solution, I determined I would use 1 µl, corresponding to 
20 Units of the enzyme per gene.  1 µl BamHI + 5 µl 1X buffer + 44 µl 
gene DNA. 
 
5. Purify digested genes using Qiaquick PCR purification kit from Qiagen 
(Valencia, CA). 
 
6. Ligate CD and annexin V genes using T4 DNA Ligase purchased from New 
England BioLabs. 
• Ligation should take place for 10 minutes @ RT using 1 µl of enzyme in 
20 µl total reaction volume. 
• Three different tubes containing the same components were used for 
ligation.   
 
7. Run agarose gel of ligated product using the following samples: 
• CD-annexin V  
• 500 bp DNA Marker 
• The band length that I was interested in was ~1500 bp (~1013 of annexin 
V + 500 of CD).  Each tube sample contained either: a) CD + CD; b) CD 
+ annexin V; or c) annexin V + annexin V.  
• The CD + annexin V sample was cut from the gel as follows. 
 
8. Cut and agarose gel purify the appropriate gene fragments using Qiaquick gel 
extraction kit protocol from Qiagen (Valencia, CA). 
• Cut the appropriate fragment from gel with clean, sharp scalpel. 
• Weigh the gel slice in a colorless tube.  (0.1451g = Gel weight) 
• Incubate at 50 oC for 10 minutes (or until gel slice is completely 
dissolved).  To help dissolve, vortex the tube every 2-3 minutes during 
incubation. 
9. Treat the ligated CD-annexin V gene with T4 DNA Polymerase (Novagen) to 
create sticky ends (LIC) on the gene. 
• Assemble the following components in a sterile 1.5 ml microcentrifuge 
tube on ice: 
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Component Volume (µl) 
0.2 pmol purified PCR 
product 4 
10X T4 DNA Polymerase 
Buffer 2 
25 mM dATP 2 
100 mM DTT 1 
Nuclease-free Water 10.6 
2.5 U/µl T4 DNA 
Polymerase 0.4 
TOTAL 20 
 
• For 0.2 pmol PCR product, # of bp in insert * 650 = pg/pmol. 
• Start reaction by adding enzyme.  Stir with pipet tip to mix.  Incubate at 
22 oC for 30 minutes. 
• Inactivate enzyme by incubating at 75 oC for 20 minutes. 
• Store prepared Ek/LIC insert at -20 oC for use at a later time, or use 
immediately.  
• From ligation gel, I estimated I had ~200 ng per 4 µl of DNA sample.  I 
needed to have 0.2 pmol of DNA for polymerase reaction, and using the 
above equation for weight per # of bp in insert, I came up with needing 
4.03 µl of DNA sample for reaction to occur – meaning 10.57 µl of 
nuclease-free water was needed.  A positive control reaction was done 
using 2 µl of a provided insert.  Also, a negative control was done by 
replacing the PCR product w/ an equal volume of nuclease-free water. 
 
10. Anneal sticky end fusion gene to pET-30 Ek/LIC linear vector from Novagen 
(Madison, WI).  
• Assemble the following components in a sterile 1.5 ml microcentrifuge 
tube: 
Component 
Volume 
(µl) 
pET-30 Ek/LIC vector 1 
Treated Ek/LIC insert (0.02 
pmol) 2 
Incubate for 5 minutes at 22 oC, than add: 
25 mM EDTA 1 
TOTAL 4 
• Mix by stirring with pipet tip.  Incubate at 22 oC for 5 minutes. 
• A positive control was done using the polymerase-treated control insert 
and a negative control was done using only water at the insert. 
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11. Transform annealed product into NovaBlue cells (GigaSingles). 
• LB + agar was made by combining 2g NaCl + 2g tryptone + 1g yeast 
extract + 3g agar (for 200 ml total volume) with pH 7.0 (one solution 
will have ampicillin and 1 will have kanamycin). Autoclave before 
using. 
• Have samples for positive control insert, test plasmid, negative control 
insert, and sample insert (CD-annexin V). 
 
12. Extract plasmids containing fused gene insert using Qiaquick plasmid 
purification kit from Qiagen (Valencia, CA). 
• Pick a successfully transfected colony from the plates.  Grow the 
bacterial cells for 16 hours in 5 ml of LB medium with kanamycin 
antibiotic. 
• Centrifuge the solution at 6,800xg & decant the supernatant. 
• Use gel extraction kit. 
 
13. Run agarose gel to determine if the plasmid is correct size (should be ~7000 bp) 
and approximate concentration it is at. 
• Use 0.5% agarose gel to see the larger size samples. 
• Run each of the 4 samples of extracted plasmids (lanes 2-5) 
• 500 bp DNA Marker (lane 1 -> on right side) 
 
14. Prepare extracted plasmid samples 2-4 for sequencing at Oklahoma Medical 
Research Foundation (OK City, OK). 
• Plasmid needs to be at ~ 100 ng/µl with at least 5 µl needed for each 
reaction. 
• OMRF provides the T7 promoter & terminator primers 
 
15. Transform the plasmid containing the correct sequence into E. coli BL21(DE3) 
host for protein expression. 
 
16. Inoculate E.coli BL21(DE3) cells that successfully grew on the agar plates in 
liquid LB medium for expression and purification. 
 
 
QIAquick PCR Purification Kit Protocol 
This protocol is designed to clean up DNA products from PCR reactions. 
130 
 
• Add ethanol (96–100%) to Buffer PE before use (see bottle label for volume). 
• All centrifuge steps are at 13,000 rpm (~17,900 x g) in a conventional tabletop 
microcentrifuge. 
 
1. Add 5 volumes of Buffer PB to 1 volume of the PCR sample and mix. It is not 
necessary to remove mineral oil or kerosene. For example, add 500 µl of Buffer 
PB to 100 µl PCR sample (not including oil). 
2. Place a QIAquick spin column in a provided 2 ml collection tube. 
3. To bind DNA, apply the sample to the QIAquick column and centrifuge for 30–
60 s. 
4. Discard flow-through. Place the QIAquick column back into the same tube. 
Collection tubes are re-used to reduce plastic waste. 
5. To wash, add 0.75 ml Buffer PE to the QIAquick column and centrifuge for 30–
60 s. 
6. Discard flow-through and place the QIAquick column back in the same tube. 
Centrifuge the column for an additional 1 min.  
IMPORTANT: Residual ethanol from Buffer PE will not be completely 
removed unless the flow-through is discarded before this additional 
centrifugation. 
7. Place QIAquick column in a clean 1.5 ml microcentrifuge tube. 
8. To elute DNA, add 50 µl Buffer EB (10 mM Tris·Cl, pH 8.5) or H2O to the 
center of the QIAquick membrane and centrifuge the column for 1 min. 
 
QIAquick Gel Extraction Kit Protocol 
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This protocol is designed to extract and purify DNA of 70 bp to 10 kb from standard or 
low-melt agarose gels in TAE or TBE buffer. Up to 400 mg agarose can be processed 
per spin column. For DNA cleanup from enzymatic reactions using this protocol, add 3 
volumes of BufferQG and 1 volume of isopropanol to the reaction, mix, and proceed 
with step 6 of the protocol.  
• The yellow color of Buffer QG indicates a pH ≤7.5. 
•  Add ethanol (96–100%) to Buffer PE before use (see bottle label for volume). 
•  Isopropanol (100%) and a heating block or water bath at 50°C are required. 
•  All centrifugation steps are carried out at 13,000 rpm (~17,900 x g) in a 
microcentrifuge. 
•  3 M sodium acetate, pH 5.0, may be necessary. 
 
1. Excise the DNA fragment from the agarose gel with a clean, sharp scalpel. 
Minimize the size of the gel slice by removing extra agarose. 
2. Weigh the gel slice in a colorless tube. Add 3 volumes of Buffer QG to 1 
volume of gel (100 mg ~ 100 µl). For example, add 300 µl of Buffer QG to each 
100 mg of gel. For >2% agarose gels, add 6 volumes of Buffer QG. The 
maximum amount of gel slice per QIAquick column is 400 mg; for gel slices 
>400 mg use more than one QIAquick column. 
3. Incubate at 50°C for 10 min (or until the gel slice has completely dissolved). To 
help dissolve gel, mix by vortexing the tube every 2–3 min during the 
incubation. 
IMPORTANT: Solubilize agarose completely. For >2% gels, increase 
incubation time. 
4. After the gel slice has dissolved completely, check that the color of the mixture 
is yellow (similar to Buffer QG without dissolved agarose). If the color of the 
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mixture is orange or violet, add 10 µl of 3 M sodium acetate, pH 5.0, and mix. 
The color of the mixture will turn to yellow. The adsorption of DNA to the 
QIAquick membrane is efficient only at pH ≤7.5. Buffer QG contains a pH 
indicator which is yellow at pH ≤7.5 and orange or violet at higher pH, allowing 
easy determination of the optimal pH for DNA binding. 5. Add 1 gel volume of 
isopropanol to the sample and mix. For example, if the agarose gel slice is 100 
mg, add 100 µl isopropanol. This step increases the yield of DNA fragments 
<500 bp and >4 kb. For DNA fragments between 500 bp and 4 kb, addition of 
isopropanol has no effect on yield. Do not centrifuge the sample at this stage. 
5. Place a QIAquick spin column in a provided 2 ml collection tube. 
To bind DNA, apply the sample to the QIAquick column, and centrifuge for 1 
min. The maximum volume of the column reservoir is 800 µl. For sample 
volumes of more than 800 µl, simply load and spin again. 
6. Discard flow-through and place QIAquick column back in the same collection 
tube. Collection tubes are re-used to reduce plastic waste. 
7. (Optional): Add 0.5 ml of Buffer QG to QIAquick column and centrifuge for 1 
min. This step will remove all traces of agarose. It is only required when the 
DNA will subsequently be used for direct sequencing, in vitro transcription or 
microinjection. 
8. To wash, add 0.75 ml of Buffer PE to QIAquick column and centrifuge for 1 
min. 
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Note: If the DNA will be used for salt sensitive applications, such as blunt-end 
ligation and direct sequencing, let the column stand 2–5 min after addition of 
Buffer PE, before centrifuging. 
9. Discard the flow-through and centrifuge the QIAquick column for an additional 
1 min at 13,000 rpm (~17,900 x g). 
IMPORTANT: Residual ethanol from Buffer PE will not be completely 
removed unless the flow-through is discarded before this additional 
centrifugation. 
10. Place QIAquick column into a clean 1.5 ml microcentrifuge tube. 
11. To elute DNA, add 50 µl of Buffer EB (10 mM Tris·Cl, pH 8.5) or H2O to the 
center of the QIAquick membrane and centrifuge the column for 1 min.  
QIAprep Spin Mini-prep Protocol 
Use to extract plasmid from bacterial cells for applications such as plasmid DNA 
sequencing. 
1. Begin a liquid culture of each colony selected from agar plates.  Transfer 1 colony 
to a 1.5 ml microcentrifuge tube containing 1 ml of LB medium + kanamycin (or the 
appropriate antibiotic).     
2. Incubate the microcentrifuge tubes at 37oC with shaking 220-250 rpm overnight 
(overnight but < 16 hours is best because cell lysis begins to occur at longer 
incubation times and reduces the amount of plasmid). 
3. Centrifuge the tubes on the table-top microcentrifuge for 3 minutes at 10000 rpm.  
Discard flow through. 
134 
 
4.  Resuspend the bacterial cell pellet in 250 µl Buffer P1 containing RNase A and 
LyseBlue reagent (in the brown 4oC fridge). 
5. Add 250 µl Buffer P2 to each tube and mix by inverting 4-6 times. 
6. Add 350 µl Buffer N3 to each tube and immediately mix by inverting 4-6 times 
(until blue color becomes white).   
7. Centrifuge for 10 minutes at 13000 rpm using microcentrifuge. 
8. Apply supernatant to a QIAprep spin column by decanting. 
9. Centrifuge for 30-60 seconds.  Discard flow through. 
10. Recommended:  Wash the column by adding 500 µl Buffer PB to each and 
centrifuge for 30-60 seconds.  Discard flow through. 
11. Wash the column by adding 750 µl Buffer PE to each and centrifuge for 30-60 
seconds.  Discard flow through. 
12. Centrifuge for another 60 seconds to remove residual ethanol. 
13. Transfer the QIAprep columns to new, sterile 1.5 ml microcentrifuge tubes.  Elute 
DNA by adding 50 µl Buffer EB to the center membrane of each column.   
14. Let the columns sit for 60 seconds. 
15. Centrifuge the columns for 60 seconds to collect the plasmid DNA. 
Agarose Gel Electrophoresis 
The following protocol is for making a 1% (w/v) agarose gel using SeaKem® LE 
agarose (Cambrex) using a BRL Life Technologies Horizon 58 electrophoretic cell with 
a total gel volume of 35 ml. 
1. Assemble the electrophoretic cell. 
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2. Weigh out 0.50g agarose and dissolve in 50 ml of 1X TE buffer (40 mM Tris, 1 
mM EDTA). Microwave 5 times in 30 second intervals on power level 5 with 
cap loosely on (cap will pop off and contents will spill out or glass will break 
otherwise).  
3. Let the solution cool to 55oC and add 2.5 µl of 10 mg/ml of ethidium bromide 
stock to the 50 ml volume (mix the solution well to evenly distribute the 
ethidium bromide). Pour the gel into the cell (up to the blue line on the comb) 
and wait 30 min for solidification. 
4. Once the gel has solidified pour the TE buffer over the gel until it covers the gel 
by about 1 mm. The gel is now ready to be loaded. 
5. To each DNA sample to be loaded, add 2 µl of sample DNA to 1 µl loading dye 
(GelPilot DNA 5x Loading Dye, Qiagen #239901).  The maximum volume of 
DNA sample is 20 µl for each well of the 8 comb gel which has a total volume 
of 25 µl. 
• Mixed 2 µl DNA from PCR + 1 µl loading dye with pipet, and then load 
into each well (for samples). 
• Mixed 2 µl blank from PCR + 1 µl loading dye with pipet, and then load 
into each well (for blanks). 
 
6. For the marker lane, add 2 µl of 500 bp ladder (Bio-Rad #170-8203) to 1 µl 
loading dye.  
7. Run the gel at 100 V (Low) until the first band gets ¾ of the way to the bottom 
of the gel. 
8. View the gel using the UV box.   
Note: 10X TE Buffer (per Liter):  1 mM EDTA (3.722g) and 40 mM Tris 
(48.456g) in DI Water. 
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Transformation Protocol for NovaBlue GigaSingles Competent Cells 
1. Place the required number of 14 ml BD Falcon round-bottom polypropylene 
tubes on ice to pre-chill.  
2. Thaw the required number of tubes of cells on ice and mix gently to ensure that 
the cells are evenly suspended and transfer the 50 µl of cells to the round-bottom 
tubes. 
3. Add 1 µl of the DNA plasmid solution directly to the cells. Stir gently to mix. 
4. Place the tubes on ice for 5 min. 
5. Heat the tubes for exactly 30 s in a 42°C water bath; do not shake. 
6. Place on ice for 2 min. 
7. Add 250 µl of room temperature SOC Medium to each tube. 
8. Incubate at 37°C while shaking at 250 rpm for 60 min. 
9. Plate 25 µl of transformation solution on agar plates with the appropriate 
antibiotic.  
Transformation Protocol for E. coli BL21(DE3) Cells 
1. Thaw the required number of tubes of cells on ice and mix gently to ensure that 
the cells are evenly suspended. 
2. Place the required number of 14 ml BD Falcon round-bottom polypropylene 
tubes on ice to pre-chill. Pipet 20 µl aliquots of cells into the pre-chilled tubes. 
3. Add 1 µl of the DNA plasmid solution directly to the cells. Stir gently to mix. 
4. Place the tubes on ice for 5 min. 
5. Heat the tubes for exactly 30 s in a 42°C water bath; do not shake. 
6. Place on ice for 2 min. 
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7. Add 80 µl of room temperature SOC Medium to each tube. 
8. Incubate at 37°C while shaking at 250 rpm for 60 min prior to plating on 
selective medium. 
9. Plate 25 or 50 µl of the transformation solution on LB agar plates containing the 
correct antibiotic (35 µg/ml Kanamycin in this case). 
Transformation of XL10-Gold Ultracompetent Cells for Quik Change XL Site-Directed 
Mutagenesis 
1.  Thaw 1 tube (135 µl) of XL10-Gold cells on ice.  For each reaction to take place, 
pipet 45 µl of cells into pre-chilled 14 ml BD Falcon round-bottom 
polypropylene tubes.  (3 tubes: mutagenesis control, sample, and transformation 
control) 
2.  Add 2 µl of the β-mercaptoethanol mix to the 45 µl of cells in each tube. 
3.  Swirl the tube gently and incubate on ice for 10 minutes, swirling gently every 2 
minutes. 
4.  Transfer 2 µl of Dpn I-treated DNA from control and sample reaction to 
individual tubes of cells.  Dilute the pUC18 control plasmid 1:10 in high-quality 
water and then add 1 µl to a third tube of cells. Swirl the transformation 
reactions gently to mix.  Incubate the tubes on ice for 30 minutes.   
5.  Heat pulse the tubes for exactly 30 seconds at 42oC.  (DO NOT EXCEED 
42oC!).  Preheat the NZY+ broth in the 42oC water bath for step 8. 
6.  Incubate the tubes on ice for 2 minutes.   
7.  Add 500 µl of NZY+ broth preheated to 42oC to each tube.  Incubate the tubes at 
37oC for 1 hour with shaking at 250 rpm.   
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8.  Plate 250 µl of the mutagenesis control transformation reaction on an Ampicillin 
+ X-gal + IPTG plate.  Plate 5 µl of pUC18 transformation control reaction in 
200 µl of NZY+ broth on an Amp + X-gal + IPTG plate.  Plate 250 µl of 
mutagenesis sample transformation on two different Kanamycin + X-gal + IPTG 
plates.  
9.  Incubate the plates at 37oC for at least 16 hours. 
QuikChange II XL Site-Directed Mutagenesis Protocol 
1. Synthesize two complementary oligonucleotides containing the desired 
mutation, flanked by unmodified nucleotide sequence. Purify these 
oligonucleotide primers prior to use in the following steps (see Mutagenic 
Primer Design).  
2. Prepare the control reaction as indicated below:  
5 µl of 10× reaction buffer  
2 µl (10 ng) of pWhitescript 4.5-kb control plasmid (5 ng/µl)  
1.25 µl (125 ng) of oligonucleotide control primer #1 [34-mer (100 ng/µl)]  
1.25 µl (125 ng) of oligonucleotide control primer #2 [34-mer (100 ng/µl)]  
1 µl of dNTP mix  
3 µl of QuikSolution reagent  
36.5 µl of double-distilled water (ddH2O) to a final volume of 50 µl  
Then add 
1 µl of PfuUltra HF DNA polymerase (2.5 U/µl) 
3. Prepare the sample reaction(s) as indicated below: 
5 µl of 10× reaction buffer  
X µl (10 ng) of dsDNA template  
X µl (125 ng) of oligonucleotide primer #1  
X µl (125 ng) of oligonucleotide primer #2  
1 µl of dNTP mix  
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3 µl of QuikSolution  
ddH2O to a final volume of 50 µl  
Then add  
1 µl of PfuUltra HF DNA polymerase (2.5 U/µl)  
4. If the thermal cycler to be used does not have a hot-top assembly, overlay each 
reaction with ~30 µl of mineral oil.  
5. Cycle each reaction using the cycling parameters outlined here.  (For the control 
reaction, use a 5-minute extension time and run the reaction for 18 cycles.)  
Note:  It is important to adhere to the 18-cycle limit when cycling the 
mutagenesis reactions. More than 18 cycles can have deleterious effects on the 
reaction efficiency. 
6. Following temperature cycling, place the reaction tubes on ice for 2 minutes to 
cool the reactions to ≤37°C. 
7. Add 1 µl of the Dpn I restriction enzyme (10 U/µl) directly to each amplification 
reaction below the mineral oil overlay using a small, pointed, pipet tip. 
8. Gently and thoroughly mix each reaction mixture by pipetting the solution up 
and down several times. Spin down the reaction mixtures in a microcentrifuge 
for 1 minute, then immediately incubate the reactions at 37°C for 1 hour. 
9. Transform E. coli XL10-Gold ultracompetent cells with the mutated L-
methioninase-annexin V plasmid using above protocol. 
10. Select several colonies with the blue phenotype and begin a 5 ml liquid culture 
containing kanamycin at 35 mg/L.  Incubate the culture for ~16 hr at 37oC. 
11. Centrifuge cultures for 10 min at 1000xg. 
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12. Extract plasmid from XL10-Gold cells using the QIAprep Spin Mini-prep 
protocol. 
13. Deliver plasmid to OMRF DNA Sequencing Core Facility in Oklahoma City, 
OK for sequencing. 
14. Compare sequencing results with the known correct nucleotide sequence for the 
L-methioninase-annexin V fusion gene. 
15. With the correctly mutated plasmid, transform E. coli BL21(DE3) cells. 
Fusion Protein Recombinant Protein Expression 
NOTE:  L-methioninase-annexin V production requires the addition of 
pyridoxal 5’-phosphate (an enzyme co-factor) to buffers.   
1. Culture 5 µl of E. coli BL21(DE3) harboring pET- 30 Ek/LIC with the fusion 
gene L-methioninase-annexin V (or pET- 30 Ek/LIC with the fusion gene 
cytosine deaminase-annexin V) in 10 ml of LB medium containing 35 mg/L 
kanamycin in a 125 ml Erlenmeyer flask overnight at 37oC with shaking at 200 
rpm.  
• LB medium: 1 liter DI H2O + 10 g Tryptone + 5 g Yeast Extract + 10 
g NaCl. 
• Add 35 mg Kanamycin to the 1 L of LB medium before taking out 
the 10 ml for the initial culture.   
 
2. Add 10 ml of the cell culture to 1 liter of fresh culture medium + kanamycin and 
incubate at 37oC with shaking (200 rpm). Take 1 mL sample of medium before 
adding the bacteria, as a blank. 
• Label 1 ml tube ‘LB.’   
• Transfer 250 ml of medium to each of 4 1L flasks.  
• Put in shaker at 37o C for 2 hr at 200 rpm. 
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• After 1.5 hr of shaking, measure optical density at 600 nm 
(absorbance) using a clear 96 well plate and microtiter plate reader of 
sample vs LB medium => using 250 µl samples of each.  When 
OD600nm ≈ 0.5, then proceed to next step. 
 
3. Add isopropyl β-D-thiogalactopyranoside (IPTG - stored at -20ºC) to a final 
concentration of 0.4 mM (24 mg IPTG per 1L flask) to each 250 ml solution in a 
1L flask and incubate at 30oC with shaking (180 rpm) for 5 h to induce protein 
expression. 
• Take 750 ml sample of solution before adding IPTG.  Label it ‘BI.’  
• Add total of 96 mg IPTG to flasks, put back in shaker at 30oC for 5 
hours.   
• IPTG stimulates the production of fusion protein.  (IPTG activates 
the promoter in the plasmid that will start the transcription of the 
gene that follows the promoter => methioninase-annexin V gene.)  
 
4. Harvest the cells by centrifugation for 10 min at 1000 x g, at 4ºC. 
• Take 750 ml sample before centrifuge.  Label sample ‘BC.’ 
• Centrifuge at 1000xg = ~3000 rpm (centrifuge uses rpm – consult 
table on machine).  Only 4 – 50 ml centrifuge tubes at a time, temp 4 
ºC, 10 mins. 
• After first centrifuge, pour out supernatant, add more culture to same 
4 tubes.  Bacteria will be stuck to side of tubes; invert to pour out. 
• Can put the 4 tubes in -20 ºC freezer for overnight storage if desired. 
 
5. Resuspend the cell pellet in 40 ml of sonication buffer. 
• 0.05 mM N- p-tosyl-L-phenylalanine chloromethyl ketone (TPCK) - 
(stored at -20ºC) => 0.704 mg. 
• 1 mM phenylmethylsulfonyl fluoride (PMSF) - (shelf) => 6.968 mg. 
• 1% HPLC ethanol - (flammables) => 400 µl. 
• Note: Dissolve TPCK and PMSF in ethanol in 
microcentrifuge tube and then add to beaker. 
• 0.02 mM pyridoxal phosphate – (-20ºC) => 400 µl of 2 mM.  
• 0.01% β-mercaptoethanol – (bench top) => 4 µl.  . 
• 0.02 M sodium phosphate dibasic – (shelf) => 113.6 mg. 
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• Correct to pH 7.4 – using HCl. 
 
• Make this buffer in the 100 ml beaker. 
• Add ~10 ml to each of the 4 centrifuge tubes and vortex to resuspend 
cell pellets. 
• Pour contents of the 4 tubes back into the 100 ml beaker. 
 
6. Lyse the cells by sonication at 4oC for 30 sec at 4.5 watts then allow it to cool 
for 30 sec on ice. This cycle was repeated for 4 times (= 5 times total) for a total 
sonication time of 2.5 min on power level 4.  
• Clean sonicator tip with ethanol before and after use.  
• Put beaker in tub with an ice while sonicating.  
 
7. Centrifuge the lysate obtained at 12,000 x g for 30 min to remove the cell debris 
and take the supernatant. 
• Pour beaker contents into 1 50 ml centrifuge tube.  Make a 
counterbalance for the centrifuge – volumes may be different 
because of weight of cells. 
• Centrifuge at 12000xg for 30 min => this equals ~10,000 rpm. 
• Take 750 µl sample after centrifuging.  Label sample ‘SS.’ The 
proteins will be in the supernatant and the cell debris will be at 
bottom of tube. 
 
Fusion Protein Recombinant Protein Purification   
WASH BUFFER 1 (500 ml) 
• 20 mM sodium phosphate dibasic => use 1.42 g 
• 40 mM imidazole => use 1.362 g 
• 500 mM NaCl => use 14.61 g 
• 0.02 mM pyridoxal phosphate => use 2.5 ml of 2 mM 
• Correct this to pH 7.4 
 
WASH BUFFER 2 (400 ml) 
• 20 mM sodium phosphate dibasic => use 0.8517 g 
• 40 mM imidazole => use 0.817 g 
• 500 mM NaCl => use 8.766 g 
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• 0.02 mM pyridoxal phosphate => use 2 ml of 2 mM 
• 0.1% Triton X-114 => 3 ml 
• Correct this to pH 7.4 
 
ELUTION BUFFER (300 ml) 
• 20 mM sodium phosphate dibasic => use 0.8517 g 
• 500 mM imidazole => use 10.212 g 
• 500 mM NaCl => 8.766 g 
• 0.02 mM pyridoxal phosphate => use 2 ml of 2 mM 
• Correct this to pH 7 
 
8. After taking supernatant sample, add imidazole (40 mM) and NaCl (500 mM) to 
the lysate to reduce non-specific protein binding.  
• 40 mM imidazole => use 0.0817 g 
• 500 mM NaCl => use 1.168 g 
 
9. Equilibrate a 5 ml HisTrap chromatography column with immobilized Ni+2 
using Wash Buffer 1 until the output reaches baseline at a flow rate of 1.6 
ml/min.    
10. Feed the soluble protein fraction into the column. Pool the drop-former fractions 
that collect while the soluble protein is being applied to the column.  Take a 750 
µl sample and label is “F1-1”. 
11. Wash the column with 70 column volumes of Wash Buffer 2 to remove 
unwanted proteins and endotoxin (350 ml). Pool the drop-former fractions that 
collect while Wash Buffer 2 is being applied to the column.  Take a 750 µl 
sample and label is “F1-2”. 
12. Wash the column with 20 column volumes of Wash Buffer 1 to wash away 
remaining Triton X-114 detergent from the protein.  The pen will reach baseline 
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(100 ml). Pool the drop-former fractions that collect while Wash Buffer 2 is 
being applied to the column.  Take a 750 µl sample and label is “F1-3”. 
13. Elute the protein from the column using Elution Buffer.  Begin collecting the 
fractions when the detector pen increases from baseline.  Pool the drop-former 
fractions that collect while Elution Buffer is being applied to the column.  Take 
a 750 µl sample and label is “E1”. 
14. Dialyze the eluted protein for 3 hours against 2 liters of dialysis buffer 
containing 20 mM sodium phosphate, 200 mM sodium chloride, and 0.02 mM 
pyridoxal phosphate at pH 7.4 to remove NaCl and imidazole from the protein 
solution and make it suitable for N-terminal His-tag cleavage.  After dialysis is 
complete, take a 750 µl sample and label is “AD1” (After Dialysis 1). 
• 20 mM sodium phosphate dibasic => 5.678 g 
• 200 mM sodim chloride => 23.376 g 
• 0.02 mM pyridoxal phosphate => 20 ml of 2 mM 
• Adjust to pH 7.4 
 
15. Regenerate the column using this procedure: 
• 25 ml of 1 M KCl => make 200 ml, use 14.91 g 
• 25 ml of 1 M NaOH => make 200 ml, use 8.0 g 
• 25 ml of DI Water 
• 25 ml of 1 M HPLC grade ethanol => 1.5 ml ethanol + 23.5 ml DI 
Water 
 
16. Measure the concentration of protein (BCA Protein assay or Bradford Protein 
Assay).   
• Add 30 ml DI Water to tube w/ cell pellet.  Take 750 µl sample and 
label it ‘SP.’ 
• For each sample => SS, E1, F1, AD1 
• 30 µl + 30 µl DI water = 2x dilution 
• 30 µl from 2x dilution + 30 µl DI water = 4x dilution 
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• 30 µl from 4x dilution + 30 µl DI water = 8x dilution 
• Use triplicates of each dilution for each sample  
• From BCA Protein assay, sample AD1 tells us the protein 
concentration (~2 mg/ml this run).  We have ~38 mg protein (19 ml 
after dialysis * 2 mg/ml = 38 mg). 
 
17. Cleave the N-terminal His-tag by adding HRV 3C protease at 10 U/mg of 
protein with the recommended 10X buffer provided (stored @ -20ºC).  Incubate 
for 16 hr at 4oC with gentle shaking. 
• We need to add 2 ml of 10x HRV 3C cleavage buffer to AD1. 
• HRV 3C protease comes as 2 U/µl and we want to use it at 10 U/mg 
protein. We have ~38 mg protein  
• ~40 mg * 10 U/mg = 400 U   
• 400 U * 1 µl/2U = 200 µl HRV 3C protease.  Add this to 
AD1. 
• Take 750 µl sample after cleavage is complete.  Label it ‘AC.’ 
 
18. Add imidazole (40 mM) and NaCl (500 mM) to the cleaved protein solution. 
19. Equilibrate a 5 ml HisTrap chromatography column with immobilized Ni+2 
using Wash Buffer 1 until the output reaches baseline at a flow rate of 1.6 
ml/min.    
20. Feed the cleaved protein solution onto the HisTrap column. 
• Collect first peak solution from the column (F2) for dialysis.  This 
contains our protein.   
• Take a 750 µl sample of flow through #2 and label it ‘F2.’ 
 
21. Elute uncleaved protein and HRV 3C protease with Elution Buffer. 
• Collect elution.  Take 750 µl sample and label it ‘E2.’ 
 
22. Dialyze purified protein for 3 hours against 2 liters of dialysis buffer containing 
20 mM sodium phosphate, 100 mM NaCl and 0.02 mM pyridoxal phosphate 
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buffer at pH 7.4.  After dialysis is complete, take a 750 µl sample and label is 
“AD2.” 
• 20 mM sodium phosphate dibasic => use 5.5678 g  
• 100 mM NaCl => use 11.688 g  
• 0.02 mM pyridoxal phosphate => 10 mg 
• Correct to pH 7.4 
• Take 750 µl sample after dialysis. 
 
23. Regenerate the column as above. 
 
24. Pass the pure protein sample thru a 0.2 µm cellulose-acetate filter.  Take 750 µl 
sample and label it ‘SF.’  
 
25. Aliquot purified protein into cryovials and put in the liquid nitrogen tank prior to 
freeze-drying.  
 
26. Do BCA Protein Assay or Bradford Protein Assay on all samples.. 
 
27. Perform L-methioninase enzyme activity assay on samples all samples with 
dilutions of 1x, 5x, 10x, 15x. 
 
28. Perform an SDS-PAGE on samples BI, SS, F1, E1, AD1, AC, F1, SF, Marker 
• Suspend 50 µl of sample + 50 µl loading buffer (95% Laemmli 
sample buffer + 5% β-mercaptoethanol). 
• For BI, centrifuge and resuspend in 100 µl of loading buffer.   
 
BCA Protein Assay Protocol 
Reagent Preparation: 
• Dilute the Reconstitution Buffer 1:1 with autoclaved DI water => Working 
Reconstitution Buffer (WRB). 
• Example: 100 µl DI water + 100 µl Reconstitution Buffer. 
• Add 100 µl of WRB to Compatibility Reagent tube.  Stir and pipet up and down 
20 times to mix.  NOTE: each well assayed requires 4 µl of Compatibility 
Reagent. 
• Determine amount of BCA Working Reagent required knowing each well needs 
260 µl.  To prepare BCA Working Reagent, mix BCA Reagent A (clear) with 
BCA Reagent B (blue) 50:1.  After addition, the solution will turn bright green.                 
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• Example: 10 ml Reagent A + 200 µl Reagent B. 
 
Assay Procedure: 
1. In a 96-well plate, add 9 µl of protein sample to well (run in triplicates). 
2. Add 4 µl of Compatibility Reagent solution to the sample in each well. 
3. Tap side of plate to facilitate mixing.  Incubate at 37oC for 15 minutes. 
4. Add 260 µl of BCA Working Reagent to each well.  Tap side of plate to 
facilitate mixing.  Incubate at 37oC for 30 minutes. 
5. Cool the plate at room temperature for 3 minutes. 
6. Measure the absorbance at 562 nm versus no protein sample (DI water only). 
7. Compare with a standard to calculate the protein concentration. 
How to make standard curve using BSA: 
[BSA] 
(mg/ml) 
BSA (μl) 
Water 
(μl) 
2 100 0 
1.5 75 25 
1 50 50 
0.75 37.5 62.5 
0.5 25 75 
0.25 12.5 87.5 
0.125 50 of the 0.25 
mg/ml solution 50 
0 0 100 
 
Bradford Protein Assay 
1. In a 96 well micro plate, mix 5 µl of enzyme sample with 250 µl of 1x Bio-Rad 
reagent. 
2. Incubate at room temperature for 10 min. 
3. Measure the absorbance at 595 nm. 
[BSA] 
(µg/ml) 
A562 nm Std Dev 
2000 1.066 0.035 
1500 0.796 0.052 
1000 0.54 0.006 
750 0.427 0.014 
500 0.289 0.013 
250 0.151 0.015 
125 0.089 0.009 
0 0 0.004 
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4. Compare with a standard to calculate the protein concentration. 
How to make Standard curve: 
1. Prepare a solution of BSA at 2 mg/ml. 
2. Do a serial dilution of the BSA according to the following table: 
[Protein] 
(mg/ml) 
BSA (μl) 
Water 
(μl) 
2 100 0 
1.5 75 25 
1 50 50 
0.75 37.5 62.5 
0.5 25 75 
0.25 12.5 87.5 
0.125 50 of the 0.25 
mg/ml solution 50 
0 0 100 
 
Bradford Protein Microassay 
1. In a 96 well micro plate, mix 10 µl of enzyme sample with 200 µl of 1x Bio-Rad 
reagent. 
2. Incubate at room temperature for 10 min. 
3. Measure the absorbance at 595 nm. 
4. Compare with a standard to calculate the protein concentration. 
 
SDS-PAGE Analysis of Proteins 
Components 
Stacking gel 
4% 
Separating 
gel 12% 
Separating 
gel 10% 
Separating 
gel 8% 
dH2O 
1.82 
ml(2*910µl) 
1.67 ml 
(2*835µl) 
1.70 ml 
(2*850µl) 
1.74 ml 
(2*870µl) 
1.5 M Tris-HCL pH 
8.8 - 
1.25  ml 
(2*625µl) 
1.25 ml 
(2*625µl) 
1.25 ml 
(2*625µl) 
1 M Tris-HCL pH 
312.5 µl - - - 
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6.8 
10 % (w/v) SDS 25 µl 50 µl 50 µl 50 µl 
Acrylamide (29%) 
Bis (1%) 333 µl 
2 ml 
(2*1000µl) 
1.97 ml 
(2*985µl) 
1.93 ml 
(2*965µl) 
Ammonium 
persulfate 10% 12.5 µl 25 µl 25 µl 25 µl 
TEMED 2.5 µl 5 µl 5 µl 5 µl 
Total 2.5 ml 5 ml 5 ml 5 ml 
*THESE VOLUMES ARE FOR 1 GEL* 
*Ammonium Persulfate – make 10 mg for 100 µl* 
1. Assemble the glass plates on the gel casting stand and fill with water to ensure 
that they are sealed. 
2. Mix the components of separating gel (use an 8% separating gel for Meth-Anx), 
adding the TEMED last. Mix well and immediately fill the glass plates, leaving 
a 1.5 cm gap at the top (for the stacking gel). 
3. Immediately add 1 ml of isopropanol on top of the gel to prevent oxygen from 
inhibiting the polymerization. Wait 20 min for solidification. 
4. Pour off the isopropanol and rinse with dH2O to remove any residual 
isopropanol. Mix the components for the 4% staking gel and pour on top of the 
separating gel. Insert the well-comb and wait 20 min for solidification. 
5. Preheat a water bath to 100ºC. 
6. Prepare the SDS-PAGE loading buffer by diluting β-mercaptoethanol 20 X 
(1:20) with the SDS-blue buffer (prepare stock of loading buffer to add to each 
sample – Example: for 3 ml total volume, add 2.85 ml of Laemmli buffer to 0.15 
ml of β-mercaptoethanol).    
7. Mix 75 µl of each protein sample with 25 µl of SDS-PAGE loading buffer.   
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8. Immediately heat the samples to 100ºC for 2 min. 
9. Allow the samples to cool down for at least one min before loading the gel. 
Assemble the solidified gels in the buffer chamber. Fill the chamber with 
running buffer (144 g Glycine, 30.3 g Tris base, and 10 g SDS to 1 L of dH2O -> 
THIS IS 10X BUFFER!).   
10. Load 10 µl of each protein sample into the wells. Run the gel at a constant 
voltage of 100 V for about 1.5 hours, or until the dye front reaches the bottom of 
the gel. Cut off the stacking gel and discard it. 
11. Stain the separating gel with a staining solution containing 45 % (w/v) dH2O, 
45% (w/v) methanol, 10 % (v/v) acetic acid, and 0.25 % (w/v) Coomassie 
Brilliant Blue R250. To stain, microwave the box containing the gel and stain 
solution in 10-15s bursts on high power (be sure there is enough stain to cover 
the gel).  Just before the solution starts to boil, remove from microwave and 
place on shaker at RT for 5 minutes.   
12. To destain the gel, pour the stain back into its container (it can be re-used 
several times) and rinse the tray with dH2O. Repeat washing with dH2O until the 
discard is clear.  To remove the extra stain on the gel, use a destain solution 
(same as the staining solution, but without the Coomassie Blue).  Put the tray on 
the shaker at RT.  Changing the destain may be necessary.  Protein bands will be 
visible immediately on a light table. 
NOTES: 
SDS – in reagents – denatures protein to monomeric form 
Ammonium Persulfate 10% (0.01g for 0.1 ml) – polymerization  
TEMED – initiation booster for polymerization 
Acrylamide (29%) Bis (1%) – polymer 
151 
 
2 Buffers – (1.5 M Tris-HCL:  23.65g for 100ml; 1 M Tris-HCL: 15.764g 
for 100ml) 
Destain (4 Liters) - 1.8 L dH2O, 1.8 L methanol, 0.4 L acetic acid 
 
 
 
L-Methioninase Enzyme Activity Assay 
 
L-methioninase will convert L-methionine to α-ketobutyrate and be developed by 
MBTH. 
1. Mix for following and incubate at 37°C for 10 min. 
 100 µL of potassium phosphate buffer 0.5 M at pH 8 (to a final 
concentration of 0.05 M) (for 10ml use 0.87g of potassium phosphate 
dibasic (MW= 174.18)) 
 125 µL of L-methionine 0.1 M (for 3ml use 0.04476g) 
 50 µL of pyridoxal phosphate 0.2 mM 
 225 µL of enzyme sample  (for the blank, replace by potassium phosphate 
buffer) 
 
2. Add 62.5 µL of 50 % (w/v) trichloro-acetic acid to terminate the reaction (for 15 ml 
use 7.5g). 
3. Centrifuge at maximum speed for 2 min. 
4. Mix the following and incubate 50°C for 30 min:  
 250 µL of the supernatant from reaction above 
 500 µL of sodium acetate buffer 1 M at pH 5 (for 20 ml use 1.6406g 
(MW=82.03) 
 200 µL of MBTH 0.1% (= 1 mg/ml MBTH: 3-Methyl-2-benzo-thiazolinone 
hydrazone hydrochloride hydrate.)  MBTH reacts with the α-ketobutyrate to 
produce the color change that we measure. 
 
5. Transfer 250 µl of sample to transparent 96-well plate. 
6. Measure the absorbance at 320 nm against the blank using a microtiter plate reader.  
Cytosine Deaminase Enzyme Activity Assay 
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Cytosine deaminase will convert 5-FC to 5-FU; spectrophotometric properties will 
be monitored at 255 and 290 nm. 
1. Prepare stock of 0.5 mg/ml of 5-FC diluted in PBS. 
2. Add 775 µl of PBS to the appropriate number of microcentrifuge tubes where 
reaction will take place. 
3. Add 225 µl of enzyme sample to the tubes.  (The following dilution example can 
be done for a 4.5x dilution: add 50 µl enzyme sample + 175 µl PBS.  When 
doing a dilution, add the PBS prior to enzyme sample). 
4. Incubate the reaction at 37oC for 30 minutes. 
5. Remove 50 µl of sample and quench it in 1 ml of 0.1 N HCl. 
6. Transfer 250 µl to a clear 96-well plate.  
7. Read absorbance at 255 & 290 nm using a microtiter plate reader. 
QCL-1000 Endpoint Chromogenic Limulus Amebocyte Lysate Endotoxin Assay 
The principle used to determine endotoxin quantities is the following:  Step 1: a 
proenzyme is converted to an enzyme by the endotoxin.  Step 2: the enzyme 
converts a substrate + water to a peptide and p-nitroaniline.  The p-nitroaniline is 
then measured at 405 nm, and an endotoxin concentration can be calculated from a 
standard curve made using known amounts of E. coli endotoxin.   
1. Reconstitute 1 vial containing lyophilized Limulus Amebocyte Lysate using 1.4 
ml/vial of lysate.  Once reconstituted, it is stable up to 1 week when stored at -
20oC immediately following reconstitution.  Thaw and use only once.  Keep in a 
dark place.  
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2. Reconstitute the E. coli endotoxin vial using 1.0 ml of LAL Reagent Water 
warmed to room temperature.  Prior to use, vigorously mix for 15 minutes 
because the endotoxin tends to attach to glass.  Our kit contained 28 EU of 
lyophilized endotoxin.  Once reconstituted, it is stable for 4 weeks when stored 
at 4oC.  Keep in a dark place. 
3. Reconstitute the chromogenic substrate by adding 6.5 ml of LAL Reagent Water 
to obtain a final concentration of roughly 2 mM.  Once reconstituted, it is stable 
for 4 weeks when stored at 4oC.  Keep in a dark place. 
4. Prepare the stop reagent => 10 g Sodium Dodecyl Sulfate (SDS) in 100 ml of DI 
Water.   
5. Prepare the endotoxin sample dilutions that will be used to construct the 
standard curve.  Make dilutions in 15 ml centrifuge tubes.   
 
[Endotoxin] 
(EU/ml)  
Endotoxin 
Stock Solution 
Endotoxin Standard 
(1 EU/ml) 
LAL Reagent 
Water 
1.0 0.1 ml - (28-1)/10 ml = 
2.7 ml 
0.5 - 0.5 ml 0.5 ml 
0.25 - 0.5 ml 1.5 ml 
0.1 - 0.1 ml 0.9 ml 
* NOTE: the bottom 3 standards are made from the 1.0 EU/ml solution made 
first.   Vigorously vortex each dilution for at least 1 minute before proceeding to 
the next dilution.  Also 28 is variable depending on the kit received – check 
literature with product for proper value to use.   
6. Using a clear 96-well plate, add 50 µl of each standard and sample into 
appropriate wells (running all samples in triplicate).  The BLANK wells should 
receive 50 µl of LAL Reagent Water in place of sample.  When adding to wells, 
use the same pattern of addition throughout the assay to be consistent.   
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7. Add 50 µl of LAL to each well and then tap on the side of the plate to facilitate 
mixing.   
8. Incubate for 10 minutes at 37oC. 
9. Add 100 µl of substrate solution (pre-warmed to 37oC) to each well.  Tap the 
side of the plate to facilitate mixing. 
10. Incubate for 6 minutes at 37oC. 
11. Add 50 µl of stop reagent (SDS).  Tap the side of the plate to facilitate mixing.   
12. Read absorbance at 405 nm.      
Biotinylation of Fusion Proteins Protocol   
It is necessary to use a protein concentration in the range of 0.2-5 mg/ml for 
labeling.   
We will use 5.32 ml (5320 µl) of protein at 0.94 mg/ml (which gives a total of 5 mg 
of protein). 
1. Buffer should be Dialysis #2 buffer or 100 mM sodium phosphate, 150 mM 
sodium chloride, and 0.02 mM pyridoxal phosphate, pH 7.4 -> use 12,000 – 
14,000 MWCO dialysis tubing for 3 hours.    
2. Dissolve SureLINK Chromophoric Biotin at 0.5 mg per 25 µL anhydrous DMF 
immediately prior to use. 
3. Using a 20-fold excess of biotin for conjugation, add the appropriate volume of 
20 mg/ml (or 25 ng/µl) SureLINK Chromophoric Biotin to the protein solution. 
4. Volume (µL) of 20 mg/mL biotin for conjugation reaction =  
        5320 µl x (0.94 mg protein) x (20 molar excess)       =  12.66 µL 
                    (316 kDa) x (25 nmole/µL) 
 
 % DMF = Vol. of biotin stock ÷ Vol. of protein to be biotinylated 
 
    = 12.66 µL  ÷  5333 µL 
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    = 0.24 % DMF 
4.   Incubate at 4oC for 4 hours with gentle agitation. 
5.   Remove the unconjugated chromophoric biotin by dialysis using a 12-14k MW 
membrane in 2L of 1X modification buffer (100 mM sodium phosphate, 150 
mM sodium chloride, and 0.02 mM pyridoxal phosphate at pH 7.4) for 3 hours. 
Change dialysate and run for 3 hours.  Change dialysate and run a final dialysis 
overnight.  All dialysis is done at 4oC with gentle stir. 
Labeling of Fusion Proteins with FITC 
Label the FP in order to visualize FP binding to cells under a fluorescence 
microscope.   
1. Weigh out FITC (stored at -20oC in foil packet to protect it from light with 
dessicant).  Ex: 0.7 mg 
2. Dissolve FITC completely in PBS to make approximately a 1 mg/ml solution of 
FITC (for all steps using FITC, use containers wrapped in foil to protect the 
FITC from light).  Ex: 0.7 ml 
3. Remove vial of lyophilized FP from -80oC freezer.   
4. Make a solution of 50 mM borate buffer by diluting the 20x borate buffer (on 
shelf) in nanopure water.   
5. Reconstitute the lyophilized FP in 500 µl of 50 mM borate buffer.   
6. Add 100 µl of the FITC solution to the FP solution.  Briefly spin down the vial 
to collect FP and FITC at the bottom of the vial. 
7. Incubate at room temperature for 1 hr. 
8. Make (2) 2-liter dialysis buffers of 20 mM sodium phosphate dibasic.   
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Ex: 5.678 g / 2 L DI H2O, pH 7.4 
9. Add the labeling solution to a dialysis cassette (slide-a-lyzer 3.5k MWCO, 
Fisher Scientific) and begin a 3.5 hr dialysis at 4oC (wrap beaker in foil). 
10. Transfer the dialysis cassette to new dialysis buffer and allow 3.5 hr dialysis at 
4oC (wrap beaker in foil). 
11. Remove labeled protein sample from dialysis cassette.  Store at 4oC, protected 
from light.  
Labeling of L-Methioninase-Annexin V with DyLight 680  
1. To protect reagents from moisture, allow DyLight NHS Esters and DMF to 
equilibrate to room temperature before opening the vials. 
2. Add 100 µL of DMF to the DyLight NHS Ester. Pipette up and down or vortex 
until it is completely dissolved. 
Note: Allow the dye to completely dissolve for 5 minutes and then vortex again.  
3. Suspend Meth-Anx in 0.05 M sodium borate buffer, pH 8.5 (or 0.1 M sodium 
phosphate, 0.15 M NaCl, pH 7.2-7.5) to be in the range of 1-10 mg/ml.   
4. Transfer the appropriate amount of reagent (based on calculations) to the 
reaction tube containing the protein. Mix well and incubate at room temperature 
for 1 hour. 
 
Calculate the amount (mg) of DyLight NHS Ester Dye to be added to the 
labeling reaction:  
    
 
=  
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Calculate the microliters of NHS-ester dye solution to add to the reaction:  
 
 
=  
 
 
5. Remove non-reacted reagent from the protein by dialysis against 2 L of 20 mM 
sodium phosphate dibasic pH 7.4, using a 12-14k MWCO dialysis membrane 
for 4 hr at 4oC.  5.678 g for 2 L DI H2O. 
Note: Wrap the beakers being used for dialysis to protect the DyLight 680 from the 
light. 
6. Transfer the dialysis cassette to new dialysis buffer and allow 4 hr dialysis at 
4oC. 
7. Transfer the dialysis cassette to new dialysis buffer and allow overnight dialysis 
at 4oC. 
8. Remove labeled protein sample from dialysis cassette.  Store at 4oC protected 
from light or lyophilize to powder and store at -80oC.  
Binding Assays for Fusion Proteins to Endothelial and Cancer Cells 
1. Grow endothelial cells in 6 T-75 flasks using F12K medium containing 10% 
FBS, ECGS, heparin, and penicillin/streptomycin until they reach 80-85% 
confluence.   
2. Transfer 5x104 cells/well to 48 wells on (2) 24-well plates. 
3. Expose phosphatidylserine (PS) on surface of endothelial cells by adding 1 mM 
H2O2.  Treat the cells in all wells with 100 µl of F12K medium with 1mM H2O2 
for 1 hour at 37oC and 5% CO2.  Remove after incubation period. 
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4. Fix the cells in all 48 wells by adding 100 µl/well PBS buffer containing 0.25% 
glutaraldehyde.  Remove before proceeding.    
5. Quench excess aldehyde groups by incubating with 100 µl/well of 50 mM 
NH4Cl, diluted in PBS buffer, for 5 min.  Remove after incubation period. 
Note: For cancer cells, perform a 1 hr pre-treatment with 0.5% BSA diluted in PBS 
at 37oC.    
6. Dilute biotinylated fusion protein in 0.5% BSA diluted in PBS buffer, with 
concentrations of 20 nM, 12 nM, 8 nM, 4 nM, 2 nM, 0.5 nM, and 0.05 nM.  Add 
300 µl to wells in Sets 1 and 2, using triplicates of each concentration.  The 
blank for each set will receive no FP.  
a. Set 2 (21 wells) gets PBS + BSA + 2 mM Ca+2 + FP 
b. Blank (3 wells) gets PBS + BSA + 2 mM Ca+2 
c. Set 1 (21 wells) gets PBS + BSA + 5 mM EDTA + FP 
d. Blank (3 wells) gets PBS + BSA + 5 mM EDTA 
7. Incubate for 2 hours at 37oC, 5% CO2. 
8. Wash 4 times with 300 µl of 0.5% BSA diluted in PBS buffer.   
9. Add 300 µl of Streptavidin-HRP (2 µg/ml) and incubate for 1 hour at room 
temperature. (Streptavidin-HRP is in 4oC glass fridge)  
10. Wash 4 times with 300 µl of PBS buffer.   
11. Add 300 µl of the chromogenic substrate O-phenylenediamine (OPD) to each 
well. (OPD is in -20oC freezer).  The OPD solution is made with phosphate 
citrate buffer (1 capsule in 100 ml DI water).  Prior to use, add 40 µl of 30% 
H2O2.  Weigh out the desired amount of OPD with a concentration of 0.4 mg/ml.   
12. Incubate for 30 minutes at room temperature and in the dark to minimize OPD 
color change.   
13. Transfer 100 µl of the supernatant to 96-well plates. 
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14. Measure absorbance at 450 nm.   
Visualization of L-Methioninase-Annexin V for Endothelial and Cancer Cells  
1. Grow 1 flask of HAAE-1 cells in F12K medium + FBS + ECGS + heparin + 
pen/strep. 
2. Place autoclaved 22x22 (mm) cover glass in a 35 mm petri dish.   
3. Coat the cover glass with 0.1% porcine gelatin. 
4. Add 250 µl of cell suspension to the cover glass.  (Use 2 petri dishes – 1 for full 
visualization; 1 for negative control -> leave out FP) 
5. Let the cells adhere for 4 hr at 37oC, 5% CO2. 
6. Add 2 ml of F12K medium to the petri dish. Incubate overnight at 37oC, 5% 
CO2. 
7. Add FP (that has been labeled with FITC) diluted to 100 nM in F12K medium + 
2 mM Ca2+.  Incubate for 2 hr at 37oC, 5% CO2. For the control plate, add only 
medium + 2 mM Ca2+ ( no FP). 
8. Wash the petri dishes 4 times using medium + 2 mM Ca2+ to remove any 
unbound CD-Anx. 
9. Remove the cover glass from the petri dish, touch the side of it to a piece of 
paper towel to remove excess liquid, and apply a drop of Fluor-gel drop (Fisher 
Scientific #NC9703847) to a glass microscope slide.  Place the cover glass with 
cells upside down on top of the Fluor-gel. 
10. Visualize the cells using fluorescence microscopy. 
Binding Stability Assay for Fusion Proteins to Endothelial and Cancer Cells  
In this assay we will be using, at the beginning, “growth medium” (F-12K + 10% 
FBS + pen/strep + ECGS + heparin) and, later on, “FP suitable medium” which is 
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composed of the “growth medium” with 2 mM Ca2+, 0.02 mM pyridoxal phosphate, 
and 1000 µM methionine (because annexin V binding is Ca2+ dependant, pyridoxal 
phosphate is a cofactor for the methioninase, and higher methionine to eliminate 
methionine depletion effect). 
1. Seed 5x104 cells in 6 wells on each of 4 plates and grow them until they reach 
70% confluence using growth medium (24 wells total).  Let the cells grow 
overnight.  
2. Add 300 µl of growth medium containing 1 mM H2O2 to expose 
phosphatidylserine. 
3. Wash 3 times (using 250 µl of FP suitable medium each time). 
4. Add 300 µl of FP suitable medium containing 100 nM FP that has previously 
been biotinylated. 
5. Incubate for 2 h at 37 ºC. 
6. Wash 3 times (using 250 µl of FP suitable medium each time). 
7. Add 1 ml of FP suitable medium. 
8. Each day (0, 1, 2, & 3), take one plate (6 wells).  Remove the medium and 
replace with 300 µl of FP suitable medium.  Perform an Alamar Blue assay to 
determine cell viability.  
a. Add 10% (30µl) of Alamar Blue 
b. Incubate for 4 hours at 37°C. 
c. Transfer 250 µl to an opaque 96-well plate 
d. Measure fluorescence: excitation – 530 nm; emission – 590 nm. 
9. Wash 2 times using FP suitable medium (using 250 µl each time). 
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10. Fix the cells by adding 100 µl/well of FP suitable medium containing 0.25% 
glutaraldehyde.  Incubate for 5 min at room temperature.  Remove after 
incubation period. 
11. Quench excess aldehyde groups by incubating with 100 µl/well of FP suitable 
medium containing 50 mM ammonium chloride (NH4Cl) for 5 minutes at room 
temperature.  Remove after incubation period. 
12. Wash 3 times using FP suitable medium (using 250 µl each time). 
13. Add 300 µl of Streptavidin-HRP. 
14. Incubate for 1 hour at room temperature.  
15. Wash 3 times using FP suitable medium (using 250 µl each time). 
16. Add 300 µl of the chromogenic substrate O-phenylenediamine (OPD) to each 
well.  The OPD solution is made with phosphate citrate buffer (1 capsule in 100 
ml DI water).  Prior to use, add 40 µl of 30% H2O2.  Weigh out the desired 
amount of OPD with a concentration of 0.4 mg/ml.  
17. Incubate for 30 minutes at room temperature and in the dark to minimize OPD 
color change.   
18. Transfer 100 µl of the supernatant to 96-well plates. 
19. Measure absorbance at 450 nm.   
Methioninase-Annexin V Cytotoxicity Assay for Endothelial and Cancer Cells  
This assay we will be using “growth medium” (F12K medium + 10% FBS + 
pen/strep + heparin + ECGS) and later on “FP suitable medium” which is composed 
of the “growth medium” with 2 mM Ca2+ (because annexin V binding is Ca2+ 
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dependent), 0.02 mM pyridoxal 5’-phosphate (co-factor), and L-methionine 
adjusted to 1000 µM (to mask the methionine depletion effect). 
1. Seed cells in 42 wells on (7) 24-well in growth medium.  Plate #1 will receive 
Meth-Anx in only 3 wells, and the rest will have no Meth-Anx with varying 
prodrug concentrations (24 wells).  Plates #2-7 will receive Meth-Anx and the 
prodrug (18 wells).  Begin the experiment the day after plating cells.            
2. Add 300 µl of growth medium containing 1 mM H2O2 to expose 
phosphatidylserine.  Note: For cancer cells, skip this step. 
3. Wash 2 times using 250 µl of growth medium. 
4. Add 300 µl of FP suitable media containing 500 µM L-methionine and 100 nM 
Methioninase-Annexin V FP to appropriate wells (21 wells).    Add 300 µl of FP 
suitable media only to those wells with no Meth-Anx (21 wells).   
5. Incubate for 2 hr at 37°C, 5% CO2. 
6. Wash 4 times using 250 µl of FP suitable medium. 
7. Add 300 µl of FP suitable medium containing varying concentrations of the 
prodrug Selenomethionine to all plates => 5000 µM, 1000 µM, 500 µM, 100 
µM, 50 µM, 10 µM.  For the BLANK (0 µM), only add FP suitable medium to 
the cells.   
8. Incubate at 37°C, 5% CO2. 
9. On Day 1, remove medium and replace with 300 µl of FP suitable medium.  
Perform the Alamar Blue assay to determine cell viability.  
e. Add 10% (30µl) of Alamar Blue. 
f. Incubate for 4 hours at 37°C, 5% CO2. 
g. Transfer 250 µl to an opaque 96-well plate 
h. Read fluorescence: excitation – 530 nm; emission – 590 nm. 
163 
 
10. Wash using 250 µl FP suitable medium. 
11. Add 300 µl of FP suitable medium containing varying concentrations of the 
prodrug Selenomethionine to all plates => 5000 µM, 1000 µM, 500 µM, 100 
µM, 50 µM, 10 µM.  For the BLANK (0 µM), only add FP suitable medium to 
the cells.   
12. Incubate at 37°C, 5% CO2. 
13. Repeat steps 9-12 for Day 2 and Day 3. 
Cytosine Deaminase-Annexin V Cytotoxicity Assay for Endothelial and Cancer Cells  
In this assay we will be using, at the beginning, “growth medium” (F12K medium + 
10% FBS + 1% Pen/Strep + Heparin + ECGS) and, later on, “FP suitable medium” 
which is composed of the “growth medium” with 2mM Ca2+ (because annexin V 
binding is Ca2+ dependant). 
1. Seed cells in 63 wells on (3) 24-well.  Begin the experiment (Day 0) the day 
after plating.  
2. Add 300 µl of FP suitable media containing 1 mM H2O2 to all wells.  For cancer 
cells, skip this step.   
3. Incubate for 1 hr at 37oC, 5% CO2.  
4. Wash using 250 µl of FP suitable medium. 
5. Add 300 µl of FP suitable media containing 100 nM yCD-Annexin V (FP) to 
plate #1 (21 wells).  Plates #2 and #3 will receive FP suitable medium only.   
6. Incubate for 2 hr at 37°C, 5% CO2. 
7. Wash 4 times using 250 µl of FP suitable medium. 
8. For plates #1 and #2, add 1000 µl/well of FP suitable medium containing 
varying concentrations of the prodrug 5-fluorocytosine (5-FC) => 2000 µM, 
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1000 µM, 750 µM, 500 µM, 250 µM, 125 µM.  For the BLANK (0 µM), only 
add FP suitable medium to the cells.  For plate #3, add 1000 µl/well of FP 
suitable medium containing 5-fluorouracil (5-FU) at the same concentrations as 
the 5-FC.  Leave 3 wells on each plate for the Alamar Blue blank (medium + 
10% Alamar Blue reagent).   
9. Incubate for 72 hr at 37°C, 5% CO2.  Replace FP suitable medium containing 
the correct prodrug/drug concentration each day to produce new 5-FC. 
10. On Day 3, remove plates from incubator; remove the medium and replace with 
300 µl of FP suitable medium containing the correct 5-FC concentration.  
Perform an Alamar Blue assay to determine cell viability.  
a. Add 10% (30µl) of Alamar Blue. 
b. Incubate for 4 hours at 37°C, 5% CO2. 
c. Transfer 250 µl to an opaque 96-well plate 
d. Read fluorescence: excitation – 530 nm; emission – 590 nm. 
 
11. Wash using 250 µl FP suitable medium. 
12. Repeat steps 2 - 9. 
13. On Day 6, remove plates from incubator; remove the medium and replace with 
300 µl of FP suitable medium containing the correct 5-FC or 5-FU 
concentration.  Perform an Alamar Blue assay to determine cell viability, as 
above.  
14. Wash using 250 µl FP suitable medium. 
15. Repeat steps 2 – 9. 
16. On Day 9, remove plates from incubator; remove the medium and replace with 
300 µl of FP suitable medium containing the correct 5-FC or 5-FU 
concentration.  Perform an Alamar Blue assay to determine cell viability.  
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a. Add 10% (30µl) of Alamar Blue. 
b. Incubate for 4 hours at 37°C, 5% CO2. 
c. Transfer 250 µl to an opaque 96-well plate 
d. Read fluorescence: excitation – 530 nm; emission – 590 nm. 
 
ELISA for L-Methioninase-Annexin V Detection in Mouse Serum 
 
Biotinylated methioninase–annexin V fusion protein clearance time determination. 
1.  Use streptavidin-coated 96 well plates from Thermo Fisher Scientific.      
2.  Add 50 µl of each serum sample to wells (2 dosage levels – 10 mg/kg and 1 
mg/kg; 4 time points per dosage level – 1 hr, 4 hr, 8 hr, and 24 hr post-injection; 
4 samples with no injection as the blank).    
3.  Cover the plate with adhesive cover and incubate for 60 min at 37oC.   
4.  Shake out the plates into a sink.  Wash the plates with Wash buffer 4 times by 
adding 200 µl and shaking out the Wash buffer into a sink.  Pat plates dry by 
inverting on paper towel.   
5.  Add 50 µl of Annexin V polyclonal antibody (rabbit) diluted to 1.25 µg/ml 
(recommended by Abcam) in Diluting Buffer to each well. 
6.  Cover the plate with adhesive cover and incubate for 60 min at 37oC.   
7.  Shake out the plates into a sink.  Wash the plates with Wash buffer 4 times by 
adding 200 µl and shaking out the Wash buffer into a sink.  Pat plates dry by 
inverting on paper towel.   
8.  Add 50 µl of anti-rabbit IgG-HRP conjugate (secondary antibody) diluted to 
1:1,000 (initially at about 1 mg/ml) using Diluting Buffer to each well. 
9.  Cover the plate with adhesive cover and incubate for 60 min at 37oC.   
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10.  Shake out the plates into a sink.  Wash the plates with Wash buffer 4 times by 
adding 200 µl and shaking out the Wash buffer into a sink.  Pat plates dry by 
inverting on paper towel.   
11.  Add 50 µl of OPD solution to each well. 
12.  Cover the plate with adhesive cover and incubate for 30 minutes at room 
temperature in the dark.   
13.  Read absorbance at 450 nm.   
Reagent List: 
1. Diluting Buffer 
- 0.5 g Tween 20 
- 2.5 g BSA (0.25%) 
- Add PBS to 1 L.   
NOTE: Do not add sodium azide with HRP-IgG method. 
2. Wash Buffer 
- 5 g Tween 20 (0.05%) 
- Add PBS to 1 L.  
 
3. OPD Solution 
- 1 phosphate-citrate capsule in 100 ml of DI H2O  
- Weigh out OPD powder at 0.4 mg/ml and put in centrifuge tube wrapped in 
aluminum foil 
- Immediately before use, add 40 µl of 30% H2O2 to initiate the reaction 
- Add necessary amount of buffer solution to tube and use ASAP 
 
Injection of MDA-MB-231/GFP Cancer Cells into Flank of Mice 
1. Grow MDA-MB-231/GFP cells to inject 3 T-75 cm2 culture flasks of cells per 
mouse.  Split the cells from 1 => 3 flasks about every 3 days.   
2. Lift and plate the cells in three 150 cm2 culture dishes. 
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3. On the day prior to lifting and injecting the cells, replace the medium with 
penicillin/streptomycin-free medium.  Use this medium until the injections.  
(Advised by colleague at HSC). 
4. On the day prior to injections, place a vial of BD Matrigel Basement 
Membrane Matrix in a beaker with water and place at 4oC overnight to thaw.  
5. On the day of injections, lift the cells as usual using 6 ml of PBS and Trypsin-
EDTA followed by 12 ml of medium.   
6. Transfer 3 plates to each 50 ml centrifuge tube.   
7. Centrifuge all tubes to combine them into one 50 ml centrifuge tube and remove 
supernatant. 
8. Add 0.1 ml * # of mice to inject = _____ ml of medium to the total cell pellet 
and resuspend. 
9. Assemble 2 sterilized 1.5 ml microcentrifuge tubes for each mouse to be 
injected in an ice/ice water bath to cool cells for transport to animal facility. 
10. Add 100 µl of BD Matrigel Basement Membrane Matrix to one 1.5 ml 
microcentrifuge tube for each mouse. 
11. Mix cell suspension and add 100 µl to the other 1.5 ml microcentrifuge tube for 
each mouse. 
12. Bring samples and 100 µl pipet with tips to animal facility. 
13. Sedate the mice using ketamine/xylazine or isoflurane.  If the mice have hair, 
shave the flank area that will receive the injection. 
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14. Combine the BD Matrigel Matrix with the cell suspension and mix.  Draw the 
suspension into a 1 ml Tuberculin Syringe with detachable 25G 5/8” slip tip 
needle. 
15. Insert needle beneath the skin of the flank and inject the cell-matrix suspension. 
16. Allow the needle to stay in place for 1-2 minutes to help the matrix solidify to 
keep the cells in place. 
17. Remove needle and place mouse back in cage and observe as directed in IACUC 
regulations.  
Detection of PS Exposed in Mice Tumors using Cryosectioning and Immunohisto-
chemistry Staining  
To detect PS that was translocated to the outer leaflet of the plasma membrane of 
tumor vascular endothelial cells and tumor cells using biotinylated Meth-Anx. 
1. Using an orthotopic model, inject 6 female SCID mice with ~7-8x106 cancer 
cells, using a 1:1 mixture of growth medium to matrigel and a total injection 
volume of 200 µl.  
2. Allow the tumors sufficient time to grow to a diameter above 3 mm, in which 
the tumors will require the development of tumor vasculature to supply nutrients 
for continued growth, using the equation:  Volume = (width)2 x length/2   
[Measurement of dimensions is done using a digital caliper (mm).] 
3. Inject 220 µl of biotinylated Meth-Anx (which corresponds to 100 µg of annexin 
V) i.p. 
4. Under isoflurane anesthetic, open the chest cavity to expose the heart.  
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5. Insert a 27G butterfly needle into the left ventricle and hook up a pump to 
deliver 10 ml of heparinized saline + 2 mM Ca+2.  The heparin is used to 
prevent coagulation of any remaining blood in circulation.    
6. Cut the ascending vena cava to allow the circulation to be emptied. 
7. Pump the heparinized saline + 2 mM Ca+2 solution at ~1.3 ml/min. 
8. Fix the tissue by pumping 0.25% glutaraldehyde + 2 mM Ca+2.  
9. Immediately resect the tumor area and soak the tissue in 20% sucrose + 2 mM 
Ca+2.   
10. Bring the mouse samples to the Imaging Core at OMRF in Oklahoma City to 
have cryoembedding and cryosectioning done.  Request 1 slide to be stained 
with H&E and 2 unstained slides.     
11. Store slides at -80oC until staining can be done. 
12. Prior to staining, remove slides from the freezer and allow them to reach RT. 
13. Rinse the slides with PBS + 2 mM Ca2+. 
14. Block the slides with PBS containing 0.5% BSA and 2 mM Ca2+ for 30 min at 
RT. 
15. Rinse the slides with PBS + 2 mM Ca2+. 
16. Incubate the slides with streptavidin-HRP for 30 min at RT. 
17. Rinse the slides with PBS + 2 mM Ca2+  and shake off excess. 
18. Incubate the slides with the activated DAB solution for 10 min at RT. 
19. Rinse the slides with reagent water for 3 min to remove excess DAB. 
20. Counterstain the slides with hematoxylin for 4 min at RT. 
21. Rinse the slides with the following to remove excess hematoxylin: 
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a. Tap water  
b. DI water 
c. Ammonia water (50 ml DI water + 0.1 ml ammonia hydroxide) – 10 
slow dips 
d. DI water 
 
22. Air dry and mount the slides with of ImmuniHistoMount (Santa Cruz 
Biotechnology # sc-45086).  Do not apply a coverslip. 
Tissue Biodsistribution of L-Methioninase-Annexin V in SCID Mice with Tumor 
To determine the quantity of Meth-Anx that binds to vasculature in individual 
organs. 
1. Using an orthotopic model, inject 6 female SCID mice with as close to 7-8x106 
cancer cells as possible, using a 1:1 mixture of growth medium to matrigel and a 
total injection volume of 200 µl.  
2. Allow the tumors sufficient time to grow to a diameter above 3 mm, in which 
the tumors will require the development of tumor vasculature to supply nutrients 
for continued growth, using the equation:  Volume = (width)2 x length/2   
[Measurement of dimensions is done using a digital caliper (mm).] 
3. When the appropriate sized tumors are present, perform an i.p. injection of 3 
mice with 10 mg/kg dose of Meth-Anx tagged with DyLight 680 fluorescent 
dye.   
4. Using the IVIS imaging system, take whole-animal images to capture the tumor 
(GFP) and Meth-Anx (DyLight 680) at 1, 12, and 24 h post-injection to 
determine location of Meth-Anx in relation to the tumor. 
5. Sacrifice the 3 mice, remove a blood sample to obtain serum, and resect out the 
major organs (tumor, lung, liver, heart, spleen, kidneys, stomach). 
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6. Image the organs of each mouse all together to see the intensity of the DyLight 
680 signal.  Present the data as photons per second/g of tissue.   
Treatment of Breast Tumors on SCID Mice with L-Methioininase-Annexin V 
This protocol is for the mouse on a normal diet.  For the methionine-deficient 
experiment, start the mice on the diet the day before the first FP injection and use a 
Selenomethionine at 5 mg/kg.   
1. Inject 7 female SCID mice per group with ~7-8x106 cancer cells using a 1:1 
mixture of growth medium to matrigel and a total injection volume of 200 µl.  
2. Allow the tumors sufficient time to grow to a diameter above 3 mm3, in which 
the tumors will require the development of tumor vasculature to supply nutrients 
for continued growth, using the equation [Volume = (width)2 x length/2].  
Measurement of tumor dimensions is done every 3-4 days using a digital caliper 
(mm). 
3. When the tumors begin to grow by average tumor volume, random mice were 
selected to be viewed with the IVIS imaging system.  A GFP signal in the flank 
region provides evidence that the MDA-MB-231/GFP tumor cells are alive. 
4. Randomize the mice into 4 groups.   
5. Begin the treatment period (Day 0) by performing intraperitoneal injections of 
all mice as shown (~5:00 pm injections): 
a. Control Group 1 – saline 
b. FP Group 2 – L-methioninase-annexin V at 10 mg/kg 
c. SeMet Group 3 – saline 
d. Treatment Group 4 – L-methioninase-annexin V at 10 mg/kg 
 
6. On days 1-3, performing intraperitoneal injections of all mice as shown (~7:00 
am injections): 
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a. Control Group 1 – saline 
b. FP Group 2 – saline 
c. SeMet Group 3 – Selenomethionine at 10 mg/kg 
d. Treatment Group 4 – Selenomethionine at 10 mg/kg 
 
7. Repeat steps 4 and 5 for 2 additional treatment cycles 
8. Measure the tumor dimensions and body weight of each mouse every 3-4 days.   
9. Observe the tumor growth for up to 4 weeks or until tumor size mandates 
termination.   
10. When tumor weight reaches ~10% of body weight, sacrifice the mouse by CO2 
overdose and cervical dislocation.  
11. Dissect out the lungs, liver, and tumor and image them in a 6-well plate using 
the IVIS imaging system in the Rodent Barrier to detect any GFP signal that 
would represent tumor metastases. 
12. Place all mouse parts in formaldehyde to fix the tissue for 2-3 days at room 
temperature.   
13. Deliver samples to Dr. Stanley Kosanke, OU HSC Pathology, to have paraffin 
blocks made.  Precision Histology, Inc will section and mount on slides and 
perform hematoxylin & eosin staining.  Dr. Kosanke will view slides and 
provide a pathology report for each mouse requested.  
Determination of Blood Flow through MDA-MB-231/GFP Tumors 
The purpose of this test is to demonstrate that there is less blood flow going through 
tumors that have been treated with methioninase-annexin V fusion protein and 
selenomethionine compared to untreated tumors.  The methioninase-annexin V + 
SeMet treatment is hypothesized to damage microvessels, causing clotting and 
reducing the amount of blood flow through the tumor. 
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1. Using an orthotopic model, inject 6 female SCID mice with as close to 6x106 
cancer cells as possible, using a 1:1 mixture of growth medium to matrigel and a 
total injection volume of 200 µl.  
2. Allow the tumors sufficient time to grow to a volume above 3 mm3, in which the 
tumors will require the development of tumor vasculature to supply nutrients for 
continued growth, using the equation:  Volume = (width)2 x length/2   
[Measurement of dimensions is done using a digital caliper (mm).] 
3. When the appropriate sized tumors are present, treat 3 mice with Meth-Anx at 
10 mg/kg and 10 mg/kg SeMet.  Use 3 mice as an untreated control.    (3 cycles 
of treatment = 12 days) 
4. Inject the DyLight 680 fluorescent dye at 1 mg/kg via i.p. injection.   
5. Allow the dye to circulate for 30-60 min. 
6. Using the IVIS imaging system, capture images of the blood flow in the region 
of the tumor.  Use 3D reconstruction of the mouse if necessary to determine dye 
intensity in treated vs untreated mice. 
7. After all of the images are taken, open the chest cavity to expose the heart under 
isoflurane anesthetic 
8. Insert a 27G butterfly needle into the left ventricle and hook up a pump to 
deliver 10 ml of heparinized saline + 2 mM Ca+2.  The heparin is used to 
prevent coagulation of any remaining blood in circulation.    
9. Cut the ascending vena cava to allow the circulation to be emptied. 
10. Pump the heparinized saline + 2 mM Ca+2 solution at ~1.3 ml/min. 
11. Fix the tissue by pumping 10 ml of 10% formalin. 
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12. Immediately resect the tumor area and soak the tissue in formaldehyde.   
13. Bring the mouse samples to Dr. Stan Kosanke (OUHSC – Pathology) to have 
paraffin embedding done and send samples for sectioning to Precision 
Histology.   
Carbon Nanotube Standard Curve 
1. Sonicate 6 mg of SWNTs in 5 ml of 1% SDS for 1 hr. 
2. Immediately, without centrifuging, make dilutions using deionized water and 
transfer 250 µl to a 96-well plate. 
3. Measure the absorbance at 800 nm using a microtiter plate reader to make a 
curve of SWNT concentration versus absorbance. 
Conjugation of F3 Peptide to SWNTs 
1. Add 6 mg of SWNTs to 5 ml of 1% SDS solution (500 mg for 50 ml).   
2. Sonicate the SWNT suspension for 1 hr at 22% power (7 watts) – put glass vial 
into beaker with cold water to dissipate heat. 
3. Centrifuge the SWNT suspension for 30 minutes at 15,700 x g (13,000 rpm 
microcentrifuge) 
4. Measure the concentration of SWNT in suspension. 
5. Set out DSPE-PEG-Maleimide linker and to warm up to room temperature (15-
20 min).  Store linker in nitrogen atmosphere.  
 When putting linker vial away, put in nitrogen glass w/ cap slightly off, 
turn on nitrogen for 1 min, and quickly close cap, turn off nitrogen. 
 
6. Dissolve DSPE-PEG-Maleimide linker at 2 mg/ml in warm DI water. 
 NOTE: If linker does not dissolve easily, incubate at 37oC or warm water 
bath for 15 minutes and then pipet up and down to dissolve. 
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7. Reconstitute 1 mg of F3 peptide in 2 ml of PBS (pH 7.4). (The F3 is in 1 mg 
aliquots) 
8. Mix 1 ml of the linker solution with the 2 ml peptide solution to create a 
suspension with a 1:2 ratio of peptide to linker. (Use an extra 1 ml PBS to wash 
out all of the F3 solution from the vials – total of 3 ml for peptide + 1 ml of 
linker solution) 
9. Stir gently for 15 hr at room temperature. (Use large shaker at 50 rpm) 
10. Treat F3-linker reaction mixture with 40 µl of L-cysteine dissolved in DI water 
at 5 mg/ml for 1 hr with gentle shaking, to block unreacted maleimide groups.   
11. Add the 4 ml F3-linker solution to the 5 ml of the SWNT suspension.   
12. Mix at room temperature and 50 rpm shaking for 30 min. 
13. Dialyze for 8 hr.  Change the buffer after 4 hr. 
 2L of DI Water with a 50k MW dialysis membrane 
 Note 1: Be very specific on the time of this dialysis because the 
nanotubes will aggregate if left longer than the 8 hours.   
 Note 2: You can take the sample out of the dialysis membrane and put it 
into a foiled 15-ml centrifuge tube and into the 4o fridge overnight and 
then continue in the morning, but a better suspension results from 
immediate centrifugation. 
 
14. Centrifuge for 1 hr at 15,700 x g to remove any SWNT aggregates. 
15. Determine the final SWNT concentration. 
16. Determine the final concentration of F3 using the Bradford Protein Microassay. 
Visualization of SWNT-F3 by Fluorescence and Confocal Microscopy 
1. Plate cells in chambered slides or in 35 mm petri dishes on 22 mm cover glasses 
to achieve ~80% confluence. 
2. Incubate for 24 hr at 37oC, 5% CO2.  
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3. Incubate the cells with SWNT-F3 at 60 mg/L (SWNT) for 2, 8, 16 or 24 hr at 
37oC, 5% CO2. 
4. Wash the cells with medium 4 times. 
5. Stain the cells with CellMask plasma membrane stain for 30 min at 37oC @ 7.5 
µg/ml in warm medium.  
6. Wash the cells with medium 4 times. 
7. Fix the cells with 10% buffered formalin for 10 min at 37oC. 
8. Wash the cells with medium 4 times. 
9. Mount on a slide with 1 drop of Fluoro-Gel to preserve fluorescence. 
10. View under fluorescence or confocal microscopy. 
NIR Laser Setup and Configuration 
It is important to wear protective eyewear during all laser experiments while the 
laser is on.  Protective glasses can be found in D201.  You must also put laser test 
warning signs on the door to the lab before beginning this experiment. 
1. Turn on laser and fix laser beam size to cover one well on a 24 well plate (1.8 
cm diameter) as follows: 
• Turn the key to the “On” position.  (O = off, I = on) 
• Place black laser test paper with black side down above laser (it may be 
necessary to place an empty 24 well plate on top of the paper to hold it in 
place). 
• Press “Standby” on the screen and hold down the foot pedal to emit the 
laser for 30 seconds. 
• Lift foot off of pedal and press the “Standby” button again to stop the 
laser. 
• Hold the black laser test paper up behind an empty 24 well plate to 
determine if the laser beam diameter is large enough to cover an entire 
well.  
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• If the beam is not the right size, move the laser fiber either up or down to 
decrease/enlarge the beam diameter and repeat the above steps until an 
acceptable beam diameter is obtained. 
 
2. Adjust the power level as follows:  
• Turn on NOVA II laser measurement device and place black box above 
laser. 
• Adjust the power on the laser using the up and down arrows on the 
screen. 
• Press “Standby” and hold down the foot pedal to emit the laser. 
• Read the equivalent power on the NOVA II device (this is the power 
actually felt). 
• Adjust the power level on the screen until the desired power is read by 
the NOVA II device. 
• Once the NOVA II device shows that the desired power level has been 
reached, remove the black box and turn off the NOVA II device; this is 
the power setting to be used. 
 
3. Irradiate each of the wells designated to receive laser treatment with a beam 
diameter of 1.6 cm and a local power of 5.86 W for 120 seconds to achieve an 
energy density of 350 J/cm2. 
SWNT-F3 + NIR Laser Test Protocol 
1. Seed 5x104 cells in each of 30 wells on a total of 3 plates and grow them until 
they reach 70% confluence using appropriate growth medium.  Wells intended 
to receive NIR treatment should be placed on the plate as pictured below. 
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2. Incubate the cells with SWNT-F3 at 60 mg/L in medium for 2, 8, 16, and 24 hr 
at 37oC, 5% CO2.  Laser only samples receive medium only. 
3. Wash 4 times using 250 µl of medium. 
4. Add 300 µl of appropriate cell medium. 
5. Setup the laser for irradiation using the appropriate power level to achieve the 
desired total energy density for each cell line.  
NOTE:   It is important to wear protective eyewear during all laser experiments 
while the laser is on.  Protective glasses can be found in D201.  You must also put 
laser test warning signs on the door to the lab before beginning this experiment. 
 
4. Irradiate each of the wells designated to receive laser treatment  
5. Once irradiated, incubate the plates at 37oC, 5% CO2 for 1 hr. 
6. Evaluate cell viability using the Alamar Blue Assay: 
• Add 10% (30µl) of Alamar Blue. 
• Incubate for 4 hr at 37°C, 5% CO2. 
• Transfer 250 µl to an opaque 96-well plate 
• Read fluorescence: excitation – 530 nm; emission – 590 nm 
 
7. Replace medium and incubate the plates at 37oC, 5% CO2 for 14 hr. 
8. Evaluate cell viability using the Alamar Blue Assay. 
